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Nhamo
Su m m a r y
The principal aim of this study was to improve the physico-mechanical 
properties of hydrogenated vegetable oil (HVO) tablets and to alter their
predominantly square-root of time release characteristics, so as to produce a
per-oral controlled release delivery system capable of being targeted to the 
proximal colon.
In the introduction to the experimental study, the physics of tablet compaction, 
tablet strength, friction and lubrication, effects of particle size effect on tablet 
strength and oral controlled drug delivery are discussed. The experimental work 
is divided into two parts: firstly a study dealing with the characterisation and 
optimisation of the physico-mechanical performance of processed HVO tablets. 
The second part of the study deals with the modification of the mechanism of 
drug release from processed HVO tablets.
Physico-mechanical properties were inproved by processing HVO with 
polymeric binders as well as a low melting point fatty acid, stearic acid, which 
acted as an “auxiliary” binder. Tablet tooling adhesion of processed HVO was 
reduced by the addition of anti-adherents. The mechanism of drug release from 
processed HVO tablets was modified by the incorporation of a low melting 
point material, Myverol. Myverol is mainly glyceryl monostearate.
The type and concentration of binder were found to affect tensile strength of
tablets produced from processed HVO. The minimum compaction force required
4
to achieve maximum tensile strength and release - sustaining characteristics was 
approximately 9 kN. However, formulations containing Myverol had compaction 
force independent release - sustaining characteristics as from 3 kN. Large 
particles were found to produce tablets with significantly better tensile strength 
and release-sustaining characteristics than small particles.
Myverol was found to alter the mechanism of drug release from processed 
HVO tablets: from Higuchi model - type kinetics to Fickian diffusion - relaxation 
model - type kinetics. It was considered that such a controlled release system of 
the latter type could be targeted to the proximal colon which:- (a) has 
increased residence time, (b) is responsive to drug absorption enhancing agents 
and (c)has decreased enzymatic activity. An increase in drug release rate with 
time would compensate for the reduced epithelial absorption and the gradual 
increase in the consolidation of faecal matter in this region.
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1.1 T h e  P h y sic s  of  T a b l e t  C o m p a c t io n  
Compaction is an irreversible change in the dimensions of a solid material as a 
result of the application of pressure. 1 Compression is a reversible or an 
irreversible dimensional change in a solid material under pressure. The former
process results in an intact compact, while the latter does not necessarily
produce a compact.
Pharmaceutical powders or granules are compacted between the upper and lower 
punches of a tablet machine and an intact compact is ejected from the die. The 
stages which occur during tablet compaction include:- transitional repacking or 
particle rearrangement, deformation at points of contact, fragmentation and/or
deformation (plastic and elastic), bonding, decompression and ejection. 2’3 These 
stages are depicted in figure 1.1.
At low applied loads the granules/powder consolidates to higher densities. This 
depends on the type of material and the particle size. However, energy
expended during this stage, is of minor consideration in the whole process of 
tablet compaction. 3 As the compaction load increases further, granule/powder 
deformation via the areas of true contact occurs. The stress is relieved by 
either fragmentation or deformation (plastic or elastic). This depends on the
12
Figure 1.1:- Stages in Tablet Compaction3
»  M
I I I
Key:- I - Initial loose particle packing
II - Rearrangement o f  particles at low pressure
III - Particle derfomation at high pressure
IV - Tablet axial relaxation
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rate of application of the load, the magnitude of the load, duration of the 
locally induced stress, physical properties of the materials) and temperature. 3,4 
Usually two or more of the above changes occur either simultaneously or
consecutively.5
Materials such as sodium chloride and microcrystalline cellulose are among the 
ones which mainly undergo plastic deformation. 6’ 7 Materials that mainly 
fragment include crystalline lactose, sucrose and Emcompress. 7’ 8 Compact 
strength in plastically deforming materials is believed to be the result of surface 
flow or slippage of one surface over another. This results in a contact area
capable of increasing both the number of bonds and their strength. In
fragmenting (brittle) materials, compact strength is due to an increase in contact
area. Plastically deforming materials generally produce stronger compacts than 
brittle materials at given applied loads. Low temperatures and fast loading 
during compaction generally facilitate consolidation by fragmentation. 9’10
For metals and most crystalline materials, after the initial elastic deformation, 
the materials undergo plastic deformation. Finally, if  the stress is high enough, 
the materials show brittle behaviour and fragment. However, most 
pharmaceutical materials are organic compounds and exhibit different 
consolidation properties from the above simple model. The main difference is 
that many pharmaceuticals seem to undergo particle fragmentation during the 
initial loading.3,8
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Several methods have been used to determine the volume - reduction 
mechanisms both qualitatively and quantitatively. These include:- scanning 
electron microscopy; work measurements from force - displacement curves; axial 
to radial tensile strength ratio (isotropy ratio); measurement of surface area 
changes and measurement of porosity changes during compaction.8
1.1.1 Mechanisms of Bond Formation in Tablets
Bond formation releases energy (exothermic process). Several mechanisms of 
bonding in the process of compaction have been postulated. Three theories put 
forward are the mechanical theory, the intermolecular theory and the liquid 
surface theory. 2
The mechanical theory proposes that, under pressure, the individual particles 
undergo elastic, plastic or brittle deformation and the edges of the particles 
intermesh, forming a mechanical bond. However, this mechanism is not a major 
one in tablet bonding. It is probably important in press-coating and is thought 
to be responsible for holding the different layers together.
The intermolecular theory proposes that molecules at the surface of solids have 
surface free energy. This energy enables the molecules to interact with other 
surface molecules on other particles, in true contact. This implies that 
absolutely clean surfaces are a requirement for the interaction of these 
intermolecular forces. Intermolecular forces are thought to constitute the majority 
of bonding forces in pharmaceutical materials.8
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Intermolecular forces include van der Waals’ forces, electrostatic forces, and 
hydrogen bonding. It is believed that the most prevalent type of force in 
materials, including tablets, are the van der Waals’ forces (75-100 % of the 
total forces). 8 Van der Waals’ forces operate in vacuum, ah and hquid 
environments up to distances of approximately 10 - 100 nm from molecular 
surfaces. They owe their origin to fluctuating electrical moments/dipoles 
produced by the movement of electrons in their atomic orbits. These dipoles 
are able to induce a corresponding and opposite dipole in an adjacent atom 
thus leading to a net attraction. Van der Waals’ forces act between all atoms 
regardless of polarity or electrical charge.
Electrostatic forces occur due to a separation of charges. They usually arise 
during mixing and compaction.
Hydrogen bonding takes place when the negative pole of a strong dipole 
approaches another dipole, positively charged, which consists of a hydrogen 
atom Hydrogen bonding is predominately an electrostatic interaction and can 
occur intramolecularly and intermolecularly. It is an important mechanism of 
bonding in materials such as microcrystalline cellulose (MCC), starch and 
lactose. 8’11 These materials have hydroxyl groups, -OH, which are responsible 
for the hydrogen bonding.
Solid bridges are due to either covalent or ionic bonds and hence do not fall 
into the category of intermolecular bonds. The main differences between solid
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bridges and intermolecular bonds are the strength of the bonds formed, the 
bond length at equilibrium and the attracting distances. 8 Hydrogen bonds have 
bond strengths ranging from 10-30 kJmol"1, equilibrium distances of 0.3-0.4 nm 
and attracting distances ranging from 10 nm to 100 nm  Hydrogen bonds and 
van der Waals’ forces have similar equilibrium and attracting distances. 
However, van der Waals’ forces have bond strengths ranging from 5 to 40 
kJmol'1; by comparison solid bridges have bond strengths of 200-800 kJmol'1, 
bond lengths of less than 0.3 nm and attracting distances of less than 1 nm  
Electrostatic forces have the same attracting distances as the other two 
intermolecular forces (hydrogen bonds and van der Waals’ forces). However, 
electrostatic forces are incapable of contributing to thermodynamically stable 
bonds between molecules or ions.
The liquid surface theory attributes bonding to the presence of a thin liquid 
film, which may be a result of fusion or solution although the bonds formed 
are usually solid bridges. 8 During compaction, an applied force is exerted upon 
the granules/powder, but locally the force is applied over a small area of true 
contact: therefore, high pressure exists at the areas of true contact. The local 
effect of the high pressure on the melting point and solubility of a material is 
important to bonding.
The relationship of pressure and melting point is expressed by the Clapeyron 
equation below:-2’12
ST/SP = T(V 1 - Vs) / AH equation 1.1
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where 3T/dP is the change in melting point with pressure, T is the absolute 
temperature, AH is the molar latent heat of fusion, and Vi and Vs are the 
molar volumes of liquid melt and the solid, respectively. As latent heat of 
fusion is positive, this equation predicts that for a solid that expands on
melting (Vi > Vs), the melting point is raised by an increase in pressure. For a 
solid that contracts on melting (Vi < Vs), the melting point is lowered by
increasing the pressure. Except for a few substances, such as water, most
solids expand on melting. Thus the Clapeyron equation indicates that during
compaction, the rise in melting point with pressure for most substances would
make it difficult for fusion to occur. This equation is derived from
thermodynamically reversible processes with systems exposed to uniform 
pressure. However, the compaction of pharmaceutical tablets is non-reversible 
and the pressure is not uniformly distributed. For these reasons and the 
existence of frictional forces, which raise temperatures during compaction, the 
potential of melt/fusion bonding of particles in tablets cannot be discounted. 
This is more so in tablets made from materials such as hydrogenated vegetable 
oils (HVOs) which have relatively low melting points.
Skotnicky2’12 derived an equation relating heat of fusion, volumes of liquid and
solid states, temperature and pressure applied to the liquid and solid phases.
For an ideal system where there is exposure to uniform pressure the relation 
reduced to Clapeyron equation. However, if the pressure at the points of true 
contact is exerted only on the solid, and any liquid being subjected to constant 
atmospheric pressure, then the relation simplifies to the equation below:-
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8T/dPs = - VST / AH equation 1.2
For such a system, the isolated pressure acting locally on the solid always 
lowers the melting point regardless of the expansion or contraction of the solid 
on melting. This is especially true for hydrophobic materials such as HVOs, 
fatty acids and waxes which have relatively low melting points.
The reasoning employed in the analysis of pressure effects on melting point 
could also be extended to changes in solubility of solids with pressure. The 
variation in solubility of a solid with uniform pressure has been expressed in 
the following equation:-12
(din x / dP)r = -(Vi - Vs) / RT equation 1.3
where x is the mole fraction of the solid in saturated solution, R is the gas
law constant and the rest are as described above. This equation predicts that 
for a solid that expands on melting (V i> V s), an increase in pressure will 
decrease solubility with the converse true for a solid that contracts upon
melting (Vi < Vs). However, consideration of pressure and stress at areas of 
true contact in tablet compaction, one could conclude that an increase in 
pressure results in an increase in solubility.
The liquid in which solution takes place is usually the film of moisture 
adsorbed on the particle surface. The strength of the inter-particulate bridge
formed depends on the amount of material deposited and the rate of 
crystallisation. High crystallisation rates produce fine crystalline structures and 
strong bridges. The poor compactibility of most water insoluble compounds and
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the relative ease of compaction of most water soluble compounds seem to 
support this compaction - solution phenomenon.2
1.2 T a b l e t  St r e n g t h  
Tablets ought to possess sufficient strength and toughness to be able to 
withstand mechanical handling and transport. 13 In addition, the mechanical 
characteristics of matrix sustained release tablets should allow the compact to 
provide reproducible drug dissolution profiles. The strength of tablets is known 
to be influenced by a number of properties such as:- the physico-mechanical 
properties of the drug and excipients, which influence the main bond type 
formed and their number; type, amount and distribution of binder and how it is 
added; the characteristics of the tablet compaction process, including the applied 
compaction force and speed; particle size and distribution of powder/granulation; 
type, amount and blending time of lubricants; size and shape of finished tablets; 
temperature and rate of drying of granulation and final moisture in granulation 
and tablets. 13 20
1.2.1 Binders and Tablet Strength
In order to improve tablet strength, a binder is usually added during 
granulation, sometimes in dry form, but usually in solution. Symecko and 
Rhodes 16 defined a binder as a substance that is included into a solid dosage 
formulation as a technical additive, to improve compatibility and flowabihty of 
powders or granules.
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Of particular importance is the binder's compatibility with other tablet 
components, especially the drug. It should impart sufficient cohesion to powders 
or granules, to allow normal processing such as sizing, lubrication, compaction 
and packaging. Ideally, binders ought to possess low elastic modulus and 
undergo high plastic deformation. Binders increase the number of bonds, 
produce stronger bonds, produce a number of bonds that can withstand stress 
relaxation and elastic recovery of the particles and deform plastically during 
powder/granulation consolidation and decompaction. 16,20 Besides this, binders 
also help in the formation of solid bridges in tablets when they crystallise and 
harden. 17 However, in HVO matrices the majority of the solid bridges are 
probably as a result of partial particle melting and localised fusion-welding.17
Generally, binders exert strong van der Waals’ forces in the presence of small 
amounts of moisture. Most binders are not effective at zero percent moisture. 
Therefore when used in the dry state, they are less effective as they exhibit 
minimal surfaces for cohesive binding in this state. As indicated initially, they 
are usually added as solutions or suspensions. 15
Binders have recently been classified in two ways namely:- (a) chemical origin 
(source) and (b) method of tablet manufacture. 16 Source is further divided 
into three groups namely:- (i) natural, (ii) semi-synthetic and (iii) synthetic. 
Method of tablet manufacture is divided into:- (i) wet granulation, (ii) slugging 
and (iii) direct compression. Binders of natural origin include acacia and gelatin. 
Semi-synthetic binders include celluloses (such as carboxymethylcellulose, ethyl
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& methylcellulose) and pregelatinised starch. Some synthetic binders are 
polyvinylpyrrolidone (PVP) and the polymethacrylates. 16 However, binders such 
as acacia are now rarely used due to their tendency of having bacterial 
contaminants. Nevertheless, starch, another binder of natural origin, is still 
commonly used as a material which tends to produce soft but firm granules. 
PVP, a synthetic binder, continues to be extensively used as a binder in water, 
alcohol or blends of each solvent. 15 Binders which are more hydrophobic are 
potentially usefid in combination with hydrogenated vegetable oils (HVOs) as 
they are likely to provide better release-sustaining characteristics.
1.2.2 Tablet Strength Evaluation
Various techniques and tests have been used to assess tablet strength, including: 
abrasion; bending; static indentation; cutting; erosion; scratch; rebound; 
ploughing and diametral crushing. 21,22 The mechanical strength of tablets has 
been quantified by means such as:- crushing strength, axial tensile strength, 
radial tensile strength, hardness and work required to cause tablet failure. 8,23
A common method for evaluating the strength of tablets involves the 
measurement of the force required to break a tablet in a diametral compression 
test. This is often termed the crushing or peak force. Tablet failure maybe due 
to more than one type of force and a tablet may fail in more than one way. 
The ways in which a tablet may fail are depicted in figure 1.2 (a). When the 
tablet fails by mechanism 1, which is pure tensile fracture, the stress 
distribution within the tablet can be calculated as shown in figure 1.2 (b).
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Figure 1.2:- Failure Patterns (al During Diametral Loading of
Tablets and Stress Distribution fbl in Pure Tensile Failure
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NB:-In (b) the applied load may be resolved into three components, ctx, a yan d az 
Where:- a x is the tensile stress applied normal to the loaded diameter 
dy is the compressive stress
g7 is the shear stress
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Large tablets will have higher crushing forces than smaller ones. This is so 
because the crushing force does not take into consideration tablet dimensions. 
Therefore in order to compare strengths of tablets having different diameters 
and thickness, tablet radial tensile strength, Ts, is normally used. Ts can be 
calculated from the crushing force, Fc, as shown below: -
Ts = 2FC/ Ttdt equation 1.4
where Ts and Fc are as described above, d and t are the tablet diameter and 
thickness respectively. However, some authors 13,23 claim that the radial tensile 
strength is sensitive to crack propagation variations, hence the determination of 
axial tensile strength, T^. 11 This can be calculated from the following 
equation:-
2
Tsx = 4FP / 7id equation 1.5
where Fp is the force required to pull the tablet apart in the axial direction 
and d is as above. Axial tensile strength has been found to be of value in 
assessing capping and/or lamination tendencies of materials. 24 Besides this, T^ 
is also used in combination with the radial tensile strength to calculate the 
isotropy ratio. This ratio has been used as a measure of particle fragmentation 
during compaction. 25,26 Isotropy ratios close to unity generally indicate that the 
material consolidates mainly by particle fragmentation while low ratios are 
obtained when plastic deformation is the predominant mechanism.26
The radial tensile strength, Ts, is believed to reflect a kind of average strength 
value, while the axial tensile strength, Tsx, is related to the weakest part of a 
tablet. 26 Therefore the former is a better indicator of tablet strength than the
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latter. The majority of pharmaceutical tablets are anisotropic and heterogeneous 
and properties such as density, porosity and strength vary in different 
directions. For an isotropic homogeneous body, radial and axial tensile strengths 
are equal.
Crushing force is often erroneously termed hardness (a surface property). 
Hardness is often defined as the resistance of a solid to local permanent 
deformation. It can be measured by static methods such as Brinell and Vickers 
hardness tests or by dynamic methods. 2123 The static methods involve the 
formation of a permanent indentation on the surface of the material and
hardness is determined by the load applied and the size of the indentation 
formed. 23 For example, the Brinell hardness tester measures directly the depth 
of penetration into a material such as a tablet face, by means of a
displacement transducer. The results are independent of tablet geometry. 2I’22 
For the Vickers hardness tester, instead of the use of a ball to penetrate the 
surface of the tablet, a pyramid is used. 21,27 Generally, for ductile materials, 
there is a linear relationship between compact tensile strength and Vickers
hardness. 22 Dynamic methods involve a pendulum which is allowed to strike 
from a known distance, or an indenter which is allowed to fall under gravity 
onto the surface of the material. Hardness is determined from the rebound 
height of the pendulum or volume of the resulting indentation.23
“Corrected” work of failure, CWf, has sometimes been termed tablet
"toughness''. A material could be strong but not tough. For example, glass is
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strong but is not tough as it shatters easily, while in contrast rubber is not 
strong but is very tough. During diametral compression testing, Rees and R ue28 
studied platen displacement as a means of assessing tablet deformation before 
failure. A displacement transducer recorded the relative movement of the platens 
until failure occurred. The load, F, was plotted against displacement, x. The 
area under the curve, calculated by integrating the load with respect to platen 
movement, represented the work done, Wf, on the tablet to cause its failure as 
shown below: -
FA max
Wf = 1 F.dx equation 1.6
F0
Wf has units of Joules. In order to correct for the size of a circular cylindrical 
compact, the work done, Wf, is divided by the cross-sectional area of failure 
to obtain the corrected work of failure, CWf, which has units of Joules rn 2. 
Rees and Rue 28 then concluded that materials with similar tensile strength 
values may show markedly different work of failure values. This is due to 
variations in their resistance to deformation prior failure.
Generally, materials that consolidate mainly by plastic deformation during 
compaction, tend to show high work of failure values. This is probably due to 
a combination of high tensile strength values and large deformation before 
failure, during a diametral loading test. In contrast, materials consolidating 
mainly by fragmentation during compaction, tend to show low work of failure 
values.
26
1.3 F r ic t io n  a n d  L u b r ic a t io n  
The atomic or molecular processes that occur at the interface of two materials 
when they are brought into contact or moved with respect to one another is 
fundamental to many technological problems such as adhesion, friction, wear, 
lubrication and fracture.29 Solid surfaces irrespective of method of formation, 
generally contain surface irregularities. When two surfaces are placed in contact, 
surface roughness causes contact to occur at discrete contact points. 
Deformation (plastic and elastic) occurs at these points depending on the 
applied stress, surface roughness and material properties. Usually, the total area 
of true contact under normal loads is a small fraction of the area that would 
be in contact if the surfaces were perfectly smooth.29,30 If this area is minimal, 
then adhesion, friction and wear would be minimised.
Studies on the interaction between two surfaces when brought close together 
and between two surfaces in contact as they are separated have been studied. 29 
Such interactions can be modified by the presence of an intervening medium 
such as a liquid or a material with a lower shear strength than the other two 
surfaces. The frictional properties of such systems have been studied by moving 
the surfaces laterally, hence providing insight into the molecular-scale operation 
of lubricants. Therefore friction force in terms of the tableting process can be 
defined as the force required to shear inter-granule/particle junctions formed at 
regions of real contact plus the force required to plough the surface of the 
softer material (tablet) by the asperities of the harder (die). However, the
27
relationship between friction and surface topography is not always simple and 
obvious.
I f  two surfaces are in true molecular contact when sliding begins, their friction 
will be high and their adhesion may be strong enough to tear them apart. 
However, if the surfaces are separated by one or more molecular layers of 
fluid lubricant and if this cushioning film remains in the liquid-like state during 
sliding, then the frictional force will be low and sliding will proceed smoothly. 
29 For example, one layer of water molecules approximately 0.25 nm thick 
between two hydrophilic surfaces can be sufficient to reduce the interfacial 
friction force to very low values. On the other hand, if the surface-fluid
interactions induce the liquid molecules to solidify, the molecular configuration 
during sliding is complicated. The film alternately melts and freezes during
motion and the resulting friction is of the “stick-slip” type. Sticking will occur
in the frozen state, giving rise to the static friction force and slipping will
occur in the shear-induced molten state, giving rise to the kinetic friction force. 
29 This stick-slip phenomenon is probably important in the compaction and 
ejection phases of tablets, especially those made from HVOs in combination 
with low melting point lubricants such as stearic acid 31 and HVO. 32 In these 
phases, powders/granules move over each other and the die wall and formed 
tablets slide along the die wall. Experiments have shown that in cases such as 
these the forces of friction and adhesion are closely related. 29
28
During the sliding of two surfaces that contain boundary layers of “surfactant” 
molecules which might be either solid-like (eg magnesium stearate), amorphous- 
like or liquid-like (eg liquid paraffin), dynamic film structures can arise. 
Generally, solid-like films exhibit stick- slip motion, amorphous-like films exhibit 
high friction due to the molecular entanglements occurring between the two 
surfaces, and liquid-like films exhibit low viscous-like friction with smooth 
sliding. This is schematically shown in figure 1.3. 29 These dynamic states are 
dependent on temperature, pressure, applied load and relative velocity of the 
shearing surfaces. High sliding speeds make the film more solid-like whereas 
slower speeds make it behave more like a liquid.
In tableting, the attainment of low adhesion, low friction and low wear (surface 
damage) is a most desirable goal. By choosing the right lubricant and in some 
cases chemically grafting molecules such as surfactants, polymers, chromium 
nitride, zinc or iron dihydrogen phosphate to the tooling surfaces, controls and 
modifies the frictional properties. 29 3133 in such cases, very small amounts of 










Figure 1.3;- Schematic Illustrations of Different Types of Dynamic
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1.3.1 Tablets and Lubricants
Lubricants are most essential components of a tablet formulation. A tablet 
lubricant has three primary functions namely:- (a) reducing friction at the tablet- 
die wall interface especially during ejection (true lubricant activity), (b) 
facilitating the flow of powder or granulation from the hopper to the feed 
shoe/frame into the die (glidant activity), and (c) preventing adherence of 
formulation to the punches and die (anti-adherent activity). 15, 30, 34 Most 
lubricants exhibit at least one or more of the above functions.
Lubricants that exert their effect by separating surfaces by the formation of a 
finite and continuous liquid film on the punches, die and granulation, are called 
fluid lubricants. Some are liquids at room temperature such as liquid paraffin,31 
while others melt at compaction pressures and temperatures such as H V O s32 
and stearic acid. 31 Most lubricants consist of long chain fatty acids and the 
polar portions of which attach to the metal oxide film on the punch and die 
surfaces and are called boundary lubricants. These include the metallic stearates 
and sodium stearyl fumarate.35
Whether a lubricant is a boundary one or a liquid film one, there is an overall 
reduction of the coefficient of friction (ratio of friction force to the normal
load). This will reduce the work required to compact the powder/granulation
and more importantly, the reduction of the work done in tablet ejection.
Coefficients of friction for fluid lubricants can be as low as 0.001 with
negligible wear of surfaces, while with boundary lubricants, coefficients are
31
higher (0.15-0.5), and wearing occurs. Ideally, for effectiveness, boundary 
lubricants ought to have low shear strength and adhere readily and firmly to 
interacting surfaces. 15,31 How boundary and fluid lubricants are thought to 
behave or align themselves on granular and die surfaces is depicted in figure
1.4. In tablets prepared by wet granulation, lubricants are added only after 
granulation has been dried prior to compaction. In direct compression, they are
added when all the other excipients have been added.
Particle size and shape are very important to lubricant distribution and 
effectiveness, with mixing time and type of mixer having an effect as well. 
However, blending time and conditions are not so critical with stearic acid as 
they are with its salts. The salts are incompatible with acid drugs such as 
aspirin, while stearic acid is incompatible with alkaline drugs such as sodium 
saccharin and sodium phenobarbital. 15 HVOs’ blending conditions are less 
critical but still important. 32 Water soluble lubricants are usually used in
effervescent tablets and other water soluble tablets and examples include 
polyethylene glycol 6000, sodium benzoate, sodium lauryl sulphate and dl
leucine. 15
Although lubricants play a very important role in tableting, they also have 
detrimental effects on tablets. These include:- (a) significant decrease in tablet 
tensile strength, (b) decrease in work of failure, (c) increase in disintegration 
times and (d) decrease in dissolution rate especially with magnesium stearate. 5’ 
31,32 The mechanism of decrease in tensile strength is thought to be due to
32
Figure 1 .4 :-Schematic Illustration of How Different Lubricants Act 31
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finer lubricant particles coating the larger excipient and drug particles and 
interrupting inter-particle bonding. Particles that show ductile/plastic deformation 
seem to be affected to a greater extent than those that show brittle 
consolidation behaviour, due to the formation of new clean surfaces in the 
latter during compaction.5
1.3.2 Evaluation of Lubrication Properties
1.3.2.1 True Lubricant Activity 
By the application of instrumentation technology to tableting equipment, true 
lubricant activity has been quantitatively evaluated by the measurement of 
parameters such as:- ejection force, R-value, residual force and force lost to 
the die wall.30’35'37
The R-value is the ratio of the maximum lower punch force to the maximum 
upper punch force or the fraction of maximum force exerted by the upper 
punch transmitted to the lower punch.38 Generally, for tablet machines with a 
stationary lower punch such as the Manesty E2 and F3, the R-values are less 
than 1. The closer the R-value to 1 the better the lubricant efficiency. There is 
a correlation between the force lost to the die wall and the ejection force.
Simultaneous measurement of compaction and lubrication forces (ejection and 
residual forces) has been always difficult, due to vastly different magnitudes 
of the forces. This has been overcome by measuring the residual area on the 
force - time curves which include both the static residual and dynamic ejection
34
event following compaction.37 Actually, there are two schools of thought as to 
whether the static (residual) or dynamic (ejection) force is more appropriate for 
the evaluation of true lubricant activity.36 The same authors then suggested that 
the former is more suitable for comparing the efficiency of different lubricants 
while the latter is more suitable for optimisation of lubricant concentrations.
1.3.2.2 Glidant Activity 
Glidant activity has been evaluated by means such as hopper flow rate 
measurements, angle of repose measurements and analysis of tablet weight 
variation. 17,30,39 Angle of repose is best suited for particles > 150 pm  17 Values 
for angle of repose < 30° generally indicate a free flowing material and values 
> 40° suggest a poor flowing material. If a granulation/powder has good flow 
properties then tablet weight variation will he minimal.
1.3.2.3 Anti-adherent Activity
•  •  30Anti-adherent activity continues to be evaluated mainly by tool inspection. 
However, a number of quantitative evaluation of anti-adherent activity of 
lubricants have been carried ou t.30,34,35
A device designed to measure the “slipping force” between tablet surface and 
upper punch has been reported. 30 Tablets were compacted on a single punch 
instrumented machine with modified upper punch assembly and a split die. The 
upper punch was not retracted after compaction. The intact upper punch-tablet 
die assembly was transferred to a device which measured the force required to
35
rotate the upper punch while the tablet was held stationary in the die. A 
number of direct compression formulations were evaluated. The data showed 
that slipping force measurement could be used to predict the tendency of 
formulations to stick.
Using an instrumented strain gauge measuring arm of a rotary tablet machine, 
the “stripp ability” of tablets was quantified. 30 Three of the formulations tested 
contained polyethylene glycol (PEG) 4000 and lactose in various proportions as 
the basic materials and 0.5 % silica-type glidant. The fourth formulation 
contained only lactose granulation and 1 % magnesium stearate. Mixtures were 
compacted at different compaction forces. It was concluded that the stripping 
force of the tablets decreased with decreasing PEG 4000 concentration in the 
mixtures and increased with increasing compaction force or with running time 
with some mixtures. However, no details of the design or calibration of the 
measuring device were given.
Mitrevej and Augsburger30 designed instrumentation to measure the adhesion of 
tablets to the lower punch face. A strain gauged cantilever beam affixed to the 
feed frame in front of the sweep-off blade detached the tablet from the lower 
punch face. The adhesion force was the total force measured by the beam less 
that due to the momentum of the tablet. A Stokes RB-2 press was used for 
the tableting. Generally, the higher the compaction force or the lower the 
magnesium stearate concentration, the higher the adhesion in three direct 
compression fillers (compressible sugar, microcrystalline cellulose, lactose). With
36
microcrystalline cellulose (MCC) and 0.1 % magnesium stearate, adhesion 
decreased with increased tablet thickness or decreased tablet diameter (constant 
thickness) at constant compaction force. Measurement of ejection forces 
simultaneously, revealed that differences in true lubricant efficiency did not 
necessarily reflect differences in adhesion. Therefore anti-adherent activity can 
not be inferred from true lubricant activity.
Studies which have been done to compare lubricated and unlubricated MCC 
suggest two opposing effects on tablet adhesion:- (a) enhancement of adhesion 
due to increased reaction at the lower punch due to reduced die wall friction, 
and (b) reduction of adhesion due to the anti-adherent effect of the lubricant.34 
In the same study, these authors found out that at any given compaction 
force, adhesion of MCC tablets lubricated with magnesium stearate appeared 
to decrease with increases in blending time or intensity of blending. Over a 
three hour running time, adhesion force increased to peak values and then 
declined with both direct compression systems (MCC and lactose). However, 
ejection forces gradually decreased to apparently limiting values in all cases. 
Even though stearic acid appeared to be less efficient than magnesium stearate 
as a true lubricant and as an anti-adherent with the MCC blends, the converse 
was true with the hydrous lactose blends at 1 % lubricant concentration. From 
this study, these authors also concluded that differences in true lubricant 
efficiency do not necessarily reflect differences in anti-adhesion efficiency and in 
some systems, the general belief that anti-adhesion efficiency increases with 
lubricant concentration is not true, especially with lubricants such as stearic
37
acid. This is so because such lubricants partially melt at compaction forces and 
temperatures.
The tendency for picking or sticking to occur in tablets during compaction can 
also be obtained from residual force measurements. 35 Non-sticking formulations 
such as those that contain high proportions of MCC tend to yield high residual 
forces. This is due to reduced tendency of the tablets to be raised away from 
the lower punch when the upper punch lifts away from the compact. 
Formulations that tend to stick or pick, such as those containing low melting 
point excipients such as HVOs, waxes, gums and stearic acid, tend to be 
slightly withdrawn from the lower punch when the upper punch lifts up 
following compaction. This reduces the residual force on the lower punch.
However, as indicated initially, evaluation of adhesion tendencies of a 
formulation is still primarily done by tool inspection as this is cheap, reliable, 
easy to perform and convenient.
1.4 T h e  E f f e c t s  o f  Pa r t ic l e  Siz e  o n  T a b l e t  St r e n g t h  
The physico-chemical and mechanical properties of pharmaceutical 
powders/granules have a profound effect on tablet strength. Physico-chemical 
properties include particle density, particle size, size distribution, particle shape 
and texture. Solid state properties include crystal hardness and hygroscopicity 
and mechanical properties include elasticity, plasticity and brittleness of the 
excipients and drugs.23 Beside affecting the ultimate tablet strength, all these
38
properties determine how a formulation will behave during tableting and its 
ultimate performance as a drug delivery system.
Alderbom and Nystrom25 studied the effect of particle size on the mechanical 
strength of tablets made from acetylsalicylic acid BP, sodium citrate dihydrate, 
a  lactose monohydrate, Sta-Rx 1500, sodium chloride, Emcompress and 
saccharose. This effect was strongly dependent on the properties of the 
materials. For Emcompress and saccharose which undergo extensive particle 
fragmentation during compaction, tablet strength was almost independent of 
particle size. As for the first three materials (acetylsalicylic acid BP, sodium 
citrate dihydrate and a  lactose monohydrate), which fragment to a lesser extent 
than Emcompress and saccharose, tablet strength decreased with an increase in 
particle size. This was attributed to the fact that smaller particles have a larger 
surface area for bonding than larger particles. For the mainly ductile materials, 
sodium chloride and Sta-Rx, tablet strength increased with an increase in 
particle size. For Sta-Rx this was thought to be due to the change in particle 
texture. Smaller particles were fairly smooth while the larger particles were 
rougher. As for sodium chloride it was thought that larger particles probably 
create stronger bonding forces than smaller ones with total contact area having 
minimal effect.
The effect of particle size on the consolidation of sodium chloride and lactose 
powder during compaction was also evaluated. 23 Particle size and size 
distribution were found to affect particle slippage and deformation and hence
39
consolidation. The ratio of particle size to diameter of die, affected the amount 
of void spaces during compaction. It was observed that contact points between 
particles and hence the number and total area of true contact depended on the 
particle size and particle size distribution as well as powder arrangement. There 
was a linear relationship between compaction force and crushing strength for all 
particle sizes of sodium chloride fractions except at high pressures. Increase in 
tablet strength was also observed with an increase in particle size and 
compaction force.
A study on the effect of particle size of crystalline and spray dried lactose on 
the density changes in tablets made from these materials, 23 revealed that 
relative volumes of compacts measured under pressure at low compaction 
speeds for smaller particles were less than those of larger particles, under the 
same conditions. However, the relationship was reversed at high compression 
speeds. The differences ceased to exist when measurements were done post­
ejection. At low speeds, time dependent volume reduction mechanisms probably 
predominate, with smaller particles producing denser and smaller compacts than 
the larger ones, with the converse true at high speeds. Post compaction, the 
differences ceased to exist probably due to equal stress relaxation.
McKenna and McCafferty 40 studied the effect of particle size on the 
compaction mechanism and tensile strength of compacts of spray-dried lactose, 
Sta-Rx 1500 and Avicel PH101. Decrease in particle size of spray-dried lactose 
and Sta-Rx 1500 resulted in stronger compacts while Avicel PH101 compacts
40
were unaffected by changes in particle size. This was probably due to larger 
surface areas for bond formation in small particles than in large particles of 
lactose and Sta-Rx. Sta-Rx results in this case, were contrary to those obtained 
by Alderbom and Nystrom. 25 The compaction mechanism was found to be 
independent of size fraction for all the 3 materials.
Particle size was found to have an effect on the compaction properties of 
sulfadimethoxine (SD) and sulfaphenazole (SP). 23 SD compacts were found to 
be more affected by changes in particle size than SP ones, although the latter 
compacts had higher tensile strengths than the former. SD compacts produced 
from larger particles had higher tensile strengths than those produced from 
smaller particles. This was attributed to more effective bonding between the 
larger particles of SD than between the smaller particles.
Katikaneni and co-workers5 also studied the effect of particle size on the 
strength of ethylcellulose compacts. Smaller particles produced stronger tablets 
which they attributed to the theory that, smaller particles allow greater packing 
density and greater number of contact points for inter-particulate bonding. All 
the tablet strength- comp action force profiles at all particle sizes studied had 
curved shapes which indicated an approach to a limiting compact strength in 
relation to compaction force.
A study of the effect of original particle size and tablet porosity on the 
increase in tensile strength during storage of sodium chloride tablets in a dry
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atmosphere was carried out by Eriksson and Alderbom. 41 Compacts were made 
from three particle size ranges, 425-500, 90-150 and 20-40 pm at a series of 
compaction forces. Tensile strength was determined immediately post-compaction 
and after storage for different time periods. For compacts formed from the two 
coarser particle sizes, tensile strength increased during storage with low 
compact porosity increasing the magnitude but decreasing the rate of compact 
strength increase. Compacts made from the smallest particle size range did not 
alter in strength during storage irrespective of applied load and porosity.
1.5 C o n t r o l l e d  R e l e a se  D r u g  D e l iv e r y  
Modem science has always been in search of economical, efficient and safe 
means of providing for the health and well being of humankind. This has been 
done by the production of active agents that manipulate the biological 
environment around and within us. The majority of active agents/drugs (70 - 80 
%) are taken per - orally, mainly as plain tablets, coated tablets or capsules, 
while the remainder are:- parenteral, rectal, ocular, intrauterine, intravaginal and 
dermal delivery systems.42,43
The use of drugs is fraught with inefficiencies due to the inability to deliver 
these agents in the right amounts, at the right time and to the specific target. 
This usually result in the agents’ loss, undesirable side effects and repeated 
dosage regimen so as to acquire and sustain the desired effect. Periodic 
dosage of drugs produce peaks and valleys in drug concentration in the blood, 
possibly between harmful and ineffective levels. The different drug
42
concentrations in blood produced by different dosage forms are shown in figure 
1.5.
Attempts to alter the persistency and effectiveness of the active agents/drugs 
through modification of the reagents themselves has been made but it has 
always proved to be difficult, time consuming and expensive. More attention is 
now being focused on methods by which drugs are administered, giving rise to 
the field of “Controlled Release”. This has been defined as the technique by 
which drugs are made available to a target site, at a rate and duration so as 
to produce a desired effect with minimum inconvenience to the patient. The 
objective is to maintain the desired concentration level. In some situations, it 
implies the delivery of drug more promptly for short periods (pulsed and 
circadian rhythm), 44 while at times prolongation of drug levels are necessary. In 
the latter case, terms such as ‘^ prolonged” or “sustained” release are employed. 
This designates only one aspect of controlled release, that is the production of 
protracted levels of drug. Controlled release implies predictable and reproducible 
release profiles, relatively independent of environment. This gives rise to a 
higher degree of control than achieved in sustained release formulations. 42 
Generally, available sustained release preparations offer some degree of 
“controlled” release but the control is incomplete, with few systems releasing 
drug at zero-order rate.
43
Figure 1.5:- Typical Drug Levels in Blood versus Time Profiles for 
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1.5.1 Oral Controlled Release Drug Delivery
A discussion of oral controlled drug delivery would be incomplete without
consideration of the gastrointestinal tract (GIT) and its advantages and 
disadvantages as a drug delivery route, since the majority of medicaments are
taken per-orally. The GIT is divided into four major parts namely:- (a)
oesophagus, (b) stomach, (c) small intestines and (d) large intestines/colon. All 
systematically acting drugs taken orally have to pass through epithelial cell 
layers to reach the target tissue or organ in order to elucidate the desired 
pharmacological effect. Different parts of the GIT have different cell types
which produce different micro-environments, due to cellular secretions. All this 
pose a challenge for drugs targeted to these GIT regions for absorption. The 
period that a dosage form remains in each region depends on the local motility
of that region. Total GIT transit time vary from 10-60 hours. 45
1.5.1.1 The Oesophagus 
Contact with the oesophagus is usually relatively short, (10-14 seconds), though 
in some pathological conditions such as achalasia, there can be prolongation of 
food bolus or dosage forms. In normal subjects, transit of heavy capsules is 
relatively faster than lighter capsules.46 Retention of a formulation in the 
oesophagus can lead to delayed drug absorption. 47 Generally, liquids are cleared
faster than solids in the oesophagus. Tablets or capsules taken in the supine
position could stick on the oesophageal wall. 48-50 Factors that predispose a 
formulation to adhere are shape and size of dosage form, position of subject, 
volume of water taken with the dosage form, and surface characteristics of the
45
formulation.48,51
1.5.1.2 The Stomach 
The stomach temporarily stores food and slowly releases it into the duodenum. 
It is divided into the fundus, body, antrum and pylorus. Each has a different 
physiological function. The body has mucous cells which produce mucous, 
parietal (oxyntic) cells which secrete gastric acid and the intrinsic factor, chief 
(peptic) cells which secrete pepsinogen and G cells which secrete gastrin. Other 
enzymes secreted include gastric lipase, gastric amylase and gelatinase. In the 
fasted state, gastric pH of healthy people ranges from 1 to 2.5 and a meal can 
increase this to 3 - 5 .52
Very little drug absorption occurs in the stomach, hence retention of drug here 
delays drug absorption in the small intestines. Gastric emptying is a major 
factor controlling the absorption of all the materials entering the body through 
the oral route. Gastric emptying, pH and motility are functions of variables 
such as diet, health, and medication. The behaviour of a dosage form in the 
stomach depends on the absence/presence of food. Liquids are generally 
emptied faster than solids. 53 Large monolithic units such as tablets and 
capsules, when given to fasted individuals, have variable gastric emptying times 
ranging from 5 minutes to 3 hours, as these rely on the inter-digestive 
migrating myoelectric complex (housekeeper waves) to effect emptying. 54-56 
Some studies51' 58 suggest a mean gastric emptying time of approximately 1 
hour, in fasted individuals and this lies within the range quoted above. When
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large monolithic units are given to healthy individuals after a light meal, gastric 
emptying is more predictable at around 2-3 hours.59 Multi-particulate or pelleted 
systems empty from the stomach as a continuous series of small boluses. 60
1.5.1.3 The Small Intestines 
The small intestines are approximately 5 - 6  metres long and can be divided 
into three major regions, namely:- (a) duodenum (20 - 30 cm long); (b) jejunum 
(= 2.5 m long); and (c) ileum (= 3.5 m long). The main function of the small 
intestines is to mix food with enzymes so as to facilitate digestion and 
absorption over its large surface area enhanced by numerous villi and an ample 
blood supply. Unabsorbed material is propelled to the colon. The duodenum 
contains Brunner's glands which secrete an alkaline (bicarbonate) secretion to 
neutralise the gastric acid. The jejunum is thicker walled and more vascular 
than the duodenum, and has more villi than the ileum The ileum has larger 
and more lymphatic follicles (Peyer's patches) than the other 2 regions. 
Intestinal cells found in all the three regions, secrete an intestinal juice called 
succus entericus, which has a pH of 7.5-8.0. The enzyme of importance in this 
juice is enteropeptidase which converts trypsinogen to trypsin.
The small intestines also receive the pancreatic juices (alkaline fluid plus 
enzymes) via the pancreatic duct, and the biliary secretions (bile acids, 
phospholipids, cholesterol and bilirubin) via the bile duct. Proximal jejunum pH 
lies within the range 5.0-6.5, rising slowly along the length to reach pH 6-7,
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although values as high as 7-9 have occasionally been found. 61 Transit times 
through the small intestines range from 1-6 hours, 62'64 with a mean of 3±1 
hours 56,64 irrespective of fed or fasted state of subject and type of dosage 
form. It is generally agreed that the majority of drugs taken per-orally are 
absorbed in the small intestines.
1.5.1.4. The Colon
The large intestine/colon is responsible for the conservation of water and 
electrolytes, the formation of solid stool and storage until a convenient time for 
defecation. The colon extends from the ileo-caecal junction to the anus and is 
approximately 125 cm long in vivo. It comprises the caecum, ascending 
(proximal), transverse, descending (distal), sigmoid colon, rectum and anus as 
shown in figure 1.6. The caecum is the widest part, approximately 8.5 cm long 
and has a pH of 6.4 ± 0.4. The proximal colon is approximately 20 cm long 
and extends from the caecum to the hepatic flexure. The transverse colon is 
normally over 45 cm long and hangs loosely between the hepatic and splenic 
flexures. The distal colon extends downward from the splenic flexure and is 
approximately 30 cm long. The sigmoid colon is approximately 40 cm and joins 
to the rectum which is approximately 12 cm which in turn is connected to the 
approximately 3 cm long anal canal.
The mean pH in the colonic lumen is 6 .4±0.6  in the proximal colon, 6 .6 1 0 .8  
in the transverse colon, and 7.0 10 .7  in the distal colon. 65 Disease states such 
as cystic fibrosis, or diet may alter differences in pH between the proximal and
48





















distal colon. Total colonic transit time ranges from 22-36 hours.45’62,66 Transit 
time through the proximal colon (caecum to mid - transverse colon), distal colon 
(mid - transverse to sigmoid colon), and sigmoid colon is approximately 7-11 
hours, 9-11 hours, and 12.5-18.5 hours respectively. 45,62
The colon contains up to 400 different microflora species. The most prevalent 
anaerobes are the Bacteroides sp. and Bifido-bacterium, while aerobes are 
enterococci and Lactobacillus. The major site of bacterial activity is the caecum 
where anaerobic bacteria ferment substrates in a liquid mixture. Bacteria make 
up to 30 % of faecal dry weight. Colonic bacteria possess exocellular enzymes 
(Upases) capable of hydrolysing fatty acid esters at the 1 & 3 positions of the 
triglyceride molecule. They also produce enzymes capable of metabolising long 
chain fatty acids such as oleic acid. Oleic acid is hydroxylated to 
hydroxystearic acid. Stilboestrol, morphine and indomethacin are excreted in bile 
as inactive sulphates or glucuronic acid conjugates. These conjugates are 
metaboHsed by bacterial enzymes in the colon, which release the active forms, 
hence prolonging their pharmacological activity via this enterohepatic loop. 65
The colon has attracted interest as a site where drug molecules that are poorly 
absorbed from the smafl intestines may have an improved bioavailabihty and for 
local action of drugs such as aminosahcylates and corticosteroids for the 
treatment of ulcerative coHtis.56,66 It is recognised as having a less hostile 
environment than the stomach and the smafl intestines, 66,67 hence an ideal 
target site for protein and peptide absorption. 68-73 In addition, the colon has a
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longer retention time and appears to be highly responsive to agents that 
improve the absorption of poorly absorbed drugs. 66 The colon has its 
drawbacks as a drug delivery site, which include:- (a) consolidation of faecal 
matter after the hepatic flexure which increases the viscosity of the luminal 
contents, hence drug entrapment, (b) reduced surface area, (c) low dissolution 
fluid volume, (d) reduced epithelium permeability to polar compounds and (e) 
the presence of bacterial enzymes and toxins. 65 However, it is believed that 
these concerns are easier to deal with than the exhaustive destruction of drugs 
within the stomach and small intestines due to acidity in the former and 
enzymes in the latter. 66
1.5.1.4.1 Colonic Drug Delivery 
Specific drug delivery to the colon is becoming increasingly important for the 
local treatment of conditions such as inflammatory bowel disease. 74 Such 
targeting can lead to improved efficacy and reduction in systemic side effects. 
Drugs can be delivered to the colon either orally or rectally. Rectal delivery, 
although it avoids many of the drawbacks of oral colonic delivery, it is 
recognised as less appealing. Rectal preparations often fail to reach even the 
transverse colon. 75 The spreading of an enema solution within the colon is 
highly variable even in healthy subjects. 75 Therefore attention will be focused 
on oral drug delivery to the colon.
Successful oral colonic drug delivery implies that the drug or drug delivery 
system reaches the proximal colon at a precise time, which minimises drug loss
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due to acidity and enzymatic activities in the stomach and small intestines 
respectively or complex formation within the faeces in the distal colon. 66 Such 
a system could be realised by the utilisation of site specific chemical or 
physical signals such as enzyme concentrations or pH values. A time controlled 
drug delivery system could be manufactured, in which the drug release profile 
corresponds to transit times through certain parts of the GIT. A combination 
of time and signal dependent release mechanisms is even more desirable. For 
example, a controlled release dosage form can release drug after 5 hours, when 
the device can be assumed to have arrived in the colon. pH sensitive coatings 
such as the Eudragits can protect the drug until its arrival in the colon or 
microbial enzymes predominantly present in the colon, can be exploited in site- 
specific drug delivery to the colon.76
Rao and Ritschel77 developed a per-oral system for the delivery of vasopressin, 
a polypeptide hormone, utilising a combination of pH-dependent and time- 
controlled release mechanisms. They used the polymers Eudragit® NE 30 D, 
Eudragit™ S100 and cellulose acetate phthalate to coat the delivery system. 
The system was designed to have a lag time of 6 hours, thereafter, vasopressin 
was released at a maximum rate between 6 and 7 hours which corresponds to 
colonic arrival time of 6.5 hours in the rat.
A significant drawback to practical colonic drug delivery is inter- and intra­
patient variability in GI transit times, with much variability arising from gastric 
residence times. GIT transit times for males and females differ slightly, with
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emotional stress altering this. 66 Neuroactive substances such as enkephalins, 
cholecystokinin, neurokinin A, and substance P affect colonic smooth muscles, 
hence colonic residence time. Fluctuations in colonic residence time could be 
overcome by the use of bioadhesives in the formulations. 66,78
Pro-drugs could be used to target drugs to the colon, such as the delivery of 
5 - aminosalicylate (5-ASA) by the use of the pro-drug sulphasalazine. 
Sulphasalazine undergoes azo-reduction by colonic resident bacteria to give 5- 
ASA and sulphapyridine. Anthracene laxatives can be converted by colonic 
bacteria into active sennosides.72
Drug granules have been coated with polymeric materials such as methacrylates 
to improve colonic delivery. 79 Azo-polymeric systems whereby the drug has 
been covalently or non-covalently entrapped within the matrix have been used 
with the intention of utilising colonic bacteria and their enzymes to release the 
drug by breaking down the matrices. For example, Brondsted and Kopecek 76 
synthesised novel hydrogels based on cross-linked azo dyes. The cross-links 
were degradable by microbial azo-reductases predominantly present in the colon, 
hence the gels appeared to be suitable for colon-specific drug delivery. The 
degree of degradability in vitro and in vivo was found to be related to the 
degree of swelling of the gels, structural and electronic factors. High faecal 
enzymatic degradation in high degrees of swelling in azo-polymers was also 
noted in some studies.68 This was attributed to a high accessibility of the 
azo bonds by the bacterial azo-reductase. Van den Mooter e ta l  80 prepared
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on-cross-linked azo polymers which were insoluble in simulated gastric and 
intestinal juices, for colon-specific drug delivery. Microbial degradation of these 
polymers was found to be dependent on the hydrophilicity of the azo polymer.81
Colonic microbial controlled drug delivery has also been attempted with varying 
degrees of success. 69’ 71’ 72, 74, 82 However, use of pro-drugs or bacterial 
degradable matrices, depending on colonic bacteria and their enzymes to do the 
conversion to the active drug form or to release the entrapped drug from the 
matrix, is fraught with problems. This is so because colonic bacterial population 
is a function of diet, health and some antibiotics. 65
Polyacrylic polymers which release incorporated drug molecules when the pH 
rises above 7 have been proposed as a potential colonic delivery system This 
was based on the assumption that there is a shift in pH from slightly acid to 
slightly basic at the ileocecal junction. However, studies suggest that the pH 
might actually decrease in the colon. 66 Macromolecular drugs such as peptides 
and proteins could have their absorption in the colon enhanced by the 
incorporation in the formulation of absorption enhancers such as citrates, non­
steroidal anti-inflammatory drugs (NSAJDS), surfactants and phenothiazines. 66,68
Acute and chronic colonic pathological conditions can affect drug delivery to 
the colon. For example, acute diarrhoea and increased muscular activity can 
reduce colonic transit time and hence decrease drug absorption. In summary,
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colonic drug delivery has attractive aspects such as:- (a) prolonged residence 
time of luminal contents, (b) reduced epithelial enzymatic activity, (c) increased 
tissue responsiveness to absorption enhancers and (d) natural absorptive 
characteristics.
1.5.1.5 Types of Materials Used for Oral Controlled Release Systems 
The majority of per-oral controlled release systems are made from either 
hydrophobic inert or hydrophilic materials.
1.5.1.5.1 Hydrophilic Systems 
Hydrophilic materials/polymers are widely used for oral controlled drug 
administration. 72,83 88 On contact with the dissolution medium or body fluids, 
these devices swell by polymer hydration and chain relaxation, forming a gel 
layer coat around a dry central core, with the two domains well defined. 83
Usually, the swelling of these hydrogels, such as the cellulose ethers, is
influenced by cross-linking, heat treatment, pH, temperature and polymer 
substitution type. 86 The hydrated surface layer forms a barrier to drug release
and further fluid ingress and is a viscous pseudo-gel.
Usually, the amount of drug released from these matrices is linearly related to 
the exposed external surface of the swollen matrix, with drug release kinetics 
sometimes dependent on the swelling kinetics. It is believed that the formation 
of the gel layer can be critical to the success or failure of the dosage form as 
a sustaining release device.83 Hydrogels can deliver drug at a predetermined
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rate for a defined period of time. 84 Mechanistically, it is believed that there 
are two distinct synchronised processes, polymer swelling and its true 
dissolution, that result in hydrogels releasing drug via zero order. 85 This 
synchronised front behaviour was reported for several hydrophilic glassy 
polymers such as polyvinyl alcohol and sodium carboxymethylcellulose (Na 
CMC) and for hydrophobic glassy polymers such as polymethyl methacrylate. 85 
A wide variety of different hydrogel materials have been described for use in 
controlled release. Some of these are synthetic while the majority are semi­
synthetic and natural, such as cellulose ethers, modified starches and the 
alginates. 88 The anionic polysaccharidic materials, A,-carrageenan and xanthan 
gum are also hydrophilic hydrogels which hydrate even at low pH values such 
as those found in the stomach.89
Rajabi-Siahboomi and co-workers 83 studied the swelling of hydrating 
hydroxypropylmethyl cellulose (HPMC) by NMR spectroscopy. They found out 
that hydration at the edges of the compacts occurred to a greater extent than 
the centre tablet surfaces giving rise to a convex shaped hydrated layer. 
However, gel layer development occurred to the same extent in both axial and 
radial directions and was similar in all the HPMC types examined. The 
predominately axial swelling of all the HPMC types examined was a result of 
the growth of the hydrated surface gel layer and expansion of the ungelled 
tablet core.
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Fernandez Degiorgi and co-workers 84 incorporated ampicillin into the hydrogel 
2-hydroxyethyl methacrylate (HEMA) produced by radiation polymerisation from 
its monomers. In-vitro release of ampicillin from the hydrogel was carried out. 
The drug-hydrogel tablets and “bullets” were also administered to dogs at a 
dosage of 20 mg/kg body weight. Drug release from the insoluble HEMA 
hydrogel was proportional to the square root of time according to the Higuchi 
equation. Bioavaiiability of the tablets and bullets was 44.2 % and 84.3 % 
respectively. The hydrogel did not produce toxic effects on cellular cultures or 
test animals.
Pham and Lee 85 investigated the synchronised dynamic swelling and dissolution 
behaviour during drug release from HPMC matrices using fluorescein as a 
model drug. They designed a flow through cell in order to provide a well 
designed hydrodynamic condition. They found out that there was a continuous 
increase in transient gel layer thickness irrespective of polymer viscosity grade 
or drug loading. This, they attributed to the faster rate of swelling solvent 
penetration than that of polymer dissolution (polymer chain disentanglement). 
However, over a longer period of time there was a shrinkage of matrix 
diameter confirming that polymer dissolution does indeed occur in HPMC 
matrices. The rates of polymer swelling and dissolution as well as the 
corresponding rate of drug release increased with either high levels of drug 
loading or low viscosity grades of HPMC. However, the two researchers 
concluded that the effect of HPMC dissolution on drug release was insignificant
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with release kinetics mostly regulated by a swelling-controlled diffusion process. 
This was most notable with high viscosity grades of HPMC.
Wan and co-workers 86 examined the kinetics of HPMC-propranolol matrices’ 
swelling according to the coupled Case I (Fickian) - Case II (Relaxational) 
equation. Previously, W an90 had described the swelling of HPMC-ibuprofen 
matrices according to first order kinetics. However, the former matrices 
deviated significantly from this square root of time relationship. Taking a as 
the original thickness of the dry matrix and s as the thickness of the swollen 
matrix, the above workers normalised the increase in the matrix thickness as a 
percentage, 8, which was used as a swelling index where:-
8 = (s-a) l a y  100 % equation 1.7
They analysed the dynamic swelling of the matrix as a function of time, t, 
according to:-
log 8 = ns log t + c2 equation 1.8
where 8 is as defined in the previous equation and ns is the exponent 
describing Fickian or anomalous swelling mechanism and C2 a constant. The 
swelling mechanism of HPMC-ibuprofen matrices in pH buffer solution was
approximately Case I (Fickian) with ns clustering around 0.5. For HPMC-
propranolol matrices, the swelling mechanism in water became non-Fickian with 
increasing amounts of HPMC thus indicating the importance of Case II
relaxational mechanism In order to ascertain the importance of the two
swelling mechanisms it was decided to consider that the swelling of the 
matrices depended on two processes:- liquid diffusion into the matrix and
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polymer swelling due to the penetrant. Approximate contribution of the two 
mechanisms was carried out by fitting the data on the second order equation 
analogous to that proposed by Peppas and Sahlin, 91 for release from swellable 
matrices. This second order polynomial equation gave the best data fit.
1.5.1.5.2 Hydrophobic Systems 
Hydrophobic, inert materials are usually used to prepare reservoir and 
monolithic oral controlled release devices. Like hydrophilic devices, they can be 
made from synthetic, semi-synthetic or natural origin materials. Oral controlled 
drug delivery systems made from hydrophobic inert materials do not generally 
interact with the dissolution medium or GIT fluids. This implies a 
predominantly difiiision-controlled mechanism of drug release from them .92
Reservoir devices consist of a drug core surrounded by a polymeric membrane 
such as ethylcellulose, with difiiision of the dissolved drug through the polymer 
as the rate limiting step. In monohthic/matrix devices the drug can either be 
dispersed as a separate phase or dissolved within the hydrophobic inert 
material. Release occurs via diffusion through the matrix or the environmental 
fluid may leach the drug out of the matrix. 92 In matrix devices, diffusion of 
the dissolved drug out of the matrix or diffusion of the drug through the 
polymer, is the rate limiting step. Due to the increase in the difiusional 
distance with time in such matrices, drug release rate is not constant in relation 
to time but rather release follows a square root of time dependency.
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In order to produce hydrophobic inert oral controlled release tablets, opium 
alkaloids such as morphine salts were homogenised with a fatty acid or its salt 
and ethylene vinyl acetate copolymer and compressed into tablets. In vitro 
dissolution studies of these tablets produced release profiles over extended 
periods of time. 93 In the same paper hydrogenated oils and polymeric 
substances were used to formulate long acting tablets for water soluble drugs 
such as diltiazem In this case, HPMC phthalate, a hydrogenated oil, lactose, 
hydroxypropyl cellulose and magnesium stearate were used to prepare the 
sustained release diltiazem hydrochloride tablets.
A once a day dose tablet formulation for diltiazem hydrochloride was prepared 
using hydrogenated castor oil and stearic acid as the hydrophobic release 
controlling fillers. The drug was mixed with lactose, hydrogenated castor oil 
and stearic acid and heated to 60° C then cooled and granulated with Na CMC. 
Tablets produced from these granules released more than 60 % of the drug 
within 5 hours during in vitro dissolution studies.93
Another sustained release hydrophobic oral system was made from glyceryl 
monostearate, sugar, MCC, PVP and magnesium stearate, with diltiazem 
hydrochloride as the drug. Its in vitro dissolution results gave release profiles of 
96 % after 24 hours. 93 The release was further delayed by coating the tablets 
with water insoluble polymers such as ethylcellulose or enteric polymers such as 
cellulose acetate phthalate or both.
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El-Shanawany94 prepared a hydrophobic oral controlled release system from 
stearic acid and glyceryl mono stearate, with nitrofurantoin as the drug. 
Granules were prepared by either fusion, solvent evaporation or melt 
granulation. The researcher also evaluated the effect of materials such as 
Aerosil, MCC and Emcompress on drug release of the matrix. Granules 
prepared by the fusion method had the best release - sustaining characteristics. 
Aerosil, MCC and Emcompress increased drug release rate with release 
following the Higuchi mechanism of release at low concentrations (0 and 5 %) 
and primarily following first order release kinetics at 10 % concentration. In 
vivo studies revealed that urinary excretion of nitrofurantoin from the test 
granules occurred over 2-8 hours post oral administration.
Bansal and co-workers 95 directly compressed a mixture of castor wax and 
hydrogenated vegetable oil (HVO), in an optimised ratio of 1:1, based on bulk 
density, particle size distribution and compression properties, to form inert wax 
matrix tablets. As drug they used chloramphenicol maleate. Increase in 
compaction force resulted in tablets with higher strengths up to approximately 
80 N. Further increase in compaction force resulted in a decrease in strength 
with apparent capping. Drug release was independent of tablet strength, shape 
and paddle rotational speed. Release was proportional to the square root of 
time. These results are in agreement with those obtained by Lockwood 96 and 
Ramzan97 from HVO compacts.
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Juul Thomsen et a l 98 prepared hydrophobic pellets by melt pelletisation using 
paracetamol, glyceryl monostearate and MCC wax. 90 % of the pellets were 
approximately 500-1 400 pm in size. In vitro dissolution studies resulted in drug
release over prolonged periods of time.
Kaewvichit and Tucker99 studied the release of the macromolecule, bovine
serum albumin (BSA), from a hydrophobic fatty acid matrix, stearic acid. They 
analysed the results in terms of BSA particle size (factor A), stearic acid 
particle size (factor B), BSA loading (factor C), compaction force (factor D) 
and the various interactions of the four factors. Drug release studies were done 
over 64 hours in an isotonic phosphate buffer pH 7.4 at 37° C.
Factors A, B and C were found to affect drug release. However, factor D was 
found to have no effect on release and this agreed with the results obtained by 
Bansal et a l 95 where they found out that compaction force had no significant 
effect on chloramphenicol maleate release from a hydrophobic matrix. 
Interactions AB, BC and ABC were found to highly affect drug release from 
the matrices. At low drug loading (5 %), surface release depended on BSA
particle size with release increasing with an increase in the drug particle size. 
At high drug loading (20 %), release increased with an increase in stearic acid 
particle size. This was probably due to the formation of a complete inter­
connected pore network which resulted in simpler pathways (low tortuosity) 
and greater porosity for diffusion while at lower loading the converse was 
true. When stearic acid particle size was small (63 -125 pm) and drug particle
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large (250-500 pm) there was an overall increase in release.
Kaewvichit and Tucker" proposed that release of the macromolecule from the 
hydrophobic monolithic system occurred through an inter-connected tortuous 
pore network. This was created by solid drug particles initially present in the 
matrix and the void space between stearic acid particles. The pores were 
randomly distributed within the matrix. The void spaces were believed to vary 
according to particle size - dependent arrangements of stearic acid and BSA 
particles.
Pentoxifylline release from hydrophobic waxy materials (palmitic and behenic 
acids) was evaluated by Otsuka and Matsuda. 100 The matrix tablets were 
prepared via co-grinding of the drug-wax and tableting. The hydrophobic waxy 
tablets produced formed a monolithic controlled release system, except for 
tablets prepared from the unground mixture which disintegrated with time. Drug 
release was proportional to square root of time according to the Higuchi 
equation.
Ibuprofen release from spherical hydrophobic cetostearyl alcohol matrices was 
analysed according to four release mechanisms namely:- (a) first order 
mechanism (b) Higuchi mechanism (c) Baker and Lonsdale model and (d) Hixson 
and Crowell cube-root equation by simulation. 101
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First Order Model:- where drug activity within the matrix is expected to 
decrease exponentially, with rate of drug release proportional to residual 
activity.
logio(100 % -Q) = kt equation 1.9
where Q is the amount (%) of drug released at time t.
Higuchi Model:- is used to describe drug release irrespective of shape of
device.
Q = k t1/2 equation 1.10
where Q and t are as above
Baker and Lonsdale Model:- where drug is dispersed within a spherical
diffusion rate-limiting matrix.
3/2 [1-(1-Qf)“ ] - Qt= kt equation 1.11
where Qfis the fraction of drug released at time t
Hixson and Crowell Equation:- describes release from systems which show 
dissolution-rate limitation and do not dramatically change in shape as release 
proceeds.
(1-Qf)1/3 = 1-kt equation 1.12
where Qfand t are as above 
The cube root model and the first order model gave satisfactory fits to the 
data although both simulations produced extents of release higher than those 
predicted for the small particles (212±54 tun). For the large particles (8621334
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pm) the simulated values were above the experimental ones especially at low 
drug release levels. The square root model and the Baker and Lonsdale models 
described the release data poorly. The experimental release data of tablets made 
from equal weight of small particles and large particles and the simulated data 
mirrored each other closely, particularly with the Hixson and Crowell cube root 
model. The researchers concluded that the particles probably behaved as 
contracting cubes in that as drug was released from the outer layers, the 
depleted layers provided relatively little diffusion resistance to drug release. 
This implied that although the particles were apparently intact at the end of the 
release process, they behaved as dissolving particles.
Pozzi et al 44 developed a per-oral controlled delivery system with a 
hydrophobic (canauba wax and white beeswax) and a surfactant 
(polyoxyethylene sorbitan monooleate) coat. They called it the “time clock” 
system The hydrophobic-surfactant layer was applied as an aqueous dispersion 
to which a hydrosoluble polymer (HPMC) was added to improve adhesion to 
the core. Cores were made as follows:- lactose, samarium oxide and dye or 
lactose and salbutamol sulphate were manually granulated with an aqueous 
solution of PVP. Cores containing samarium oxide and the dye, E l 10, were 
used for scintigraphic evaluation and in vitro dissolution characterisation while 
those containing salbutamol sulphate were for pharmacokinetic evaluation. After 
drying and sieving of the granules, magnesium stearate and com starch were 
added prior to compaction. The coat was applied post-comp action in a fluid 
bed.
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The above system was able to release drug after a predetermined lag time 
which was independent of normal physiological conditions such as pH, digestive 
state of subject and the anatomical position at the time of release. At the 
end of the lag time, disaggregation of the core was both rapid and 
complete. Such a system could be ideal for colonic drug targeting. The lag 
time would be equivalent to gastric residence time plus small intestine transit 
time. The rapid drug release post lag period is desirable for GIT areas such 
as the proximal colon which have reduced epithelial drug absorption due to 
reasons mentioned in section 1.5.1.4.1.
The types, classifications, characteristics, advantages, disadvantages and ideal 
attributes of various oral controlled drug delivery systems available have been 
described extensively by Merkus, 42 Fan and Singh. 92
1.5.1.6 Difiiision in Polymers 
Diffusion can be defined as a process of mass transfer of individual molecules 
of a substance, brought about by random molecular motion. It is associated 
with a concentration gradient. Diffusion has always been analysed in terms of 
Fick's first and second laws. Fick's first law states that the amount, M, of a 
material flowing through a unit cross section, S, of a barrier in unit time, t, is 
known as the flux, J.
=> J = dM / Sdt equation 1.13
The flux in turn is proportional to the concentration gradient, dC/dx.
=> J = -DdC/dx equation 1.14
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where D is the difiiision coefficient of the diffusant, C is the concentration of 
the diffusant and x is the distance of movement perpendicular to the surface of 
the barrier. The negative sign indicates that diffusion occurs from a region of 
higher concentration to a region of lower concentration. D does not necessarily 
remain constant as it may change at higher concentrations and is affected by 
factors such as temperature, pressure, solvent properties and chemical nature of 
the diffusant. In diffusion the natural assumption is that the driving force is the 
concentration gradient.
Fick's second law of diffusion examines the rate of change of diffusant 
concentration at a point in the system The equation's emphasis is on the 
change in concentration with time at a definite location. The concentration of 
diffusant in the volume element changes with time, AC/At, as flux or amount 
diffusing changes with distance, AJ/Ax, in the x direction. Hence, Fick's second 
law states that:- the change in concentration with time in a particular region is 
proportional to change in the concentration gradient at that point in the system 
=>dC/ dt  = - 3 J / d x  equation 1.15
Differentiation of equation 1.14 with respect to x results in:-
-dJ / dx = D d C / dx equation 1.16
Substituting dC / di from equation 1.15 into equation 1.16 results in:-
dC / dt = D d C / dx equation 1.17
Equation 1.17 represents diffusion in the x direction only. In order to express 
concentration changes of diffusant in three dimensions, Fick's second law is 
written in the general form:-
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=> 3C / dt = D (d C / dx + d C / dy + d C / d z )  equation 1.18
1.5.1.6.1 Drug Release in Matrix Type Delivery Systems Such as HVOs 
Higuchi 102 offered the first model for release from these types of devices. In 
such devices the drug is homogeneously dispersed in the matrix as discrete 
crystals or solid particles. It is believed that drug molecules can elute out of 
the matrix only by dissolution in the environmental fluid and then difriision 
through the polymer porous structure. The drug solids in the layers close to 
the surface of the device elute first, and when this is exhausted, the drug in 
the next layer then begins to be depleted. This is schematically illustrated in 
figure 1.7. As the drug is released the diffusional distance becomes increasingly 
longer.
From Fick's first law:- 
dM / Sdt = dQ / dt = DCS / h equation 1.19
where dQ / dt is the drug release rate per unit area of exposed surface of 
matrix. As the boundary between drug matrix and the drug depleted zone 
recedes with time, the thickness of the empty matrix, dh, through which the 
drug diffuses increases with time, h is the hydrodynamic/static diffusion layer, 
while Cs is the solubility or saturation concentration of the drug in the matrix 
and A is the total concentration (amount per unit volume), dissolved and 
undissolved, of the drug in the matrix. As the drug passes out of the matrix 
the drug boundary represented by the vertical dotted line moves to the left by 
a very small (infinitesimal) distance, dh. The infinitesimal amount, dQ, of drug 
released is approximately:-
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NB:- (a) Heterogeneous granular matrix after drug has been leached out 
(b) Schematic illustration of matrix and receding boundary as drug 
diffuses from dosage form
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dQ = Adh - l/2Csdli equation 1.20
dQ of equation 1.20 is substituted into equation 1.19:-
=> (A - l/2Cs)dh = DCsdt / h equation 1.21
Integration of equation 1.21 results in:-
(2A - Cs) / 2DCS J h db = \ dt equation 1.22
=> t = {(2A - Cs)h / 4DCS} + C equation 1.23
The integration constant, C, can be evaluated at t = 0, when h = 0, giving: -
t  = (2A - Cs)h / 4DCS equation 1.24
1/2
h = {4DCst / (2A - Cs)} equation 1.25
The amount of drug depleted per unit area of matrix, Q, at time t, is obtained
by integrating equation 1.20 to yield: -
Q = hA - l/2hCs equation 1.26
Substituting equation 1.25 into 1.26 produces:-
1/2
Q = {DCst / (2A - Cs)} (2A - Cs) equation 1.27
1/2
=> Q = {D (2A - Cs)Cst} equation 1.28
Equation 1.28 is known as the Higuchi equation which can simply be written as:- 
Q = kt1/2 equation 1.10
Drug release rate at time t is obtained by differentiating equation 1.28 with
respect to t, to obtain:-
1/2
dQ/dt = 1/2{D(2A - CS)CS / 1} equation 1.29
Generally, A » C S, and equation 1.28 reduces to:-
1/2
Q = (2ADCst) equation 1.30
Equation 1.29 becomes: -
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1/2
dQ / dt = (ADCS / 2t) equation 1.31
Drug release from a granular matrix involves simultaneous penetration of the 
surrounding medium, after surface wetting, dissolution of the drug and leaching 
out of the drug through the interstitial channels/pores. The volume and length 
of the opening in the matrix is accounted for by a difiiision equation, which is
a second form of the Higuchi equation:-
1/2
Q = {D e/i(2 A -eC s)Cst} equation 1.32
In which e is the porosity of the matrix and t is the tortuosity of the
capillary system. Both terms are dimensionless. Porosity, e , is the fraction of 
the matrix that exists as pores into which the eluting medium can penetrate. It 
is the total porosity after the matrix has been leached of drug. This is equal to 
the initial matrix porosity, e 0, before leaching starts, and the porosity created 
by the extraction of the drug.
=> e = e G+ A ( l / p )  equation 1.33
where p is the drug's specific density. Since the initial porosity, e G, of
compressed tablets is very small relative to that created by dissolution and 
removal of the drug from the tablets, it can be estimated that:-
e = A / p equation 1.34
The tortuosity factor, t, accounts for the increase in the pathlength of 
diffusion, due to the branching and bending of the pores, compared to the
shortest “straight through” pores. Tortuosity tends to decrease drug release, 
while porosity tends to enhance drug release. Methods of obtaining factors such 
as tortuosity, porosity and diffusity have been described. 103 While equation
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1.28 is suitable for release from homogeneous tablets that gradually erode and 
release drug into the medium, equation 1.32 applies to drug release mechanism 
whereby the eluting medium enters the matrix, dissolves the drug before it 
diffuses out leaving a shell of matrix with empty pores. Such is the case of 
hydrogenated vegetable oils matrices. 96,97
1.5.1.6.2 Diffusion coupled with Relaxation 
Peppas and Sahlin 91 developed an equation coupling Fickian diffusion and 
relaxation contribution (Case-II) for drug release in controlled delivery systems. 
Case-II relaxation release is associated with stresses and state - transition in 
polymers. This equation was developed from a simple exponential expression 
shown below:-
Q= k tn equation 1.35
where Q is the amount of drug released at time t, k is a kinetic constant and 
n is the diffiisional exponent for drug release. This equation can be used to 
analyse the first 60 % of a release curve regardless of geometric shape of the 
delivery device. However, for a device releasing drug by both diffusion and 
relaxation, these two phenomena can be considered additive as shown below:-
Q = kitm + k2t2m equation 1.36
where the first term on the right hand side is the Fickian contribution and the
second term being the Case-II relaxation contribution. The coefficient m is the
purely Fickian diffusion exponent for a device of any geometrical shape which 
exhibits controlled release. Regardless of geometry of device, the value of the
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exponent for the Case-II relaxation mechanism is twice that of pure Fickian 
difiiision. The Fickian diffusion coefficient varies with the aspect ratio (diameter 
to height/thickness) of the device. For example, for a controlled release tablet 
of diameter 8 mm and thickness 2.8 mm, m « 0.46 and 2m « 0.92 thus resulting 
in>
Q = kit046 + k2t°92 equation 1.37
Equation 1.36 can be written as shown below: -
Q= kitm {1 + (k2/ki)tm} equation 1.38
Therefore the fraction of drug release due to Fickian mechanism, F, is>
F = 1/{1 + (k2/ki)tm} equation 1.39
Solute release from any device, irrespective of geometry, can be evaluated in 
terms of Fickian and relaxation contribution as indicated by equations 1.36 and 
1.37. m = n when relaxation mechanism is negligible. The diffusion-relaxation 
mechanism could be used in analysing drug release from some hydrophobic 
inert matrices such as HVO, which contain surfactants that facilitate erosion 
and/or relaxation of the matrices. In such cases drug releases often fail to 
follow pure Fickian diffusion.
Typical curves for zero order release mechanism (Q = kt), first order 
mechanism (logio(100 %  - Q) = kt), and Higuchi release mechanism (Q — kt1/2) 














































Figure 1,9;- Typical Curve for First Order Drug Release

























F igure 1.10:- Typical Curve for Square Root o f Time (Higuchi)










2.1 A im s  a n d  O b je c t iv e s  
Hydrogenated vegetable oils (HVO) matrices, like other controlled delivery 
systems, release drug predominantly by diffusion over long periods of time, 
without significant dimensional changes. 95 97 The drug release occurs through 
water filled tortuous pores within the matrices. Systems such as these, exhibit a 
gradual decrease in release rate with time, hence their non-linear concentration - 
time curves due to the longer distance that the drug in the deeper layers of 
the matrix has to travel to exit the matrix. Therefore such devices might 
actually deliver sub-therapeutic drug levels after extended periods of time. 
"Controlled" release partly implies reproducible drug delivery at a predetermined 
rate which may be constant. HVO matrices partly fulfil this aspect of controlled 
release.
For the maintenance of an optimum bioavailability over a prescribed period of 
treatment, the fraction of a drug dose released from a controlled release device 
and absorbed during a given time should be enough to compensate for the 
active drug species metabolised and/or excreted from the body during the same 
period. This is determined by the rate of drug release from the device. In most 
situations a constant rate of drug release (zero order) is presumed to be
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optimal. For most oral controlled release devices, the rate o f  drug release and 
not the rate o f  drug absorption or removal is the rate limiting step. Altering 
the geometry of devices such as HVO matrices to achieve zero order release 
has been attempted by some researchers. 96,104 106 The basic principle involved in 
these cases was to coat a matrix completely with a water impermeable 
polymer. A circular hole was made in the middle of the flat face of the 
hemispherical device. As drug was released, the section of the device depleted 
of drug continued hemispherical in shape, constantly increasing in radius, hence 
increasing the area of drug available for diffusion. This compensated for 
increase in diffusional distance, making drug release constant. Staniforth 107 
invented a controlled release tablet with an impermeable membrane such as 
ethylcellulose, having an orifice, although the tablet was not necessarily 
hemispherical. Zero order release was achieved by altering the size of the 
orifice. However, the search for simpler methods of providing constant release 
rate still remains a challenge. Besides this, most designs of controlled delivery 
systems are a result of research work carried out in laboratories of commercial 
organisations, hence the majority are patented with their clinical data not 
readily available. 93
For drugs that cause down-regulation at the site of action or those to which 
patients might develop a tolerance over a period of time, such as morphine 
sulphate and nitrates, 44 oral controlled release devices that are designed for 
them, ought to be pre-programmed to release the active agent at gradually 
increasing release rates with time, so as to compensate for the tolerance. In
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some cases, a reduction of drug dosage also counteracts tolerance. When 
considering the proximal colon as a possible site for oral controlled release 
tablet targeting, an increasing release rate with time is desirable. This is so, 
because, as the formulation moves up the colon, the colonic contents gradually 
become viscous due to faecal consolidation. 66 More drug release per unit time 
will counteract this effect and probably maintain drug bioavailability.
A number of highly water soluble drugs such as diltiazem, captopril and 
morphine salts93 are readily absorbed in the proximal colon. However, these 
hydrophilic drugs are more difficult to deliver orally in sustained or controlled 
release manner than lipophilic drugs. This is due to their relatively short plasma 
half-lives which ranges from 2-4 .5  hours hence they require 3 -4 divided doses 
daily. Despite this, these hydrophilic drugs such as captopril, diltiazem 
hydrochloride and morphine sulphate are prescribed to chronically ill patients 
who require them for long periods in order to benefit therapeutically. Therefore 
sustained and controlled release systems for them, targeted to the appropriate 
site of the GIT such as the proximal colon, is desirable. Many attempts have 
been made to regulate highly water soluble drugs’ release by the incorporation 
of hydrophobic inert fillers such as ethylcellulose, hydrogenated castor oil, 
stearic acid and glyceryl monostearate. 93 Besides such water soluble drugs, 
proteinaceous drugs such as vasopressin, are probably better absorbed in the 
colon than in the stomach and small intestines. The acid in the stomach
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denatures the proteinaceous drugs, while the small intestines enzymatically 
degrade them. 66
Besides exhibiting decreasing release rates with time, HVO compacts have a 
low compact strength. 96,97 Due to the fact that HVOs probably partially melt 
and fuse to form compacts/matrices on compaction, the HVO adheres to the 
tablet tooling, impeding the tableting process. 96,97
Therefore the present study was aimed at:-
• Improving the tensile strength of HVO compacts.
• Reducing compact adherence to tablet tooling.
• Enhancing drug release of the HVO matrix.
• Using simple methods to alter the release mechanism of the HVO matrix to 
obtain:-
• zero order release,
• increasing release rate with time.
The overall aim was to formulate an oral controlled release system with 
adequate physico-mechanical properties capable of being targeted to the 
proximal colon.
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2.2  M a t e r ia l s
Sterotex K  (hydrogenated castor/soybean oil), Batch number 333360, supplied 
by Aston Chemicals Ltd, England.
Sterotex K is a hydrogenated vegetable oil (HVO), consisting mainly of 
glyceryl-tris-12-hydroxystearate 108 and mixed esters of long chain fatty acids. 
Such long chain fatty acids include:- stearic acid, 12-hydroxystearic acid and 
palmitic acid. Small quantities of free fatty acids are expected in Sterotex K as 
well. In the study, Sterotex K was used as the basic release - sustaining 
hydrophobic matrix material. It has a melting range of 62-88° C. 108,109 Its uses 
include:- (i) stiffening/hardening agent in some formulations, (ii) sustained release 
coating material, (iii) preparation of delayed release drug matrix and (iv) tablet 
lubricant. 108
PVP K-30 (polyvinylpyrrolidone), Batch number 90916, supplied by Dykem 
Chemicals, England.
PVP K-30 has a relative molecular weight of approximately 40 kDa and a 
softening point of about 150° C. 110 In pharmaceutical technology, it has the 
following uses:- (i) tablet binder, (ii) carrier for drugs, (iii) dispersing agent, (iv) 
suspending or viscosity builder, (v) coating agent and (vi) tablet diluent. 110 It is 
soluble in water and is hygroscopic. It was used as a binder in the study.
PVP K-90, supplied by Dykem Chemicals, England.
The relative molecular weight of PVP K-90 is approximately 360 kDa. 110 It has 
pharmaceutical uses similar to those for PVP K-30. Due to its high molecular
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weight, it produces higher viscosity solutions with water than PVP K-30 does. 
In the present study it was used as a binder as well.
Stearic acid (octadecanoic acid), Batch number 11H3414, supplied by Sigma 
Chemical Company, USA.
Stearic acid has been used as follows:- (i) tablet and/or capsule lubricant, (ii) 
enteric coating ingredient and (iii) emulsifying agent in ointments and creams. 112 
It usually contains some palmitic acid. 111 Interestingly, stearic acid has been 
used as a hydrophobic binder in direct granulation. 109112 it has a relatively low 
melting point range (51-69° C), 109, 111 which makes it susceptible to 
softening/melting during compression. 34 This partial melt-fusion characteristics of 
stearic acid reinforces compact strength. Therefore in the present study, it was 
primarily used as an "auxiliary" binder to PVP. It was also used as an anti­
adherent. Before use as an anti-adherent, it was passed through a 125 pm test 
sieve.
Propranolol hydrochloride, Batch number 3658, supplied by Industrie Chimiche 
Italiane.
Propranolol hydrochloride was one of the two drugs selected for the 
assessment of the release characteristics of the matrix because of its 
applicability to sustained release medication. It is a non-selective (3-adrenoceptor 
antagonist: therefore it is used as:- (i) an anti-hypertensive, (ii) anti-anginal and 
(iii) anti-arrhythmic drug. Due to its non-selectivity, it is contra-indicated in 
patients suffering from bronchospasm and diabetes. 113 Propranolol hydrochloride
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is readily soluble in water, with a maximum solubility of 5 % w/v. 114 It has a 
pKa of approximately 9.5. 114 It is UV-assayable, with probably the naphthalene 
ring as the main chromophore. Propranolol hydrochloride has a maximum 
absorbance at approximately 290 nm. 114
Theophylline, Batch number 102H0521, supplied by Sigma Chemical Company, 
USA; Batch number 5348833, supplied by Aldrich Chemical Company, England. 
Theophylline is used to relieve bronchospasm in asthma. 115 It is relatively 
cheap. Aldrich manufacturers stated that their sample was 99 % pure, while 
Sigma manufacturers stated that their sample was 90 % pure. Therefore the 
former was used in preparation of tablets for dissolution tests, while the latter 
was used in preparation of tablets for tensile strength evaluation. The Sigma 
sample was also used in the anti-adherent evaluations. Theophylline was 
selected because unlike propranolol hydrochloride, it is not so readily soluble 
in water. It has a maximum solubility of approximately 0.833%. 115 Like 
propranolol hydrochloride, theophylline is readily assayable by UV/visible 
spectrophotometry. It has a maximum absorbance at approximately 272 nm. 115
Compritol 888 ATO (glyceryl tribehenate), Batch number 18641-57-1, supplied 
by Gattefosse, France.
In the study, Compritol was used as an alternative release sustaining matrix 
material to Sterotex K and as an anti-adherent. Before use as an anti-adherent, 
it was passed through a 125 pm test sieve. Unlike Sterotex K, which is 
chiefly a Ci8 fatty acid ester, glyceryl-tris-12-hydroxystearate, 108 Compritol is
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mainly composed of a C22 fatty acid ester, glyceryl tribehenate. Compritol has a 
melting point range of 67-72° C. 109 It has the following uses:- (i) tablet 
lubricant5 and (ii) hydrophobic binder in combination with glyceryl monostearate 
in direct granulation. 109 It is relatively new and has been reported to be less 
prone to tablet strength and dissolution problems.5
Luviskol Batch number 05-7199-05, supplied by BASF, Germany.
Luviskol is a copolymer of polyvinylpyrrolidone and polyvinyl acetate. It is a 
tablet binder which is heat labile. It was used for this purpose in the present 
study.
Polyplasdone XL-10, supplied by Gaf Chemicals, USA.
Polyplasdone is cross-linked polyvinylpyrrolidone. This material has sometimes 
been termed "super-disintegrant" due to its excellent disintegrating properties. It 
is effective at 2-5 % concentration and has been reported to be an effective 
binder-disintegrant in tablets made by wet granulation. 15 It also appears to be 
more effective than other agents in disintegrating water soluble tablets though 
it is not soluble in water itself. In the present study it was used as a binder. 
Since it is water insoluble, it was gradually dispersed in the water with the aid 
of heat, while stirring with a spatula.
Magnesium Stearate, Batch number 9595340E, supplied by BDH Chemicals, UK 
Magnesium stearate is a well known, currently and most commonly used tablet 
and capsule formulation lubricant. 5,116 It is also used as a glidant and anti­
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adherent. It exist in two pseudo-polymorphic forms namely, trihydrate acicular 
form and dihydrate lamellar form .31 The latter form possesses greater lubricant 
activity than the former. In the study it was employed as an anti-adherent.
L -  Leucine, Batch number 001FKCK, supplied by Forum Chemicals, Ltd, UK 
Leucine is a white crystalline amino acid. It is one of a group of water 
soluble lubricants such as sodium benzoate, which find use in water soluble 
tablets such as lozenges. Leucine appears to be a better lubricant for ductile 
materials than for brittle ones. 31 Leucine sublimes at 145-148° C. 117 In the 
study, it was used as an anti-adherent. Before use, it was ground in a glass 
mortar using a glass pestle and then passed through a 125 pm test sieve.
Myverol 18 - 99, batch number D 1832-1092, supplied by Eastman Chemical 
Company, USA.
Myverol consists mainly of distilled monoglycerides of stearic and palmitic 
acids, with smaller quantities of di- and triglycerides of the same acids. 
However, Myverol also contains very small amounts of water, propylene 
glycol, phosphoric acid, glycerol and citric acid. It is a non-dispersible non-ionic 
agent with a melting point range of 53-61° C. 109118 It has the following uses:- 
(i) non-ionic emulsifier, (ii) stabiliser, (iii) emollient, (iv) plasticiser (v) anti-tack 
agent in a variety of food, pharmaceutical and cosmetic products 118 and (vi) 
binder in direct granulation. 109 In the study, Myverol was used to alter the 
drug release mechanism of the Sterotex K matrix.
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Some monoglycerides such as mono - olein have been known to form cubic 
phase structures in water at approximately 37° C. 119 These cubic phase 
structures release water soluble drugs in a sustained release fashion. Cubic 
liquid crystalline phases are common in surfactant and surfactant - like lipid 
systems at temperatures above the Kraffi; point. 120 They are transparent, viscous 
systems, with a wide range of stiffness. These systems are thermodynamically 
stable. Current proposals of cubic phase structures are:- (a) spherical aggregates 
(b) short rod like aggregates and (c) lamellar structures. 120 Structures in (a) 
and (b) could be either of the type ‘Svater-in-oil” or “oil-in-water” with units 
either closed or forming continuous networks.
Hydrogenated rapeseed oil, Batch number AVR 60, supplied by Anglia Oils 
Ltd, UK
This is another HVO, primarily containing stearic acid mono-, di-, and 
triglycerides. 121122 Small quantities of palmitic acid glycerides, trace amounts of 
behenic acid glycerides and the respective free fatty acids are also found in 
hydrogenated rapeseed oil. 121122 Like Myverol, hydrogenated rapeseed oil is a 
semi-solid with a relatively low melting point. In the study, it was used as an 
alternative to Myverol.
Imidazole, Batch number 81327, supplied by Aldrich Chemical Company, 
England.
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Imidazole is readily soluble in water. In the study, it was used in combination 
with hydrochloric acid to prepare biological buffer solutions used in the 
dissolution tests.
Hydrochloric acid (HC1), supplied by BDH Chemicals, England.
Hydrochloric acid was used in combination with either imidazole or potassium 
chloride (KC1) to prepare various biological buffer solutions used in the 
dissolution tests.
Potassium Chloride, Batch number 108551C294, supplied by Fisons, UK 
Potassium chloride, analytical grade, was used in combination with hydrochloric 
acid to prepare the biological buffer solutions used in the dissolution tests.
Aerosil® 200, Batch number 1084, supplied by Degussa, Germany.
2
Aerosil 200 is fumed silicon dioxide with a surface area of 200 ± 25 m /g and 
a particle size of approximately 12 nm. 123,124 It has siloxan (Si-O-Si) 124 and 
silanol groups (Si-OH) 124’ 125 on the surface of the particles. The latter are 
supposed to render it hydrophilic. Aerosils tend to form aggregates due to 
hydrogen bond formation via the silanol groups. 124 Aerosil 200, like all the 
other types of Aerosil, is used as follows:- (i) suspending agent, (ii) viscosity 
increasing agent, (iii) glidant, (iv) anti-caking agent, (v) flow conditioning agent 
and (vi) tablet disintegrant. 123 125 In the present study, Aerosil 200 was used as 
a carrier for Myverol, since the latter has a relatively low melting point and is 
very soft.
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Aerosil® R 974, supplied by Degussa, Germany.
Unlike Aerosil 200, Aerosil R974 is supposed to be a hydrophobic silica with 
Si - CH3 on the particulate surfaces. 125 These surfaces are chemically modified 
by treatment with organosilanes to change the hydrophilic nature to one which 
is predominantly hydrophobic. Aerosil R 974 has a mean particle size of 12 nm 
and a surface area of 170 ± 20 m2/g. It is used as a (i) glidant and (ii) 
thickening agent. 125 In the present study, Aerosil R 974 was used as a carrier 
for Myverol.
Sipernat® D17, Batch number 8629, supplied by Degussa, Germany.
Sipemat D17 is precipitated silicon dioxide, having siloxane groups (Si-O-CHy.
126 These groups are supposed to render it hydrophobic. Sipemat D17 is a free 
flowing powder. It has the following uses:- (i) anti-caking agent for powders 
sensitive to moisture and (ii) adsorbent and carrier in the feedstufifs industry. 126 
In the present study it was used as a carrier for Myverol.
Sipernat® 22, supplied by Degussa, Germany.
Sipemat® 22 is spray dried silicon dioxide with a high absorptive capacity and 
an optimised particle size spectrum Like Sipemat D17, Sipemat 22 is also 
used in the feedstuffs industry as a carrier for various solutions such as choline 
chloride solution. 126 It was also used as a carrier for Myverol.
Starch 1500, Batch number, 9046612C, supplied by BDH Chemicals Ltd, 
England.
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Starch 1500 is partially hydrolysed relatively free flowing maize starch. Its uses 
are as follows:- (i) tablet binder, (ii) tablet disintegrant and (iii) filler in direct 
compression at times. 15 In the present study, it was incorporated into the HVO 
matrix formulation so as to function as a drug release enhancer.
Avicel PH 102, Batch number 5814, supplied by Honeywill and Stein Ltd, UK 
Avicel PH 102 is partially agglomerated microcrystalline cellulose. It is derived 
from a special grade of purified alpha wood cellulose by partial acid hydrolysis. 
15 It has an average particle size of 100 pm. 127 Avicel is a well known direct 
compression filler-binder-disintegrant. 15 It mainly deforms plastically on 
compaction. 15,127 In the present study it had the same role as Starch 1500.
Eudragit S100, Batch number 05-80017, supplied by Rohm Pharma, Germany. 
Eudragit S is an anionic polymer synthesised from methacrylic acid and 
methacrylic acid methyl ester with an average molecular weight of 
approximately 135 kDa. 128 The ratio of the free carboxyl groups to the ester 
groups is approximately 1:2. It is insoluble in acids and pure water, rendering 
it an excellent enteric coat. It slowly dissolves in neutral to weakly alkaline 
solutions by forming salts with the alkalis. Eudragit S is soluble in solvents 
such as isopropyl alcohol, acetone and ethyl alcohol. Its uses include:- (i) 
enteric coat for capsules, tablets and pellets, (ii) protection of tablets and 
capsules against moisture, light and air, (iii) insulation of hygroscopic cores, (iv) 
isolation of porous cores and (v) controlled release coating film in combination
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with Eudragit L. 128 In the present study, Eudragit S 100 was used to enhance 
zero order release mechanism of the tablets.
Junlon PW110, supplied by Honeywill & Stein Ltd, UK
Junlon is a cross-linked polymer of acrylic acid known by the approved name 
carbomer. It is similar to Carbopol 934P. It has the following empirical 
formula:- -(C3H40 2)x. (-C3H5-Sucrose) - . 129 Junlon is soluble in water and is
very hygroscopic. It has the following uses:- (i) emulsifier (0.1-0.5 %), (ii) 
suspending agent (0.5-1.0 %), (iii) gelling agent (0.5-2.0 %), (iv) binder in 
sustained release formulations and (v) thickening agent in ointments and creams. 
129 In the present study, Junlon was used as an alternative drug release 
enhancer to Avicel and Starch 1500.
Lipase and Esterase, both supplied by Sigma Chemical Company, USA.
Lipase and esterase are both enzymes. Lipase was supplied as a lyophilised 
powder containing 25 units of enzyme per mg solid. One unit was supposed 
to produce 1.0 pmole of glycerol from a triglyceride per minute at pH 7.0 
and 37° C. Esterase was supplied as a crystalline suspension in ammonium 
sulphate (pH 8.5) with 100 units per mg protein. One unit was supposed to 
hydrolyse 1.0 jimole of o-nitrophenol butyrate to butyric acid and o-nitrophenol 
per minute at pH 7.5 and 25° C. In the study, both enzymes were used in an 
attempt to degrade the ester linkages of glyceryl-tris-12-hydroxystearate in 
Sterotex K so as to enhance drug release in relation to time.
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2.3 M e t h o d s
2.3.1 Preparation of Composite Excipients 
The term “composite excipient” is used here to mean a single 
powder/granulation used as a tableting excipient, but containing more than one 
inert ingredient. The composite excipients (CEs) described here, all have use as 
matrix controlled release tablet components.
2.3.1.1 Composite Excipients Containing l ess Than or Equal to Three Ingredients 
In each case (unless otherwise stated), either HVO or Compritol was processed 
with a binder and stearic acid. The binders used were either PVP K-30, PVP 
K-90, Luviskol or Polyplasdone. PVP K-30 was used at concentrations ranging 
from 0 - 30 % w/w. The rest of the binders were used at one concentration, 
7.5% w/w. Stearic acid was also used at one concentration, 5 %  w/w.
The binder was gradually dissolved (in the case of PVP) or dispersed (in the 
case of Luviskol and Polyplasdone) in water, with the aid of heat. The volume 
of water used in each case was equivalent to 20 % v/w of the total composite 
excipient (CE). A temperature of approximately 60° C was selected for the 
following reasons:- (a) it is within the melting point range of stearic acid (51- 
69° C ) ,109,111 (b) it is below the melting point range of Sterotex K (62-88° C) 
108, io9 ^  js below the melting point range of Compritol (67-72° C) 109 and 
(d)not too hot for excess evaporation to occur.
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Molten stearic acid was gradually added to the aqueous binder solution or 
dispersion while vigorously stirring with a spatula. This resulted in a warm 
stable colloidal dispersion. The dispersion was gradually added to either the 
HVO or Compritol in a high speed mixer granulator (Kenwood, Type FP600, 
Kenwood Ltd., UK). This was mixed at speed setting 5 (approximately 1000
rev min"l) for approximately 1 minute and then for a further 1 minute at
speed setting 8 (approximately 1450 rev min~l). This type of food processor 
used, has been reported to be a good model high speed granulator. 97
In the case of CE containing no stearic acid, the binder solution was used 
alone. For CE containing no binder, the molten stearic acid was added to the 
hot water with no other changes to the preparation protocol. All the CEs 
prepared were tray dried at 40° C in a convective oven (Baird and Tatlock 
Ltd., UK), overnight. The different dried CEs were subsequently passed through 
a 710 pm process sieve. They were then stored in tightly sealed plastic bags at 
room temperature and humidity, prior to use.
2.3.1.2 Composite Excipients Containing More Than Three Ingredients 
In each case, HVO was processed with PVP K-30, stearic acid and one or 
more other ingredient(s), selected from:- Avicel, Starch 1500, Junlon PW110, 
Eudragit S100 and Myverol. In all cases, the ratio of HVO : PVP K-30 : stearic 
acid was kept at either 90 : 5 : 5 or 87.5 : 7.5 : 5.
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2.3.1.2.1 Composite Excipients Containing Hither AviceL Starch or Junlon
In all cases, either Avicel, Starch 1500 or Junlon was added at 5 % w/w of 
the total composite excipient (CE). The CEs were prepared as described in
section 2.3.1.1 with the exception that the fourth component (either Avicel, 
Starch 1500 or Junlon) was mixed with the HVO powder in the mixer
granulator at speed setting 5 for approximately 40 seconds, before addition of 
the granulating dispersion. The resulting wet CEs were treated as described 
above in section 2.3.1.1.
2.3.1.2.2 Composite Excipients Containing either Hydrogenated Rapeseed oil 
Myverol or Myverol and Eudragit 
In each case, HVO was processed with PVP K-30, Stearic acid and either
hydrogenated rapeseed oil, Myverol or Myverol and Eudragit. In all cases, the
amount of water used was equivalent to 20 % v/w of the total CE.
When hydrogenated rapeseed oil or Myverol was used as the fourth
component, it was gradually melted at approximately 60° C and mixed with the 
molten stearic acid at the same temperature. The molten mass was then
gradually added to the aqueous binder (PVP K-30) solution while stirring
vigorously with a spatula. The resulting colloidal dispersion was slowly added 
to the HVO in the processor granulator. This was then processed as described 
in section 2.3.1.1.
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When Myverol and Eudragit were incorporated as the fourth and fifth 
ingredients respectively, the former was treated as described above, while the 
latter was mixed with the dry HVO powder in the granulator. The two dry 
powders were mixed at speed setting 5 for approximately 40 seconds. The rest 
was done as described in section 2.3.1.1.
2.3.1.3 Preparation of Mwerol - Based W ater-Free Composite Excipients 
Myverol was processed with either of the following silicas:- Aerosil 200,
Sipemat D17 and Sipemat 22 in the ratio 60 : 40 respectively. When Myverol
was processed with the silica Aerosil R 974, the ratio of the former to the
latter was 60 : 32. Myverol was melted at approximately 60° C (melting point 
range is 53-61° C). 109,118 The silica was then gradually incorporated into the 
molten Myverol while stirring with a spatula. As the Myverol adsorbed onto
the silica, a free flowing CE was gradually formed. The resulting CEs were 
passed through a 710 pm process sieve and left at room temperature and 
humidity overnight. They were then stored as described in section 2.3.1.1.
Formulae of all CEs prepared are shown in tables 2.1 (a) -2.1 (e).
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Table 2.1 (al:- Formulae o f Composite Excipients Containing Different
PVP K-30 Concentrations (NB;- all concentrations are in % w/w)
Code Sterotex K PVP K-30 Stearic acid
CE1 95.00 0.00 5.00
CE2 92.00 3.00 5.00
CE3 90.00 5.00 5.00
CE4 89.00 6.00 5.00
CE5 87.50 7.50 5.00
CE6 85.00 10.00 5.00
CE7 80.00 15.00 5.00
CE8 75.00 20.00 5.00
CE9 70.00 25.00 5.00
CE10 65.00 30.00 5.00
CE11 92.50 7.50 0.00
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Table 2.1 (bl:- Formulae o f Composite Excipients Containing Alternative Binders
Ingredient
(NB: all concentrations are in 
Code
£ 11
CE12 CE13 CE14 CE15
PVP K-90 7.50 0.00 0.00 0.00
PVP K-30 0.00 0.00 0.00 7.50
Luviskol 0.00 7.50 0.00 0.00
Polyplasdone 0.00 0.00 7.50 0.00
Sterotex K 87.50 87.50 87.50 0.00
Stearic acid 5.00 5.00 5.00 5.00
Compritol 0.00 0.00 0.00 87.50
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Table 2.1 (cl:- Formulae o f Composite Excipients Containing either AviceL
Starch or Junlon (NB:- all concentrations are in % w/w)
Ingredient Code
CE16 CE17 CE18
Avicel 5.00 0.00 0.00
Starch 0.00 5.00 0.00
Junlon 0.00 0.00 5.00
Sterotex K 83.12 83.12 83.12
PVP K-30 7.13 7.13 7.13
Stearic acid 4.75 4.75 4.75
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Table 2.1 (dl;- Formulae of Mwerol - Based Water - Free Granulated
Composite Excipients (NB:- all concentrations are in % w/w)
Ingredient Code
CE19 CE20 CE21 CE22
Aerosil® 200 40.00 0.00 0.00 0.00
Sipemat® D17 0.00 40.00 0.00 0.00
Sipemat® 22 0.00 0.00 40.00 0.00
Aerosil® R 974 0.00 0.00 0.00 34.78
Myverol 60.00 60.00 60.00 65.22
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Table 2.1 (el:- Formulae o f Composite Excipients Containing either
Hydrogenated Rapeseed Oil Mvverol or Myverol and Eudragit 
(NB:- all concentrations are in % w/w)
Code Sterotex K  PVP K-30 Stearic acid Myverol Eudragit
CE23 78.75 6.75 4.50 10.00 0.00
CE24 70.00 6.00 4.00 20.00 0.00
CE25 61.25 5.25 3.50 30.00 0.00
CE26 52.50 4.50 3.00 40.00 0.00
CE27 45.00 2.50 2.50 30.00 20.00
CE28 36.00 2.00 2.00 30.00 30.00
CE29* 35.00 3.00 2.00 30.00 30.00
CE30* 61.25 5.25 3.50 30.00 0.00
Key:- CE = Composite Excipient
* PVP K-90 was used instead of PVP K-30
# hydrogenated rapeseed oil was used instead Myverol
NB:- For all the composite excipients in tables 2.1 (a) - 2.1 (e), the drug, either 
propranolol hydrochloride or theophylline was added post-granulation and 
post - reconstitution (see also table 2.2, i.e. as a standardised direct compression 
system). In all cases, a drug content of 40 m s  per 150 m s  tablet was used.
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2.3.2 Preparation of an Active Composite Excipient Containing 
Propranolol Hydrochloride
In this case, the HVO : PVP K-30 : Stearic acid ratio was 87.5 : 7.5 : 5. The 
Stearic acid was melted at approximately 60° C (melting point range = 51-69° C) 
109,111 and then slowly brought up to approximately 85° C. The HVO was 
melted at approximately 85° C (melting point range = 62-88° C). 108,109 The two 
molten masses were then mixed thoroughly at approximately 85° C. The 
resulting molten mass was gradually cooled at room temperature while 
continually stirring with a spatula.
The powdered binder was gradually added to the thickening molten mass 
while stirring. As the molten mass continued to cool to a semi-solid (visual 
inspection) the drug, propranolol hydrochloride, was gradually incorporated 
while mixing. The ratio of propranolol hydrochloride to excipients was 40 : 110. 
Before the mass hardened completely, it was forced through a 710 pm process 
sieve. The resulting granulation was left at room temperature and humidity 
overnight. It was stored as described in section 2.3.1.1. This particular 
granulation produced an active composite excipient which was ready for direct 
compression into tablets without further processing was coded: ACE.
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2.3.3 Size Fractionation and Reconstitution of Composite Excipients and
Active Composite Excipient
Release-sustaining characteristics and tensile strength of compacts can be 
affected by variations in particle diameter distribution of granulations or 
powders. 88 Therefore in order to eliminate these effects, the various composite 
excipients (CEs) (unless otherwise stated) and active composite excipient (ACE) 
(see section 2.3.2) were fractionated and reconstituted. Also in order to 
evaluate the effect of particle diameter on release-sustaining characteristics and 
tensile strength of compacts, fractionation had to be done.
Fractionation was done by passing each CE or ACE through a series of test 
sieves (B. S. 410 / 1969, Endecotts Ltd, UK), which complied with international 
standards for nominal aperture size 710 pm, 500 pm, 355 pm, 250 pm, 180 pm, 
125 pm, 90 pm, 63 pm and 45 pm. Approximately 50-60 g of each CE or ACE 
was fractionated at a time so as to avoid overloading the sieves. The stack of 
sieves, in order of decreasing aperture size from top to bottom with the 
sample on the top sieve, was vibrated on a sieve vibrator (Fritsch Analysette 
Vibrator, Type 03.502, Christison Ltd., UK).
Each sample was shaken until the end point was reached. This was determined 
according to the following procedure (B. S. 410/1976):- The whole sample was 
initially sieved for 5 minutes at amplitude 2. The weight of the material 
remaining on each sieve was recorded by subtracting the weight of the sieve 
from that of the sieve plus the CE or ACE. The sieves were then vibrated
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repeatedly each time for 2 minutes at amplitude 2, until the weight of material 
passing through each sieve in 2 minutes was less than 0.2 % of the original 
test sample. A shaking period of 15 minutes at amplitude 2 was selected as a 
result of the preliminary tests. The sieve vibrator provided a three-dimensional 
controlled motion which produced a continuous movement of particles on the 
sieve screen.
The various fractions:- 710-500 pm, 500-355 pm, 355-250 pm, 250-180 pm, 
180-125 pm, 125-90 pm, 90-63 pm, 63-45 pm and < 45 pm exclusively, were 
weighed individually on a balance after vibrational separation. The following 
size fractions:- 500-710 pm, 355-500 pm, 250-355 pm, 180-250 pm and < 180 
pm from CE5 and CE24 (tables 2.1 (a) and 2.1 (e)) were each, dry blended 
with drug, propranolol hydrochloride (ratio = 110 : 40 respectively) and tableted.
The reconstituted particle size distributions of the various CEs and ACE used 
in tablet preparation are shown in table 2.2. Blend 1 (Bl), was selected 
because most of the CEs prepared from stearic acid, PVP K-30 and HVO had 
approximately this particular particle diameter distribution. Blend 2 (B2), was 
selected after a series of experiments with B l. Blend 3 (B3), was not a 
reconstituted blend. In this case, the CEs were passed through a 710 pm test 
sieve only, before use.
The different fractions were reconstituted using geometric dilution. Mixing was 
carried out for 5 minutes on a clean A4 piece of paper, using a spatula. Care
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<710 — — 100
500-710 25 50 N/D
355-500 35 25 N/D
250-355 25 15 N/D
180-250 10 7 N/D
<180 5 3 N/D
NB:- N/D = not determined 
Therefore all the formulations were coded according to formula, particle size 
distribution and drug:- e.g. C E l/B l/Prop or CEl/Bl/Theo 
where:- CE1 is composite excipient 1 (see table 2.1(a))
B l is blend 1 particle size distribution (table 2.2)
Prop is propranolol hydrochloride 
Theo is theophylline
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was taken so as not to damage the granules. Approximately 40 g of blend of 
each CE or ACE was made at a time. The resulting reconstituted CEs or 
ACE were stored in sealed plastic bags at room temperature and humidity until 
further use.
2.3.4 Drug and Composite Excipient Drv Mixing
A drug dosage of 40 mg per 150 mg tablet was selected (drug : excipient ratio 
= 40 : 110). This particular dosage was chosen for the following reasons:- (a) so 
as to have a maximum absorbance value of less than 1 and this reduces the 
effects of stray light, which is particularly notable at absorbance values above 1 
in most UV-visible spectrophotometers; and (b) it is one of the standard 
dosages of propranolol hydrochloride. A target tablet weight of 150 mg was 
selected partly due to:- (a) the punches size (8 mm) and (b) the maximum die 
depth. Also tablets with large diameters enhance tablet tooling adhesion.30
The drug (propranolol hydrochloride or theophylline), and CE were weighed 
separately on an analytical balance. They were then carefully mixed together 
geometrically for 5 minutes. Mixing was done on a clean A4 piece of paper. 
For each batch of tablets prepared for dissolution tests or tensile strength 
measurement, approximately 5 g of CE - drug mixture was made at a time. For 
evaluation of formulation adhesion to tablet tooling, approximately 150 g was 
made at a time.
104
2.3.5 Differential Scanning Calorimetry (DSC1
When two or more substances are mixed together and temperature is raised, as 
occurs in tableting, the possibility of chemical reaction(s) cannot be discounted. 
Chemical reactions in tablets are not desirable since they can have an effect on 
factors such as drug bioavailability, tablet strength and release sustaining - 
characteristics. Therefore in order to determine whether chemical reaction(s) 
between the excipients and propranolol hydrochloride were likely, differential 
scanning calorimetry (DSC) was carried out on samples of CE5/B1, 
CE5/B 1/Prop (see tables 2.1 (a) and 2.2), propranolol hydrochloride, stearic 
acid, palmitic acid and propranolol hydrochloride - fatty acid mixtures. The ratio 
of propranolol hydrochloride to excipients in the samples was 40 : 110. The 
above fatty acids were selected because they are found in Sterotex K (see 
section 2.2). In the study, Sterotex K was the main basic release - sustaining 
characteristics matrix material. DSC is an easy and quick method for screening 
solid mixtures for likely chemical reactions. Usually, if a chemical reaction 
occurs between substances mixed together, on performing a DSC test, beside 
the transitions corresponding to the initial substances showing on the 
thermogram, transitions) corresponding to the new product(s) is/are evident as 
well.
A differential scanning calorimeter (Type 910, Du Pont Instr. Wilmington, 
USA) connected to a computerised thermal analyser and a data acquisition 
unit (Type 9900, Du Pont Instr.) was used in the study. The instrument was
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calibrated using Indium to obtain a cell constant of 1.1083 and a slope of - 
4.21. All experiments were run at a heating rate of 10° C per minute. An 
initial fast ramp was used to raise the temperature quickly to 30° C and then a 
constant heating rate of 10°C per minute was used up to 180° C under 
nitrogen atmosphere. Samples ranging from 1-5 mg were weighed into 
aluminium DSC pans on an analytical balance. The pans containing the 
samples were then sealed before the analysis. The heat of transition was 
automatically calculated by the analyser. At the end of each test the data was
printed (see section 3.2 in chapter 3).
2.3.6 Anti-adherent Addition
Anti-adherents were added to CEll/Bl/Theo (see tables 2.1 (a) and 2.2) 
formulation. CE11 was prepared as described in section 2.3.1.1. The ratio of 
theophylline to the CE was 40 : 110. The anti-adherents added, each at 1 %
w/w and 5 % w/w concentrations, were magnesium stearate, stearic acid,
Compritol and leucine.
The anti-adherent and CEll/Bl/Theo were mixed geometrically on a clean 
white A4 paper. Total mixing time was 5 minutes. The resulting lubricated 
formulations were immediately evaluated for adhesion.
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2.3.7 Tableting
2.3.7.1 Equipment and Preparation of the Tablets 
An instrumented single punch Manesty E2 tablet machine equipped with 8 mm 
diameter flat faced punches was used to prepare the tablets used in tensile 
testing and dissolution. The fly-wheel of the machine was manually operated as 
the software could not process the collected data fast enough for power 
operation. It was found out that it was impossible to maintain exactly the same 
contact time for replicates of the same formulation at the same compaction 
force.
Formulation for each tablet was individually weighed on an analytical balance 
into small glass tubes to 0.1 mg. This was done for the achievement of the 
target tablet weight (150 mg) and constant compaction forces. Therefore each 
formulation sample for a tablet weighed 152.5 - 153.0 mg. Each sample was 
carefully tipped into the die and the fly-wheel manually turned in order to 
compact the formulation. Tablets were made at compaction forces ranging from 
3 to 18 kN.
The first 5 tablets made at each compaction force for each formulation were 
rejected. For each formulation, 20 tablets were made for tensile testing, while 
12 tablets were made for dissolution tests. All the tablets were stored in 
tightly sealed glass containers in desiccators containing saturated solutions of 
potassium acetate which produced a relative humidity of approximately 37 % at 
20°C as measured by hygrometer and thermometer respectively. This relative
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humidity was significantly higher than the literature value of 23 % at the same 
temperature. 130
23.1.2 Data Acquisition and Manipulation 
The upper punch signal was monitored by a pre-calibrated load cell (Type 
9021, Kistler Instr. Ltd., UK). This load cell was calibrated by the 
manufacturers. The upper punch holder was modified so as to hold the load 
cell as well as the load distribution washer. This was arranged so that the top 
end of the upper punch pressed directly against the washer. The upper punch 
was loosely held in position by a retaining screw so as to allow movement and 
reduction in force lost to the screw during compaction. The conditioning 
amplifier (Type 5054A, Kistler Instr. Ltd., UK) converted the changes in 
capacitance into changes in voltage.
Force transmitted to the lower punch was monitored by two strain gauges 
(Welwyn Strain Measurement Ltd., UK) bonded to the lower punch holder. 
Signals from these strain gauges were passed through a conditioning amplifier 
(Type 2120, Welwyn Strain Measurement Ltd., UK) where changes in 
resistance were converted to changes in voltage. The pre-calibrated load cell 
was used to calibrate the strain gauges in situ. The punches were brought into 
contact and readings from both the load cell and strain gauges monitored and 
collected. It was realised that these results changed slightly with time, hence 
there was need for routine calibration of the strain gauges. The changes were 
time dependent rather than machine operation dependent. The strain gauges
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were recalibrated whenever the readings altered significantly (e.g. when the 
recorded lower punch force was equal or greater than the upper punch force).
The analogue signals from the load cell and the strain gauges were both fed 
via an analogue-digital converter connected to a 1 MHz Bus of a 
microcomputer (Master series, British Broadcasting Co., UK). 500 digital values 
were obtained from each of the mentioned devices during one complete 
compaction cycle. These values were stored in the memory of the
microcomputer and processed at the end of each run. The software provided
the following parameters for each tablet produced:-
• peak upper punch force
• peak lower punch force
• time to peak force
• total compaction time
• peak upper punch to peak lower punch force ratio
• peak lower punch to peak upper punch force ratio
A typical set of calibration data for the strain gauges is shown in table 2.3
while the corresponding plot is shown in figure 2.1.
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Table 2.3:- Calibration Data Corresponding to Electronic Digital Lower Punch 
Outputs at Given Applied Loads from the Upper Punch In Situ
Upper Punch Lower Punch
Force (N) (Digital Values)
2 584 6 704
4 499 9 344
5 682 10 848
6 933 12 464
8 191 14 240
9 449 16 048
10 707 17 872
11 904 19 568
13 018 21 152
14 017 22 576
14 899 23 856
15 719 24 960
16 464 25 856
17 736 27 424
Slope = 1.389
Intercept = 3001

















Figure 2,1:- Calibration Plot for the Strain Gauges Corresponding
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2.3.7.3 Evaluation o f Adhesion to Tablet Tooling
A power operated single punch Manesty F3 tablet machine equipped with 8
mm diameter punches was used to evaluate the adhesion of lubricated and
unlubricated CEll/Bl/Theo (tables 2.1 (a) and 2.2) formulation to the upper 
punch face. CE11 was prepared as described in section 2.3.1.1. The anti­
adherents used were magnesium stearate, stearic acid, Compritol, leucine and 
each was added at 1 % w/w and 5 % w/w concentrations to CEll/Bl/Theo as 
described in section 2.3.6.
Before each run, the die and punch set were thoroughly cleaned with 95 %
alcohol. The lower punch was set so that tablets of approximately 150 mg 
were made while the upper punch was fixed at its maximum position. Tablets 
were made at the minimum force required to produce the maximum crushing 
force (Schleuniger, type 2E, Germany) for each formulation. Once the die depth 
and compaction force had been set, the upper punch was carefully removed
and thoroughly cleaned again using 95 % alcohol. It was then weighed on an
analytical balance to 0.1 mg and secured back to the maximum position on the
upper punch holder, with the aid of a retaining screw.
After every 40 cycles, the upper punch was carefully removed and weighed to 
0.1 mg. For each formulation 1000 cycles were run except for one formulation 
containing 5 % stearic acid as anti-adherent, where only 240 cycles were run 
due to flowabihty problems. The weight of the upper punch was subtracted
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from the series of data collected so as to obtain the actual quantity of 
formulation sticking on the face of the upper punch.
2.3.8 Tablet Tensile Strength Measurement
Tensile testing was done 48 hours post-comp action. A tensile tester (Type 
T5000, JJ Lloyd Instr. Ltd., UK), capable of measuring force from 0.05 to 
5000 N, fitted with a compression cage, was used to determine the diametral 
crushing force of the tablets. The tensile tester was calibrated annually by the 
manufacturers. The schematic representation of the compression cage used is 
shown in figure 2.2. The machine was operated in the compression mode. 
Before testing, tablet dimensions (diameter and thickness) were measured by 
means of a digital micrometer. Tablet weight was determined as well. 15 
replicates were used for calculation of the mean values for each batch.
During the diametral loading test the force required to cause failure was 
monitored by a 100 N pre-calibrated load cell (JJ Lloyd Instr.) fitted to the 
centre of the moving cross-head and to the compression cage. Like the tensile 
tester, the load cell was calibrated by the manufacturers on a yearly basis. The 
tablet was placed on the bottom platen of the compression cage. As the two 
platens gradually moved towards each other during the test, the tablet was 
crushed in between them The frictional force due to the movement of the 
platens was approximately ± 0.1 % of the lowest crushing force obtained. 
Therefore it was not taken into consideration. The cross-head speed was set at 
1 mm/minute and the load cell sensitivity at x 1.
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Figure 2.2:- Schematic Representation of the Compression Cage used
in Evaluating the Crushing Force of the tablets
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The displacement of the cross-head was measured by a self-contained transducer 
which had a precision of 0.1 mm. Tablet deformation before failure was in 
the range of 0.01-0.10 mm This tensile tester used did not have an external 
extensometer such as a linear variable differential transformer, for accurate 
measurement of displacement or deformation. Consequently, although a work of 
failure was automatically calculated by the computer (Viglen Contender, Viglen 
Ltd., UK) interfaced with the tensile tester, this was not accurate and hence 
could not be used in the study.
The signal from the load cell was conditioned and amplified and then fed into 
a microcomputer (Viglen Contender) via an analogue digital converter. The 
values obtained were stored in the computer's memory and processed at the 
end of the experiment. The processed data was presented as stress versus 
strain curves by the microcomputer. From the maximum crushing force 
obtained, radial tablet tensile strength was calculated according to equation 1.4.
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2.3.9 Determination of Wavelen2ths of Maximum Absorption and 
Beer-Lambert Plots for Aqueous Solutions of Propranolol Hydrochloride
and Theonhvlline
A series of aqueous solutions of propranolol hydrochloride or theophylline in 
the range of 5-50 mg/litre were prepared. A scan of 30 nm on either side of 
the literature value for wavelength of maximum absorption, 290 n m 114 and 272 
nm 115 respectively was performed using a double beam UV-visible 
spectrophotometer (Model CE594, Cecil Instruments, Cambridge, UK) and 1 cm 
pathlength quartz cuvettes. This procedure was carried out in order to 
determine the exact wavelength of maximum absorption of the two drugs 
on this particular instrument. The maximum absorbance for propranolol 
hydrochloride was at 289 nm, while that for theophylline was at 269 nm against 
a blank of distilled water.
For theophylline, the maximum concentration that gave a maximum absorbance 
just below 1 (0.989) was 20 mg/litre. This implied that the possible maximum 
theophylline content was 20 mg in an approximately 70 mg tablet of 8 mm 
diameter. Such a tablet was too thin for practical purposes. To allow the 
required amount of theophylline (40 mg per 150 mg tablet) to be incorporated 
and assayed it was decided to use a wavelength of 287 nm  Such an 
adjustment with theophylline has been done before with reliable results. 96 
Therefore all the subsequent aqueous drug concentrations had their absorbances 
read at 289 nm for propranolol hydrochloride and at 287 nm for theophylline, 
against a blank of distilled water.
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In order to establish whether any interference in the assays would be caused 
by any of the excipients which might dissolve from the tablets during the 
assays, the dissolution properties of blank tablets (tablets containing all the 
ingredients except the drug) were evaluated at the critical wavelength over 12 
hours. Absorbance readings at all sample times were zero. This showed that 
the excipients used made a negligible contribution to the absorbances at the 
respective wavelengths selected. Therefore distilled de-aerated water was used 
as blank in all the dissolution tests.
The calibration data and plots for propranolol hydrochloride and theophylline in 
distilled water are shown in table 2.4, figure 2.3, table 2.5 and figure 2.4.
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Table 2.4:- UV/Visible Spectrophotometric Calibration Data o f Aqueous
Solutions of Propranolol Hydrochloride v = 289nm
Cone Absorbance
mg/1 1 2 3 4 5 6 Mean sd
10 0.189 0.189 0.179 0.188 0.189 0.200 0.189 0.007
20 0.382 0.389 0.378 0.383 0.386 0.384 0.384 0.004
30 0.573 0.574 0.570 0.562 0.569 0.574 0.570 0.005
40 0.750 0.759 0.762 0.750 0.766 0.770 0.760 0.008
50 0.947 0.955 0.936 0.948 0.955 0.946 0.948 0.007
NB:- Cone = Concentration and sd = standard deviation. 
Slope = 0.01894 ±0.00013 
Intercept = 0.00202 ±0.00531 
Corr. Coefficient = 0.99987 ± 0.00008 








Figure 2.3:- Calibration Plot for Propranolol Hydrochloride in
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Table 2.5:- UV/Visible Spectrophotometric Calibration Data o f Aqueous
Solutions of Theophylline. X = 287 nm
Cone
mg/1 1 2 3
Absorbance 
4 5 6 mean sd
5 0.086 0.088 0.087 0.087 0.086 0.087 0.087 0.001
10 0.175 0.177 0.176 0.174 0.176 0.175 0.176 0.001
35 0.606 0.607 0.607 0.607 0.608 0.609 0.607 0.001
40 0.697 0.697 0.694 0.695 0.692 0.693 0.695 0.002
45 0.785 0.790 0.787 0.787 0.789 0.788 0.788 0.002
50 0.866 0.867 0.867 0.865 0.862 0.866 0.866 0.002
Slope = 0.01736 ± 0.00002 
Intercept = 0.00091 ± 0.00065 
Corr. Coefficient = 0.99995 ± 0.00003 
Key:- Cone. = Concentration, sd = standard deviation








Figure 2.4:- Calibration Plot for Theophylline in Distilled Water
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2.3.10 Preparation of Buffer Solutions
2.3.10.1 Buffer pH » 6.8:- Imidazole / HC1131 
25 ml 0.2 M Imidazole (13.62g/L) + 31.4 ml 0.1 M HC1 made up to 100 ml.
Amount prepared = 8 Litres 
Amount of Imidazole in 8 litres of buffer:- 
(8000/100)x(25xl3.62/1000) = 27.24 g.
Moles of 0.1 M HC1 in 100ml of bufifer:- 
(31.4/1000)x0.1 = 0.00314 moles.
Moles of HC1 in 8 litres of buffer:- 
(8000/100)x0.00314 = 0.2512 moles.
Volume of 1 M HC1 required = 0.2512x1000 = 251.2 ml.
The imidazole was dissolved in distilled water with the aid of low heat (« 37° 
C) while stirring in a 10 litre flat-bottomed flask. The acid was added and the 
buffer made up to volume with distilled water and stirred. The buffer was then 
de-aerated by bubbling helium gas through the solution. The above formula is 
for pH 6.8 at 25 ° C ,131 yet the dissolution tests were carried out at 37 ±0.5 ° 
C. Preliminary studies had shown that buffers prepared at 37 ± 0.5 ° were 
usually ±0.2 of the literature value. However, the above buffer was supposed 
to be equivalent to small intestines pH which normally ranges from 6.5 to 7.0 
in healthy subjects. 61 Therefore the above buffer was used as prepared without 
any adjustment. Also studies which have been performed indicate that HVO 
matrix release properties are not significantly affected by pH changes. 96,97
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2.3.10.2 Buffer pH 7.0:- Imidazole / HC1131 
25 ml 0.2 M Imidazole (13.62 g/L) + 25.4 ml 0.1 M HC1 made up to 100 ml.
The calculations were done as in section 2.3.10.1.
=> 27.24 g Imidazole + 203.2 ml 1 M HC1 made up to 8 litres.
This buffer solution was used with enzymes and hence had to be accurately 
prepared. In this case, preparation was done as in section 2.3.10.1 with buffer 
adjustment done by the addition of either a little base or acid.
2.3.10.3 Buffer p H «  1.4:- KC1/HC1 (Clark & Lubs Buffer!131
25 ml 0.2MKC1 (14.91 g/L) + 23.2 ml 0.2 M HC1 made up to 100 ml.
Calculations were done as in section 2.3.10.1.
=> 29.82 g KC1 + 371.2 ml 1 M HC1 made up to 8 litres.
Preparation was as in section 2.3.10.1 with the buffer solution used as 
prepared without any adjustment. Gastric pH ranges from 1 to 2.5 in healthy 
fasted subjects.
2.3.11 Determination of Beer-Lambert Plots for Propranolol 
Hydrochloride in Buffers Solutions
This was done as in section 2.3.9, but instead of de-aerated distilled water, the 
respective de-aerated buffer solutions were used. All absorbances were read at 
wavelength (A) 289 nm  In each case, the respective buffer solution was used 
as the blank instead of distilled water. The respective calibration data and 
calibration plots for propranolol hydrochloride in the buffer solutions are shown 
in table 2.6, figure 2.5, table 2.7 and figure 2.6.
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Table 2.6:- UV/Visible Spectrophotometric Calibration Data o f Propranolol
Hydrochloride in Buffer Solution:- p H » 6.8
X = 289 nm
Drug Cone. ABSORBANCE
(mg/1) 1 2 mean sd
5 0.094 0.093 0.094 0.001
10 0.184 0.185 0.185 0.001
20 0.378 0.374 0.376 0.003
30 0.568 0.564 0.566 0.003
40 0.752 0.739 0.746 0.009
50 0.938 0.933 0.936 0.004
Slope = 0.01872 ±0.00013 
Intercept = -0.00002 ± 0.00044 
Corr. Coefficient = 0.99995 ± 0.00002 
Key:- Drug Cone. = Drug Concentration, sd = standard deviation 








Figure 2.5:- Calibration Plot for Propranolol Hydrochloride in
Buffer Solution:- Imidazole/Hydrochloric acid pH »  6.8. 
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Table 2.7:- UV/Visible Spectrophotometric Calibration Data o f Propranolol
Hydrochloride in Buffer Solution:- p H » 1.4
X = 289 nm
Drug Cone. ABSORBANCE
(mg/1) 1 2 mean sd
5 0.097 0.094 0.096 0.004
10 0.194 0.194 0.194 0.000
20 0.392 0.382 0.387 0.007
30 0.587 0.580 0.584 0.005
40 0.765 0.754 0.760 0.008
50 0.969 0.959 0.964 0.007
Slope = 0.01918 ±0.00014 
Intercept = 0.00178 ± 0.00116 
Corr. Coefficient = 0.99986 ± 0.00003 
Key:- Drug Cone. = Drug Concentration, sd = standard deviation 








F igure  2.6:- Calibration Plot for Propranolol Hydrochloride in 
Buffer Solution:- Potassium Chloride/Hvdrochloric acid p H « 1.4,





0 . 2 -
0.0
0 10 20 30 40 50
Propranolol Hydrochloride Concentration (mg/litre)
127
2.3.12 Measurement of Release Characteristics of Tablets Made from the
Various Formulations using an Automated Dissolution Technique
Dissolution tests were done 24 hours post-compaction. In all cases six tablets 
were assayed in one run. In order to automate the dissolution testing 
procedure, a cell controller with a motorised cell changer (Model CE830, Cecil 
Instr., UK) and 6 flow through quartz cuvettes of 1 cm pathlength (Cecil 
Instr.) were used with the UV-visible spectrophotometer (Model CE954, Cecil 
Instr.). Solutions were pumped out of the 6 dissolution vessels through the 
appropriate cuvettes in the cell changer via latex plastic tubing (Type TWR- 
350-110T, Fisons Scientific Equipments, UK) by use of a peristaltic pump 
(Model 502S, Watson Marlow, UK). Vinyl peristaltic tubes (Type 980-0279- 
000, Watson Marlow) were used at the pump head.
The water bath housing the dissolution vessels was fitted with a temperature 
controller (TE CAM TE7 Tempette) which maintained temperature at 37 ±0.5 ° 
C. This, it did by automatically switching on and off the heating element. A 
stirrer (Model 6ST, G.B. Caleva Ltd., UK) dissipated the heated water around
-i
the bath. The dissolution vessels’ paddles were set to rotate at 50 rev min . 
Both the inlet and outlet tubes were inserted into the dissolution vessels to a 
depth of approximately a third of the depth of each dissolution vessel so that 
fluid was always removed and returned to the same point in each vessel. The 
outlet tubes were fitted with 60 pm filters (Type 091 501, G.B. Caleva Ltd.) 
to filter off any material above this size so as to avoid any interference with 
absorbance readings.
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The solutions were pumped at 39 % maximum rate attainable by the pump in 
order to minimise turbulence in the dissolution vessels and to maximise pump 
and peristaltic tubing life. The cell changer was programmed to move each cell 
into the beam at the required time interval. The resulting absorbance reading 
was relayed to a microcomputer (BBC Model B, Acorn Computers, UK) which 
was interfaced with the spectrophotometer. A Basic programme was used to 
record the absorbance values and convert them to concentration values 
according to the data obtained from the calibration plots. Dissolution profiles 
were determined by calculating the cumulative percentage drug released with 
time and this data was printed and kept for subsequent analysis. The 
dissolution media was either de-aerated distilled water or de-aerated buffer 
solutions.
2.3.13 Scanning Electron Photomicrography of Tablet Surfaces
The outer flat faces of tablets made from CE5/B 1/Prop and CE5/Prop (tables
2.1 (a) and 2.2) before and after dissolution testing, were examined using a 
scanning electron microscope (Model JSM T330, Japanese Electron Optics Ltd., 
Tokyo, Japan).
The samples were mounted on 10 mm diameter cylindrical aluminium stubs of 
approximate 20 mm length using colloidal graphite adhesive. A layer of gold 
was deposited onto the sample surface using a sputter coater (Model S150B, 
Edwards High Vacuum, Crawley, UK). Sputter coating was carried out for
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5 minutes. The coated samples were then examined at various magnifications 
using an electron beam potential of 10 keV. A low electron voltage had to be 
used due to the susceptibility of the HVO matrix to melting (mp = 62-88° C).
108,109
130
RESULTS AND DISCUSSION 
CHAPTER 3
INVESTIGATION OF THE OPTIMISATION OF PHYSICO-MECHANICAL 
PERFORMANCE CHARACTERISTICS OF PROCESSED HVO
3.1 O b je c t iv e s
The main objectives in this part of the study were to optimise the tensile 
strength of HVO compacts and to reduce processed HVO formulations’ 
adhesion to tablet tooling. In most cases the effect of formulation and process 
changes were studied in relation to release - sustaining characteristics.
All the tensile strength measurements and the dissolution tests were carried out 
as described in sections 2.3.8 and 2.3.12 respectively. All tablets, except those 
used in evaluation of adhesion to tablet tooling, were made as described in 
section 2.3.7.1. All the error bars on the figures are standard error of mean; 
values associated with means, quoted in the text and in the tables are standard 
deviations.
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3.2 Ch a r a c t e r isa t io n  of M a t e r ia l s  
PVP, Luviskol and Polyplasdone formed stable colloidal dispersions with stearic 
acid in hot water. PVPK-30 and PVPK-90 dissolved in water, with PVPK-90 
forming a more viscous solution than the former. Luviskol and Polyplasdone 
formed suspensions with the hot water. As the concentration of PVP K-30 
increased, the colloidal dispersions formed with stearic acid gradually became 
viscous semi-solids. Myverol formed free flowing composite excipient (CE) 
powders/granulations with the various silicas used (Aerosil© 200, Sipemat® 
D17, Aerosil® R974 and Sipemat® 22).
The differential scanning calorimetry (DSC) results are summarised in table 3.1 
and figure 3.1. Table 3.1 shows the heat of fusion, AH, and the peak 
transition temperature, Tm, of the materials tested. The thermograms of some of 
the materials tested are shown in figure 3.1.
The thermogram of a propranolol hydrochloride sample showed a sharp 
endothermic transition at 165.13° C, with an onset of transition at 162.47° C 
(table 3.1 and figure 3.1). The heat of transition was 135.3 J/g. This 
experimental transition temperature corresponds to the literature melting range 
of propranolol hydrochloride which is 163-164° C. 132
The thermogram of CE5/B1 (tables 2.1 (a) and 2.2), showed a broad 
endothermic transition with four distinct peaks at approximately 54.5° C, 60.0° 
C, 67.0° C and 77.0° C (figure 3.1). However, the average peak transition
132
Table 3.1:- Differential Scanning Calorimetry Results
Component DSC Results
1 2 1
Tm(° C) AH (J/g)
2
Tm (° C) AH (J/g)
Drug — 165.13 135.3 — —
Palmitic acid — 63.25 205.1 — —
Stearic acid — 69.85 209.3 — —
CE5/B1 — 59.48 147.9 — —
Palmitic acid Drug = 63.27 137.4 147.80 35.02
Stearic acid Drug = 69.98 162.7 150.20 28.17
CE5/B1 Drug 59.21 100.3 155.87 29.61
NB Drug = Propranolol Hydrochloride 
Key:- Tm = Peak transition temperature
AH = Heat of fusion
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temperature was 59.48° C with an onset of transition at 50.47° C. The heat of 
transition was 147.9 J/g. This broad endothermic thermogram of CE5/B1 with 
its four peaks partly confirms the fact that HVO, Sterotex K, is composed of 
various fatty acid esters and their respective fatty acids. These fatty acids and 
their respective fatty acid esters probably have different melting points, with the 
majority having a melting point of approximately 60° C. Due to the fact that 
there were no exothermic peaks observed, which usually indicate degradation,133 
it was concluded that CE5/B1 was relatively stable. CE5 was prepared as 
described in section 2.3.1.1.
The two fatty acids analysed, palmitic acid and stearic acid, had sharp 
endothermic transitions at their expected melting point ranges. 134 None of the 
thermograms had any exothermic peaks indicating that the fatty acids had no 
degradation products.
All the respective thermograms of the fatty acids (palmitic acid and stearic 
acid) plus propranolol hydrochloride, with a drug to fatty acid ratio of 40 : 
110, had sharp endothermic transitions at low temperature and distinctly small 
slightly broad endothermic transition at high temperature (see figure 3.1). The 
low temperature transition represented the respective fatty acid, while the high 
temperature endotherm was for propranolol hydrochloride. In both cases, the 
transition/melting temperature and the heat of fusion of propranolol 
hydrochloride were depressed by the fatty acids. This is common in mixtures of 
substances which have different melting points but do not react chemically. 133
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In the presence of low melting substances such as fatty acids, the energy, AH, 
required to convert (from solid to liquid), high melting substances such as 
propranolol hydrochloride, is lower than when it is pure. The temperature at 
which the transition of the “impure” propranolol hydrochloride occurs, Tm, is 
also depressed. This is due to a lowered degree of crystallinity of the
propranolol hydrochloride in the presence of the low melting fatty acids. In 
contrast the transition temperatures of the fatty acids (palmitic acid and stearic 
acid), were not altered by the presence of the drug (table 3.1). This is to be 
expected since the mixtures contained almost 3 times as much fatty acid as 
propranolol hydrochloride (ratio = 110 : 40 respectively). Therefore the drug had 
minimal effect on the melting point of the fatty acids. However, the respective 
heats of fusion of the fatty acids were lowered by the presence of the
propranolol hydrochloride (table 3.1).
The thermogram of CE5/B 1/Prop (see tables 2.1 (a) and 2.2) had a distinct 
broad endothermic four peaked transition (Tm = 59.21° C) corresponding to 
CE5/B1 and a smaller endothermic transition at 155.87° C corresponding to
propranolol hydrochloride (see figure 3.1). The depression of the melting point
and heat of transition of propranolol hydrochloride was attributed to the 
reasons given above.
None of the DSC studies revealed exothermic transitions (indication of 
degradation), or notably inexplicable or unexpected endothermic peaks (general 
indication of the presence of a new compound as a result of a chemical
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reaction). Therefore the DSC results were taken to indicate that CE5/B1 and 
the fatty acids (palmitic acid and stearic acid) had not chemically reacted with 
propranolol hydrochloride in the solid state during the period, post-mixing.
3.3 Ch a r a c t e r isa t io n  o f  P a r t ic le s  o f  C o m p o sit e  E x c ip ie n t  3 
Particle size distribution of CE3 (table 2.1 (a)) was evaluated by the sieving 
technique as described in chapter 2, section 2.3.3. CE3 was prepared as 
described in section 2.3.1.1. Particle size distributions, whether unimodal or 
bimodal, can affect the final performance of a formulation. This factor, 
including the degree of kurtosis and skewness of the distribution, may be 
important in optimising mechanical properties, content uniformity and release- 
sustaining characteristics of a formulation. 88 The summary of the particle size 
distribution of CE3 is shown in table 3.2, figure 3.2 and figure 3.3.
From table 3.2:- 
Volume mean diameter, dv = Zwd/Zw = 37 365.3/99.8 = 374 pm  
Surface mean diameter, (L = 7w/7YwAD = 99.8/0.310723 = 321 pm.
Geometric mean diameter, dg= (xi172 x x23()()x  x xg0,1)1/99-8 = 349.5 pm.
where xi, x2, •••• and x8 are 605 pm, 427.5 pm •— and 54 pm respectively.
The surface mean diameter is of practical significance as it is inversely 
proportional to the specific surface area of a powder or granulation sample. 17 
The surface area of a powder or granulation is important in tablet bonding. 
Also the surface area of the granulation/powder may affect dissolution rate,
138














500-710 605 17.2 82.6 10 406 0.028430
355-500 427.5 30.0 52.6 12 825 0.071075
250-355 602.5 36.5 16.1 11 041.25 0.120661
180-250 215 12.1 4.0 2 601.5 0.056279
125-180 152.5 1.9 2.1 289.75 0.012459
90-125 107.5 1.4 0.7 150.5 0.013023
63-90 76.5 0.6 0.1 45.9 0.007843
45-63 54 0.1 0.0 5.4 0.001852
<45 - 0 - - -
Totals (Z) 1 940.5 99.8 37 365.3 0.310723
Key:-
w = % w/w frequency















Figure 3.2:- Cumulative Percent Undersize Curve for Composite
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Figure 3.3:- Percent Frequency Sieve Analysis Curve of
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ease of compaction and flowability. However, the three above diameters are 
approximately within the same range.
From figure 3.2:- 
Median diameter (a) = antilog 2.62 = 10262 = 417 pm 
Lower quartile diameter (b) = antilog 2.52 = 10252 = 331 pm 
Upper quartile diameter (c) = antilog 2.74 = 10274 = 550 pm
The inter-quartile coefficient of skewness (IQCS), which indicates the degree of 
skewness, can be calculated from the equation below. IQCS can have a value 
range of -1 to +1 (0 value indicates curve symmetry between the quartile 
points).
.\ IQCS = {(c-a)-(a-b) / (c-a)+(a-b)}
=> IQCS = (133-86) / (133+86) = 47 / 219 = 0-21
From the IQCS and figure 3.3, the distribution of CE3 particles is positively 
skewed (skewed to the right). This is typical of powders produced by 
granulation and indicates that the majority of CE3 particles are large with 
minimal fines. This is desirable in a formulation since an excess of fines impede 
flowability and promote destructive capping.
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3.4 Dr u g  R e l e a se  M e c h a n ism  o f  P r o c e sse d  HVO M a t r ic e s
Previous studies on controlling drug release from hydrophobic matrices for
direct compression, have been carried out using Emvelop. 96 Emvelop is mainly 
hydrogenated cotton seed oil. In the present study, using composite excipients 
(CEs) based on hydrogenated castor oil/soybean oil (Sterotex K), tablets were 
prepared at approximately 12 kN from CE5/B 1/Prop, CE5/Bl/Theo (see tables 
2.1(a) and 2.2) and ACE/BI (see section 2.3.2 and table 2.2) and subjected to 
dissolution testing. CE5 was prepared as described in section 2.3.1.1. A 
compaction force of 12 kN was selected because it produced compacts with 
constant reproducible drug release profiles and it is within the range of 
compaction forces used in industry to produce tablets. The tablet thickness 
before and after dissolution was measured using a digital micrometer.
The release data up to approximately 60 % from CE5/B 1/Prop, CE5/Bl/Theo 
and ACE/BI tablets was evaluated according to the Higuchi and first order 
release mechanisms. For the Higuchi model, drug release was plotted against 
square root of time. For first order release, logio {amount o f  drug (either
propranolol hydrochloride or theophylline) remaining} was plotted against time. 
Linear regression analysis on the resulting plots for each individual tablet was 
carried out with the aid of a microcomputer software programme, Microcal
Origin. The summary of the linear regression analysis data for each tablet of
the above three formulations is shown in appendix 1, tables A9 and A10.
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The drag release profiles from CE5/B 1/Prop, CE5/Bl/Theo and ACE/BI tablets 
are shown in figure 3.4. The summary of the in vitro release kinetics from the 
tablets according to the above mechanisms is shown in table 3.3. The values ± 
sd quoted are for the mean of the six individual tablet dissolution profiles.
As can be seen from figure 3.4, drag release from processed HVO does not 
follow zero order kinetics. The Higuchi model appeared to describe drag 
release from CE5/B 1/Prop, CE5/Bl/Theo and ACE/BI matrices better than 
the first order mechanism (r = 99958, 0.99942 and 0.99497 respectively) (table 
3.3). The Higuchi mechanism assumes that the matrix device is completely 
wetted at time zero and that there is complete removal of air. Ideally, the 
intercepts ought to be zero.
The release kinetics data (table 3.3), coupled with the fact that the tablet 
dimensions failed to alter significantly after dissolution, confirmed diflusion 
controlled release of drag from HVO matrices. Therefore drag release from 
HVO matrices probably involved leaching by the dissolution fluid that contacted 
the embedded drag. This formed pore - channels and cracks through which 
further fluid entered and leached out more drag. Due to the increase in the 
difiusional distance with time, release rate gradually decreased with time.
CE5/B 1/Prop and ACE/BI matrices had higher release rates than CE5/Bl/Theo 
matrices (figure 3.4). Theophylline has a lower aqueous solubility (0.833 % w/v) 
115 than propranolol hydrochloride (5%  w/v), 114 hence lower release rates in
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Figure 3.4:- Propranolol Hydrochloride and Theophylline Release 















Key:- — CE5/ B 1/Prop
 A  ACE/B1
— ■—  CE5/B 1/Theo
NB:- for details of CE5/B 1/Prop, CE5/Bl/Theo and ACE/BI formulations 
see tables 2.1 (a) and 2.2 and section 2.3.2.
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Table 3.3:- In  Vitro Release Kinetics Data of Propranolol Hydrochloride and
Theophylline from CE5/B 1/Prop. CE5/Bl/Theo and ACE/BI Matrices Made at




Slope (%hr'1/2) 33.10 ±0.67
Intercept (%)
First Order:- logmflOO % - O) = kt
-0.11078 ± 0.00400 -0.01160 ± 0.00088 -0.04763 ± 0.00207 
1.9009 ± 0.0051 1.9262 ± 0.0060 1.8902 ± 0.0045
0.99838 ± 0.00064 0.99835 ± 0.00040 0.98778 ± 0.00088






0.99958 ± 0.00030 0.99942 ± 0.00033 0.99497 ± 0.00056
NB:- for details of CE5/Bl/Prop, CE5/Bl/Theo and ACE/BI formulations 
see tables 2.1 (a), 2.2 and section 2.3.2.
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tablets containing the former than in those containing the latter. As drug 
solubility in dissolution medium decreases, release becomes more and more 
dependent on drug dissolution rather than diffusion in hydrophobic matrices 
such as those made from processed HVO. ACE/BI matrices had lower 
propranolol hydrochloride release rates than CE5/B 1/Prop matrices (figure 3.4). 
In the preparation of ACE by melt - granulation (section 2.3.2), some of the 
drug was probably completely encapsulated by the hydrophobic HVO. This, 
probably, is the main reason why drug release was retarded in ACE/BI 
matrices.
3.5 E n h a n c e m e n t  o f  T e n sil e  St r e n g t h  o f  P r o c e sse d  HVO C o m pa c t s  
As indicated at the beginning of this chapter, process changes were studied in 
relation to the release - sustaining characteristics of the processed HVO tablets. 
The release - sustaining characteristics of processed HVO matrices could be 
inferred from the time for 50 % drug release (T50) or from the Higuchi 
release constant. Release - sustaining characteristics were directly related to T50 
and inversely related to the Higuchi release constant. T50 was used as the 
preferred method of summarising release data and release - sustaining 
characteristics, due to the directness of comparison with previously published 
data and because it enabled simple qualitative interpretation of a given 
controlled release efficiency.
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3.5.1 Effect of Binder Concentration on Tensile Strength and Release -
Sustaining Characteristics 
In this section, CE1/B 1/Prop - CE10/B 1/Prop (see tables 2.1(a) and 2.2) tablets 
made at approximately 12 kN were used. A compaction force of 12 kN was 
selected for the same reasons given in section 3.4. CE1 - CE10 were prepared 
as described in section 2.3.1.1. Effects of binder concentration on tensile 
strength and release-sustaining characteristics of the compacts are summarised in 
figures 3.5 and 3.6. Each point on the curve in figure 3.5 is a mean of 15 
tablets, while each point on the curve in figure 3.6 is a mean of 6 tablets. 
Tensile strength and release-sustaining characteristics values for each individual 
tablet are shown in appendix 1, tables A3 and A4.
Student t - tests and one way analysis of variance (ANOVAR) at 5 % 
significant level were carried out on the data. The calculated t value, tcai, and 
calculated F value, Fcal, as in the case of one way ANOVAR, were compared 
with values in the statistical tables (ttab, Ftab) at the appropriate degrees of 
freedom and probability, p, of 0.05.
Increase in binder concentration resulted in increase in tensile strength of the 
compacts (figure 3.5). Reports in the literature show that increasing amount of 
binder produce granules of greater strength than those of low binder 
concentrations,16,17 hence strong tablets. This is probably due to the formation 
of more and stronger inter-particulate bonds within the granules at high binder 
concentrations than at low ones.
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Figure 3.5:- Effect of PVP K-3Q (Binder) Concentration on Tensile
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NB:- for details of C E l/B l/Prop - CEIO/Bl/Prop formulations, see tables 2.1 
(a) and 2.2
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Figure 3. 6:- Effect of PVP K-30 (Binder) Concentration on Release 
-Sustaining Characteristics of C E1/B1/Prop - CE1Q/B1/Prop Matrices 
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PVP K-30 Concentration (% w/w) 
CE1/B1/Prop --------------------------- ► CE10/B1/Prop
NB:- for details of C E l/B l/Prop - CEIO/Bl/Prop formulations, see tables 2.1 
(a) and 2.2
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One way ANOVAR on the tensile strengths of tablets made from CE1/B 1/Prop 
- CE4/B 1/Prop (0 - 6 % w/w binder concentrations respectively) revealed that 
these tensile strengths were not significantly different (Fcai = 0.51, Ftab ~ 2.76, p = 
0.05). Therefore the minimum binder concentration that imparted appreciable 
improved tensile strength to the HVO compacts was approximately 7 % w/w
(figure 3.5). The maximum tensile strength was obtained with tablets made
from CE10/B 1/Prop (30 % binder concentration). As tensile strength improved, 
the release - sustaining characteristics gradually depreciated as shown in figure 
3.6. This was attributed to the hydrophilicity of the binder, PVP K-30, which 
probably enhanced drug leaching by acting as a channelling agent. Matrices 
containing 0 - 7.5 % binder concentration (CE1/B 1/Prop - CE5/B 1/Prop tablets) 
had the same release - sustaining characteristics (Fcai = 0.73, Ftab = 2.76). This was 
probably due to the feet that up to approximately 7 % binder concentration, 
the hydrophilicity nature of PVP K-30 had minimal effect on the release -
sustaining characteristics of the matrix. Above 7.5 % binder concentration, 
release - sustaining characteristics depreciated significantly (T50 = 1.79 ± 0.08 hr at
7.5 % (CE5/B 1/Prop) and T50 = 1.47 ± 0.13 hr at 10 % (CE6/B 1/Prop); tcai > 
5.13, ttab = 2.23, p = 0.05). Since PVP K-30 at approximately 7 %  improved
tensile strength but had negligible effect on release - sustaining characteristics, 
processed HVO containing 7.5 % w/w PVP K-30 (CE5/B 1/Prop) was 
investigated further.
Apparently the PVP K-30 did not alter the release mechanism of the processed 
HVO matrices. The binder probably gradually increased the porosity factor, e ,
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in the Higuchi equation which increased release. This is depicted by the shift 
to the left of the release profiles with increase in PVP K-30 concentration as
shown in figure 3.7 and the increase in the Higuchi release constant with
increase in binder concentration as shown in figure 3.8.
The characteristics of compacts made from the formulations containing varying 
concentrations of PVP K-30 (CE1/B 1/Prop - CE10/B 1/Prop) are shown in table 
3.4. As binder concentration increased the tablet relative density increased, 
being most marked from 15 % w/w to 30 % w/w binder concentration
(CE7/B 1/Prop - CE10/B 1/Prop respectively). This increase in compact relative 
density with increase in binder concentration was matched by a decrease in 
tablet thickness. This was possibly due to the formation of stronger and
possibly more bonds within the compacts at higher binder concentration than at 
lower ones. Total compaction time and tablet weight were relatively constant at 
all binder concentrations. However, dense strong tablets had poor release - 
sustaining characteristics due to the hydrophilic nature of PVP K-30.
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Figure 3.7:- Effect of PVP K-30 (Binder) Concentration on
Propranolol Hydrochloride Release from CE1/B 1/Prop, CE5/B 1/Prop. 
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7.5 % w/w 
20 % w/w 
30 % w/w
NB:- for details of CEl/B l/Prop - CEIO/Bl/Prop formulations, see tables 2.1 
(a) and 2.2
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F igu re  3.8:- Propranolol Hydrochloride Release According to the 
Higuchi M echanism, from C E l/B l/P rop . C E5/B l/Prop and 
CEIO /B l/Prop M atrices made at approximately 12 kN
Square Root Time (HourA1/2) 
PVP K-30 cone. Slope (%hr~1/2l Intercept (%)
Key:- — ■— 0 % w/w 
— • —  7.5%  w/w 































where:- CEl/B l/Prop contains 0 %  binder, CE5/Bl/Prop contains 7.5 %  
binder and CEIO/Bl/Prop contains 30 %  binder.
NB:- for details of CEl/B l/Prop, CE5/Bl/Prop and CEIO/Bl/Prop 
formulations see tables 2.1 (a) and 2.2. conc. = concentration
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Table 3.4:- The effect o f PVP K-30 Concentration on Properties of
CE1/B 1/Prop - CE10/B 1/Prop Tablets made at approximately 12 kN (n = 15)
[PVP] Tab. Rel. Dens. Tot. Comp. Tim. Tab. Weight Tab. Thickness 
% w/w (gem'3) (s) (mg) (mm)
mean sd mean sd mean sd mean sd
0 1.037 0.002 0.48 0.02 152.1 0.4 2.919 0.008
3 1.030 0.002 0.47 0.02 151.7 0.4 2.931 0.008
5 1.035 0.001 0.48 0.06 151.5 0.3 2.914 0.005
6 1.037 0.002 0.46 0.02 151.9 0.3 2.914 0.007
7.5 1.038 0.002 0.47 0.03 151.5 0.3 2.904 0.003
10 1.036 0.001 0.49 0.02 151.7 0.2 2.913 0.007
15 1.045 0.002 0.47 0.03 152.2 0.2 2.897 0.007
20 1.049 0.002 0.48 0.02 152.2 0.3 2.886 0.006
25 1.052 0.002 0.49 0.03 152.0 0.4 2.874 0.006
30 1.056 0.002 0.48 0.02 152.4 0.2 2.871 0.008
NB.- Tab. Rel. Dens. = Tablet Relative Density
Tot. Comp. Tim = Total Compression Time (contact time) 
Tab. Thickness = Tablet Thickness 
[PVP] = PVP K-30 Concentration
NB:- for details of CEl/Bl/Prop - CEIO/Bl/Prop formulations see tables 2.1 
(a) and 2.2
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3.5.2 Effect of Type of Binder on Tensile Strength and Release-
Sustaining Characteristics 
In this section, tablets were made at approximately 12 kN from CE1/B 1/Prop, 
CE5/B 1/Prop, CE12/B 1/Prop, CE13/B 1/Prop and CE14/B 1/Prop (see tables 2.1 
(a), 2.1 (b) and 2.2). CE1, CE5, CE12, CE13 and CE14 were prepared as 
described in section 2.3.1.1. Subsequent tablets had their tensile strength (15 
tablets per batch) and dissolution properties (6 tablets per batch) evaluated. The 
effect of the type of binder on tensile strength and release-sustaining 
characteristics of processed HVO tablets is summarised in figure 3.9. Student t 
- tests were done on the data obtained with results evaluated at the 5 % 
significance level.
Besides retaining the basic release-sustaining characteristics, CE12/B 1/Prop, 
which contained PVP K-90 as binder, (T50 = 1.90 ± 0.19 hr for CE12/Bl/Prop 
tablets and T50 = 1.85 ± 0.14 hr for CE1/B 1/Prop tablets; tcai = 0.52, ttab = 2.23, 
p = 0.05) produced tablets with significantly superior strength to those made 
from CE5/B 1/Prop, which contained PVP K-30 as binder, (tensile strength = 
1.362 ± 0.066 MN/m2 for CE12/B 1/Prop tablets and 1.246 ± 0.060 MN/m2 for 
CE5/B 1/Prop tablets; tcai = 5.22, ttab = 2.05). Since the former has a higher 
relative molecular mass (RMM = 360 kDa) than the latter (RMM = 40 kDa), this 
probably is the main reason why it is a better binder. PVP K-90 is also less 
hydrophilic than PVP K-30, therefore it has negligible effect on the release- 
sustaining characteristics of processed HVO tablets.
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Figure 3.9:- Effect of the Type of Binder in C E l/B l/P rop, 
CE5/Bl/Prop and CE 12/BI/Prop - CE14/B1/Prop tablets on Tensile 
Strength and Release - Sustaining Characteristics (F o rces  12 kN)
IT
CM 1.6-









Key:- 1 = CE1/B 1/Prop, no binder
2 = CE5/B 1/Prop, binder = PVP K-30
3 = CE13/Bl/Prop, binder = Luviskol
4 = CE12/B 1/Prop, binder = PVP K-90
5 = CE14/B 1/Prop, binder = Polyplasdone
NB:- for details of CEl/Bl/Prop, CE5/Bl/Prop and CE12/Bl/Prop- 
CE14/Bl/Prop formulations see tables 2.1 (a), 2.1 (b) and 2.2
T50
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Polyplasdone which has sometimes been termed a “super-disintegrant”, produced 
tablets (CE14/B 1/Prop tablets) with the best tensile strength compared to the 
other three binders (PVP K-30, PVP K-90 and Luviskol). However, it totally 
destroyed the release-sustaining characteristics of processed HVO matrix, as 
dissolution was complete within 15 minutes. Although Polyplasdone is insoluble 
in water, it is highly hydrophilic. Upon absorption of water, the lattice 
structure of Polyplasdone expands, 15 rupturing the processed HVO matrix. 
Unlike PVP which forms soft granules, Polyplasdone forms hard granules, hence 
stronger tablets than the former.
Luviskol imparted the same tensile strength properties to the processed HVO 
matrix (CE13/B 1/Prop) as PVP K-30 (CE5/B 1/Prop) although compacts made 
with the former had a slightly numerical higher value for strength than the 
latter (tensile strength = 1.267 ± 0.062 MN/m2 for CE13/B 1/Prop tablets and 
1.246 ± 0.060 MN/m2 for CE5/B 1/Prop tablets; tcai = 0.80). Furthermore, there is 
no significant difference between the release - sustaining characteristics of the 
tablets containing Luviskol and PVP K-30 as binders (tcai = 0.61). However, 
Luviskol unlike PVP, is a copolymer of PVP and polyvinylacetate. Further, this 
copolymer is not very stable because it is labile in hot solutions, or when 
subjected to vigorous stirring. Consequently, PVP K-30 was selected over 
Luviskol as binder.
PVP K-90 was selected over the other three binders for use in the final 
optimum composite excipient. It imparted significantly better tensile strength to
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processed HVO compacts than either Luviskol or PVP K-30 (tcai = 4.07 and 
5.22 respectively). Unlike Polyplasdone which destroyed the release-sustaining 
characteristics of processed HVO, PVP K-90 had negligible effect on the release
- sustaining characteristics of the matrix (tcai = 0.52).
The binders in order of increasing tensile strength of the tablets they produced 
were as follows:- PVP K-30 < Luviskol < PVP K-90 «  Polyplasdone. The 
order of the binders in reducing release - sustaining characteristics of processed 
HVO tablets followed the order:- Polyplasdone »  PVP K30 > Luviskol > 
PVP K-90.
3.5.3 Effect of Type of Matrix on Tensile Strength and Controlled
Release Efficiency
In this section, the basic release sustaining matrix material was either Sterotex 
K (CE5/B 1/Prop) or Compritol (CE15/B 1/Prop) (see tables 2.1 (a), 2.1 (b) and 
2.2). CE5 and CE15 were prepared as described in section 2.3.1.1. Tablets 
made at approximately 12 kN from the two formulations were subjected to 
dissolution tests and tensile strength measurement. The results are summarised in 
figure 3.10. The data was subjected to Student t - tests with results evaluated 
at the 5 % significance level.
CE5/B 1/Prop matrices, which contained Sterotex K (HVO) as the basic release
- sustaining characteristics matrix material, had significantly superior release- 
sustaining characteristics to CE15/B 1/Prop matrices, which contained Compritol
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Figure 3.10:- Effect of Type of Basic Release - Sustaining Matrix
Material on Tensile Strength and Release - Sustaining Characteristics
(Compaction Force » 12 kN)


















K e y :-1 = CE15/B 1/Prop Compritol Tensile strength
2 = CE5/B 1/Prop Sterotex K E— J  T50
NB:- for details of CE5/Bl/Prop and CE15/Bl/Prop formulations, see tables
2.1 (a), 2.1 (b) and 2.2
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(tcai = 4.66, ttab = 2.23, p = 0.05). However, there was no significant difference in 
tensile strength of the tablets made from the two formulations (tcai= 0.8, ttab = 
2.05). HVO was thus selected over Compritol for use in further studies as the 
basic release - sustaining characteristics matrix material due to its superior 
controlled release efficiency.
3.5.4 Optimisation of Tensile Strength and Release Sustaining 
Characteristics of Processed HVO Compacts
In this section, release - sustaining characteristics were inferred from T50 values 
rather than from the Higuchi release constants for the same reasons mentioned 
in section 3.5.
3.5.4.1 Effect of Particle Size on Tablet Tensile Strength and Release -
Sustaining Characteristics 
The general consensus is that one of the most important factors determining 
the strength of tablets is the particle size of the granulation or powder from 
which the compacts have been made. 18,23,25,135 Due to this fact, there is 
now more interest in particle engineering with a perspective of optimising 
compaction behaviour. 1 Therefore in order to utilise this property, in an 
attempt to optimise the tensile strength and release-sustaining characteristics of 
processed HVO, tablets were prepared at approximately 12 kN from different 
size fractions of CE5 (500-710 pm, 355-500 pm, 250-355 pm, 180-250 pm and 
<180 pm exclusively), plus propranolol hydrochloride (ratio = 110 : 40 
respectively). CE5 was prepared as described in section 2.3.1.1, while
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fractionation was done as described in section 2.3.3. The tablets made from 
these various size fractions plus drug, were subjected to tensile strength
evaluation (15 tablets per batch) and dissolution testing (6 tablets per batch). 
Tensile strength and release-sustaining characteristics values for each individual 
tablet are shown in appendix 1, tables A2 and A5 respectively.
The effect of particle diameter on compact tensile strength is summarised in
figure 3.11, while the effect of particle diameter on release - sustaining 
characteristics is summarised in figure 3.12. The properties of the resulting
compacts are shown in table 3.5. The data was subjected to Student t - tests
and one way ANOVAR, with evaluations done at the 5 % significance level.
Tablet tensile strength was found to increase with an increase in particle size, 
at small particle diameters and at large particle diameters (figure 3.11). The 
three medium particle diameters (180-250 pm, 250-355 pm, 355-500 pm)
produced tablets with the same tensile strength (Fcai = 0.7, Ftab ~ 3.23, p = 0.05).
There was a significant difference in tensile strength between tablets made from 
the smallest particles (< 180 pm) and tablets from the three medium particle 
size ranges (tcai > 3.49, ttab = 2.05). Further, significant difference in tensile
strength exists, between compacts made from the three medium particle size
ranges and compacts made from the largest particles (500-710 pm) (tcai ^  3.14).
This trend was almost mirrored by the effect of particle size on release -
















Figure 3.11;- The Effect o f Particle Diameter on Tensile Strength o f 

















Figure 3.12;- The effect of Particle Diameter on Release - Sustaining
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NB:- for details of CE5/Prop formulation see table 2.1 (a)
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Table 3.5:- The Effect o f Particle Diameter on Properties o f Compacts Made
from CE5/Prop at approximately 12 kN (n = 15)
Particle Size 
(pm)






mean sd mean sd mean sd mean sd
500-710 0.893 0.004 1.039 0.002 151.3 0.3 2.896 0.008
355-500 0.891 0.004 1.036 0.002 150.9 0.3 2.898 0.008
250-355 0.888 0.008 1.034 0.002 150.8 0.5 2.902 0.009
180-250 0.890 0.004 1.030 0.002 149.9 0.6 2.895 0.013
< 180 0.888 0.004 1.027 0.002 149.6 0.5 2.899 0.009
NB:- mean total compaction time = 0.48 ± 0.02 seconds 
Key:- Tab. Rel. Dens. = Tablet Relative Density 
Tab. Weight = Tablet Weight 
Tab. Thick. = Tablet Thickness 
NB:- for details of CE5/Prop formulation see tables 2.1 (a) and 2.2
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matrices made from the smallest particles (< 180 (im) had the same release - 
sustaining characteristics as matrices made from the three medium particle size 
ranges (180-250 [im, 250-355 (im, 355-500 pm) (Fcai = 1.5, Ftab = 3.10). However, 
compacts made from the largest particles (500-710 pm) had significantly 
superior release - sustaining characteristics to those made from the rest particle 
size ranges (tcai > 5.68).
Generally, for particles that mainly undergo plastic deformation, an increase in 
particle size result in weak compacts. High drug release rates are also expected 
with large particles due to increased inter-particulate porosity. However, in some 
systems, 94 drug release has been shown to decrease with an increase in particle 
size due to a reduction in surface area exposed to the dissolution medium. 
Literature generally suggest that the compaction of smaller particles of ductile 
materials such as HVOs, result in stronger compacts than larger particles. 
Smaller particles yield larger areas of true contact than larger particles after the 
rearrangement phase of consolidation, which promote the formation of more 
and/or stronger bonds than the latter do. 5’25,136,137 However, in some studies 
involving sodium chloride the reverse has been found. ’ ’ Generally, with 
ductile materials such as HVO, the difference in packing density is usually 
retained throughout the compaction process, with tablet strength and porosity 
dependent on initial particle size distribution.5
The larger particles of CE5/Prop had initial high die fill volumes compared to 
the'smaller particles, prior compaction. This implied different initial packing
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densities for the various particle size fractions. 5 Therefore the larger particles 
had a higher deformation potential than the smaller particles, 18 which resulted in 
significantly stronger compacts with the former than with the latter.
The fraction of the upper punch force transmitted to the stationary lower 
punch (R-value) significantly decreased with decrease in particle size (tcai =
2.16), between the 500-710 pm and 250-355 pm particles. Tablets made from
the two smallest particle size ranges (< 180 pm and 180-250 pm) had 
significantly smaller tablet weights than tablets made from the rest of the 
particle size ranges (tcai ^  4.10). This reason is probably sufficient to explain the
anomaly in the R-values post 250-355 pm (table 3.5).
Generally, there is a decrease in particle die wall friction as particle size 
increases due to a decrease in the true area of contact between the die wall 
and particles. A decrease in the ejection force as particle size increased has 
been reported.25,30 This has been attributed to an decrease in the force lost to 
the die wall due to two factors namely:- (a) a decrease in the total contact 
area and (b) a decrease in the effective shear strength. Therefore all these 
factors will cause larger particles to have:- (i) lower die wall contact areas, (ii) 
lower force lost to the die wall and (iii) more upper punch force transmitted 
to the lower punch; than smaller particles, on compaction. All this results in 
the production of stronger and less porous compacts with larger particles than 
with smaller particles, as obtained in this study.
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Generally, there is an increase in the force per unit area (pressure) on 
compaction of larger particles than smaller particles 137 due to the smaller total 
surface area of the former than the latter. This probably results in more partial 
melt-fusion (cold welding phenomenon) of the HVO and stearic acid in the 
formulation containing larger particles than that containing smaller particles. This 
promotes the formation of more solid bridge tablet bonds within the former 
than within the latter. In addition, large particles generally possess more 
strength than small ones, hence the formation of stronger compacts from the 
former than from the latter.
Nystrom and co-workers 8 found that for plastically deforming materials that 
probably partially melted during compaction (such as HVO), bonding with solid 
bridges occurred only for the coarser particles. The compacts produced were 
quite strong even though the surface area involved in the solid bridge 
formation, as measured by gas adsorption, was small in relation to the total 
surface area of the compact.
The constant compact strength with the three medium particle size ranges (180- 
250 pm, 250-355 pm, 355-500 pm) in figure 3.11, corresponding to the constant 
release - sustaining characteristics in figure 3.12, was attributed to the 
compensation between partial melting/fusion effects and ductile effects of these 
particles during compaction. It was concluded that large particles of CE5 (500- 
710 pm) containing propranolol hydrochloride, produced tablets with significantly 
superior tensile strength and release - sustaining characteristics than particles
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smaller than 500 jim. Therefore the final optimum formulation, CE29/B2/Prop 
(see tables 2.1 (e) and 2.2), contained a large proportion of large particles.
3.5.4.2 Effect of Compaction Force on Tablet Tensile Strength and Release-
Sustaining Characteristics 
The magnitude of the compacting load is one of the major determinants of the 
tensile strength of compacts. This is because it increases:- (i)the area of true 
contact between particles and (ii) the strength and/or number of bonds formed.3’ 
99 In the case of HVOs and other low melting substances, compaction force 
influences the extent of the partial melt - fusion phenomenon thereby affecting 
the number of solid bridges produced.
In order to determine the effect of compaction force on tensile strength and 
release - sustaining characteristics of processed HVO matrices, CE5/B 1/Prop 
(table 2.1(a) and 2.2), was compacted at 3 - 18 kN. The resulting tablets were 
evaluated for tensile strength and release - sustaining characteristics. The results 
are summarised in figures 3.13 and 3.14. The tablet properties are shown in 
table 3.6. For the tensile strength results (figure 3.13), each point on the curve 
is a mean of 15 tablets (except at approximately 6 kN, where n = 12), while 
for release - sustaining characteristics (figure 3.14), each point on the curve is a 
mean of 6 tablets. Tensile strength and release-sustaining characteristics values 
for each individual tablet are shown in appendix 1, tables A1 and A6 
respectively. Statistical analysis done on the data include Student t - tests and 
















Figure 3.13;- The Effect of Compaction Force on Tensile Strength
of Tablets Made from CE5/Bl/Prop
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Figure 3.14;- Effect of Compaction Force on Release - Sustaining
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NB:- for details of CE5/Bl/Prop formulation, see tables 2.1 (a) and 2.2
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Table 3,6:- The Effect o f Compaction Force on Properties o f Compacts Made
from CE5/Bl/Prop at approximately 12 kN (n =15)
Com For. Time R-value Tab. Mass Tab. Thick. Density
(kN) (s) (mg) (mm) (gem3)
mean sd mean sd mean sd mean sd mean sd mean sd
3.3 0.1 0.37 0.02 0.597 0.019 151.9 0.3 2.962 0.006 1.020 0.002
6.1 0.1 0.41 0.02 0.720 0.006 151.7 0.4 2.920 0.009 1.034 0.002
9.1 0.1 0.43 0.02 0.802 0.007 151.6 0.3 2.906 0.005 1.038 0.002
11.7 0.1 0.47 0.03 0.861 0.006 151.5 0.3 2.904 0.003 1.038 0.003
15.1 0.1 0.52 0.02 0.850 0.004 151.4 0.3 2.900 0.006 1.039 0.002
18.3 0.1 0.59 0.03 0.866 0.003 151.1 0.3 2.890 0.006 1.040 0.001
Where:-
Com For. = Compaction Force 
Time = Total Compression Time 
Tab. Thick. = Tablet Thickness 
Density = Tablet Relative Density 
sd = standard deviation 
NB:- for details CE5/Bl/Prop formulation see tables 2.1 (a) and 2.2
172
Compact tensile strength was found to increase with the compacting load to a 
limiting value/plateau (figure 3.13). Compacts made at approximately 9 kN - 15 
kN had constant maximum tensile strength (Fcai = 1.05, Ftab ® 3.23, p = 0.05) 
plus constant maximum relative density (table 3.6). This probably implied 
constant tablet porosity at these forces. Therefore the minimum force required 
to achieve maximum tensile strength was approximately 9 kN. Compacts made 
at approximately 6 kN and below had significantly lower tensile strength values 
than those made at approximately 9 kN and above (tcai ^ 2.60, ttab = 2.05, p = 
0.05).
The above results were mirrored by the effect of compaction force on release- 
sustaining characteristics of CE5/B 1/Prop matrices, summarised in figure 3.14. 
Tablets made at approximately 9 kN to 18 kN had the same maximum release - 
sustaining characteristics (Fcai = 0.6, Ftab ~ 2.76), confirming constant minimum 
matrix porosity at these compaction forces, thus the minimum force required to 
produce the maximum release - sustaining characteristics was also approximately 
9 kN. Tablets made at approximately 6 kN and below had significantly inferior 
release - sustaining characteristics to those made at approximately 9 kN and 
above (tcai ^  2.36).
Besides the magnitude of the compacting load, the duration and rate of 
application of a compacting load are also important in the final strength of a 
compact.3 The application of force to a material imparts work to that material. 
The amount of work is a function of the distance the upper punch penetrates
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into the die and power is a function of time over which the load is applied.
The greater the area under the force versus distance curve the greater the
work done. The work done is also a function of the magnitude of the 
compacting load. Due to manual operation of the tablet machine it was 
impossible to obtain constant compaction times at the different compaction 
forces (see table 3.6).
The rate of application of the load influences the materiars reaction to the
load while being compacted. During a compaction cycle, when the particles are
confined and exhibiting their characteristic flow properties, the rate of
application of the load is a major factor in determining compact strength. 3 
Generally, for ductile materials such as HVOs, slowing the press speed and 
increasing dwell/contact time favours more time-dependent deformation, 
producing stronger tablets than high press speed.5
However, as compaction force increased, it was noted that there was an
increase in CE5/B 1/Prop adhesion to tablet tooling. This was so, even though 
the tablet-die wall contact area decreased (tablet thickness = 2.962 mm at 
approximately 3.3 kN and tablet thickness = 2.890 mm at approximately 18.3 kN,
tcai = 32.86). This was attributed to an increased reaction at the lower punch.30
Also the fraction of the upper punch force transmitted to the lower punch 
increased with an increase in compaction force (R - value = 0.597 at 
approximately 3.3 kN and R - value = 0.866 at approximately 18.3 kN), thereby 
enhancing formulation adherence to tablet tooling surface.
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3.5.5 Scanning Electron Photomicrography of Tablet Surfaces
In this section, scanning electron photomicrography was carried out (as 
described in section 2.3.13) on CE5 (table 2.1(a)) fractionated plus propranolol 
hydrochloride (ratio 110:40 respectively) tablet surfaces and on CE5/B 1/Prop 
(table 2.1(a) and 2.2) tablet surfaces before and after dissolution. Tablets made 
from the fractionated formulations (i.e. various particle sizes of CE5), were 
made at approximately 12 kN, while those from CE5/B 1/Prop were made at 
approximately 3 -1 2  kN. The study was more of qualitative analysis rather than 
quantitative analysis. The aim was to visualise the surfaces of the compacts pre 
and post - dissolution so as to qualitatively assess the differences in terms of 
release - sustaining characteristics versus particle diameter and compaction force. 
Lockwood 96 used mercury porosimetry and helium diffusion through leached 
HVO matrices, to quantitatively determine the nature of the pore structure 
within the matrices. He found out that a wide pore size distribution existed 
within the HVO matrices.
In this study, single surfaces of tablets from different batches were examined at 
xl5 and x35 magnification. Four different fields from each tablet surface were 
examined for regularity and reproducibility. If these were all considered regular 
and representative of each other qualitatively, then one field was photographed 
twice to provide the record. The scanning electron photomicrography results are 
shown in figures 3.15 - 3.17. Figure 3.15 depicts photographs of CE5/Prop 
matrices made from:- (a) < 180 jam, (b) 250-355 pm and (c) 500-710 pm size
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Figure 3.15:- Scanning Electron Photomicrography of 
Tablets Made from Different Fractions of CE5/Prop. 
at approximately 12 kN. Imaged Before Dissolution
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1 0  K U
(a) Particle diameter = < 180 urn
(b) Particle diameter = 250-355 i^m
(c) Particle diameter = 500-710 pm
NB:- Compaction force « 12 kN
Figure 3.16:- Scanning Electron Photomicrography of 
Tablets Made from Different Fractions of CE5/Prop, 
at approximately 12 kN, Imaged After Dissolution
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1 0 K U
(a) Particle diameter = < 180 |im
1 0 K U
*
*
(b) Particle diameter = 250-355 jini
1 0  K U
(c) Particle diameter = 500-710 pm
NB:- Compaction force « 12 kN
Figure 3.17:- Scanning Electron Photomicrography of
Tablets Made from CE5/Bl/Prop at 3 Different 
Compaction Forces, Imaged After Dissolution
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(a) Compaction force » 3 kN
1 0 K U
(b) Compaction force « 6 kN
1 0KU 1 m m  0 3 0 0 4 8
(c) Compaction force » 12 kN
fractions, plus drug (propranolol hydrochloride), before dissolution. Figure 3.16 
shows photographs of CE5/Prop matrices made from the above size fractions 
plus drug, after dissolution. Figure 3.17 depicts photographs of CE5/B 1/Prop 
matrices made at:- (a) « 3 kN, (b) « 6 kN and (c) « 12 kN, after dissolution.
The scanning electron photomicrography results in figure 3.15 seemed to 
confirm the fact that processed HVO partially softened and/or melted on 
compaction and fused on decompaction to form solid compacts. The tablet 
surfaces made from the three different particle diameters ranges:- (a) <180 pm, 
(b) 250-355 pm and (c) 500-710 pm; plus drug (ratio = 110 : 40 respectively), 
before dissolution hardly show any particle structure.
As particle size increased the number of pores seemed to decrease in figure 
3.16 (compare (a) <180 pm and (c) 500-710 pm). This partly confirmed the 
theory that large particles partially melted and fused to a greater extent than 
small ones. These results seem to tie in with those in figure 3.12, which show 
better release - sustaining properties with tablets containing large particles (500- 
710 pm) than with those containing particles less than 500 pm in diameter (tcai ^  
5.68).
Compacts of CE5/B 1/Prop made at the two lower compaction forces 
(approximately 3 and 6 kN) did not seem to look different from each other 
(figure 3.17). However, the tablet made at approximately 12 kN appeared to
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have less pores than those made at the two lower forces. These results seem 
to tie in with those shown in figure 3.14, which depict significantly better 
release - sustaining characteristics at approximately 9 - 18 kN than at 
approximately 3 - 6  kN (tcai^  2.36).
3.6 R e d u c t io n  o f  A d h e sio n  o f  P r o c e sse d  HVO t o  T a b l e t  T o o l in g  
In this section, adhesion of lubricated and unlubricated CEll/Bl/Theo (tables 
2.1(a) and 2.2) to the upper punch face was evaluated. CE11 was prepared as 
described in section 2.3.1.1. The anti-adherents used were magnesium stearate, 
stearic acid, leucine and Compritol. Anti-adherent addition to CEll/Bl/Theo 
was done as described in section 2.3.6. Evaluation of formulation adhesion to 
the upper punch face was done as described in section 2.3.7.4.
The effect of the different anti-adherents at two different concentrations (1 % 
and 5 %) on CEll/B l/Theo’s adhesion to the upper punch face is summarised 
in figure 3.18, while the effect of the anti-adherents on the tensile strength of 
compacts made from CEll/Bl/Theo at approximately 12 kN is summarised in 
table 3.7. The tensile strengths of tablets made from CE11/B1 and 
CE11/B 1/Prop at approximately 12 kN are also shown in table 3.7. The data 
on tensile strength was subjected to Student t - tests and results analysed at the 
5 % significance level.
With all the anti-adherents used except magnesium stearate, adhesion was found 
to gradually increase with time (figure 3.18). Magnesium stearate was an
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Figure 3.18:- Effect of Type and Concentration of Anti-adherent on
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— *—  Stearic acid 5%
 No antiadherent




Table 3.7;- The Effect o f Type and Concentration o f Anti-adherent on the
Tensile Strength o f Tablets Made from CEll/Bl/Theo at approximately 12kN
Anti-adherent Formulation Tensile Strength (MNm'2)
added mean sd
None CE11/B1 0.964 0.066
None CE11/B 1/Prop 1.267 0.073
None CEll/Bl/Theo 1.370 0.084
Mg Stearate 1 % CEll/Bl/Theo 1.277 0.053
Leucine 1 % CEll/Bl/Theo 1.330 0.050
Leucine 5 % CEll/Bl/Theo 1.310 0.057
Compritol 1 % CEll/Bl/Theo 1.353 0.063
Compritol 5 % CEll/Bl/Theo 1.455 0.070
Stearic acid 1 % CEll/Bl/Theo 1.378 0.078
Stearic acid 5 % CEll/Bl/Theo 1.543 0.070
NB:- for details of CE11/B1, C E ll/B l/P rop  and C E ll/B l/Theo 
formulations, see tables 2.1 (a) and 2.2
(n = 15)
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effective anti-adherent for CEll/Bl/Theo at both concentrations (1%  and 5%). 
After 700 cycles there was negligible difference in anti-adherent activity between
1 % magnesium stearate and 5 % magnesium stearate. There was, however,
marked capping in tablets containing 5 % magnesium stearate such that no
tensile strength measurements were performed on these tablets. The 1 % 
magnesium stearate tablets’ adhesion to tablet tooling was negligible but their 
loss in tensile strength was significant (tcai = 3.64, ttab = 2.05, p = 0.05)
(compared to CEll/Bl/Theo tablets without anti-adherent). Magnesium stearate 
and stearic acid have the same basic carbon chain, Cig, with the former having 
a higher melting point (approximately 88.5° C) 116 than the latter (51-69°). 109111 
This probably accounts for the different anti-adherent properties of the two 
materials.
Compritol at both concentrations reduced adhesion to tablet tooling. However, 
tablets containing 5 % Compritol showed minor capping during the cycle run. 1 
% Compritol and 1 % stearic acid did not significantly alter the tensile strength 
of CEll/B l/Theo compacts (tcai = 0.63 and 0.27 respectively) (compared to 
CEll/Bl/Theo without anti-adherent). However, both lubricants at 5 %
concentration, significantly improved tensile strength (tcai = 6.12 for stearic acid 
and tcai = 3.02 for Compritol), with stearic acid having a significantly more 
marked effect than Compritol (tcai = 3.44). This was attributed to the lower 
melting point of stearic acid (51-69°) 109,111 than that of Compritol (67-72° C). 
109 Due to their relatively low melting points, Compritol and stearic acid 
probably partially melt upon compression just as the HVO does, and on
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decompression they fuse (cold welding effect). This, possibly, helps in the 
formation of strong and/or more bonds/solid bridges. Even though 5 % stearic 
acid had deleterious effects by enhancing CEll/Bl/Theo adhesion to tablet 
tooling, due to the fact that it had a more significant positive effect on tensile 
strength than 5 % Compritol, it was included in future CE formulations, so as 
to function as an “auxiliary” binder to the PVP.
There was hardly any difference between the adhesion of CEll/Bl/Theo 
containing 1 % stearic acid and CEll/Bl/Theo without anti-adherent (figure 
3.18). CEll/Bl/Theo containing 5 % stearic acid had very poor flowabihty 
properties and this is the reason why only 240 cycles were run with this 
formulation. Generally, as glidant concentration increases in a formulation, 
flowabihty improves up to a certain point, thereafter it is impeded. 17 Therefore 
this could be responsible for the poor flowabihty properties of this formulation.
Up to approximately 500 cycles, 1 % leucine had better anti-adherent effect 
than 5 % Compritol (figure 3.18). The former at 1 % concentration had no 
negative effect on the tensile strength of CEll/Bl/Theo compacts (tcai = 1.59), 
(compared to CEll/Bl/Theo without anti-adherent), but, 5 % leucine had a 
significant negative effect on tensile strength (tcai = 2.28). Despite this, 5 % 
leucine had superior anti-adherent properties than ah the other anti-adherents, 
except magnesium stearate. However, 1 % magnesium stearate had a greater 
negative effect on the tensile strength of CEll/Bl/Theo compacts (tcai = 3.64) 
than 5 % leucine (tcai = 2.28), therefore leucine was selected over magnesium
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stearate for use in the final optimum formulation to function as an anti­
adherent.
Theophylline (CEll/Bl/Theo tablets without anti-adherent) imparted significantly 
better tensile strength properties to the HVO matrix than propranolol 
hydrochloride (CE11/B 1/Prop tablets without anti-adherent) (tcai = 3.57). 
However, both formulations produced tablets with higher tensile strength values 
than those produced from CE11/B1.
Lubricants generally interfere with particle bonding by forming a lubricant film 
around the particle during blending. 15 Fragmenting particles like lactose, are 
less sensitive or even insensitive to lubricants as compared to plastically 
deforming solids such as HVO, sodium chloride and starch. This is due to the 
creation of clean surfaces free of lubricant during fragmentation of the former.5 
The anti-adherents used in order of increasing anti-adherent activity are as 
follows:-
stearic acid < Compritol < leucine < magnesium stearate.
Therefore the beneficial effects of processed HVO include:- (i) significantly 
improved tablet tensile strength, (ii) improved release - sustaining characteristics, 
(iii) inproved anti-adhesion properties, (iv) compaction force independent drug 
release and release - sustaining characteristics after approximately 9 kN and (v) 
comp action force independent tablet tensile strength after approximately 9 kN.
191
CHAPTER 4
MODIFICATION OF THE MECHANISM OF DRUG RELEASE 
FROM PROCESSED HVO MATRICES
4.1 O b j e c t iv e s
In this part of the study, the main objective was to alter the release profile of 
processed HVO tablets from the predominantly Higuchi type drug release 
(square root of time depended drug release) to zero order or still more 
desirably, to an increase in drug release rate with time. Drug release was 
evaluated in terms of the data fit to the above mechanisms, as well as first 
order and difliision-relaxation models. The overall objective was to formulate a 
per-oral controlled release tablet system capable of releasing all the drug within 
12 hours in the proximal colon.
All the dissolution tests were carried out as described in section 2.3.12. As in 
chapter 3, the error bars on all the figures in this chapter are standard errors 
of mean, while the ± values quoted in the text and the tables are standard 
deviations.
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4.2 E n h a n c e m e n t  o f  D r u g  R e l e a s e  f r o m  P r o c e s s e d  HVO M a t r ic e s
Although processed HVO matrices fulfil the “protracted” drug release aspect of 
controlled release, the release rate is probably not high enough for the 
maintenance of therapeutic blood levels. This is especially important where the 
target site is the proximal colon where drug absorption is reduced due to 
consolidation of faecal matter and poor absorption capability by colonic 
epithelium. 66 Therefore this section was aimed at increasing the release rate of 
processed HVO tablets with time as a means of compensating for the factors 
mentioned above.
Three hydrophilic materials, Junlon, Avicel and Starch 1500; were each 
incorporated into composite excipient formulations at 5 % concentration as 
described in section 2.3.1.2.1 to produce CE16 - CE18 (see table 2.1 (c)). 
Tablets made from CE16/B 1/Prop - CE18/B 1/Prop (see also table 2.2) at 
approximately 12 kN were subjected to dissolution testing. The resulting release 
data up to approximately 60 % was analysed according to the Higuchi model 
and first order mechanism. For the Higuchi mechanism, cumulative drug release 
was plotted against the square root of time. For first order release, logio 
(<amount o f  propranolol hydrochloride remaining in the matrix), was plotted 
against time. Linear regression analysis (with the aid of a microcomputer 
software programme, Microcal Origin) was carried out on the resulting plots 
for each individual tablet.
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Linear regression analysis data for each tablet is shown in appendix 1, tables A9 
and A10. The in vitro propranolol hydrochloride release kinetics from tablets of 
the above formulations is summarised in table 4.1, while their release profiles 
are shown in figure 4.1.
The hydrophilic materials tested can be arranged with respect to their effect on 
enhancing propranolol hydrochloride release in the following order:- Avicel < 
Starch < Junlon (figure 4.1). The in vitro release kinetics revealed that drug 
release fitted square-root of time kinetics better than first order mechanism 
especially with CE18/B 1/Prop tablets which contained Junlon. However, with 
CE17/B 1/Prop and CE16/B 1/Prop tablets, which contained Starch 1500 and 
Avicel respectively, first order mechanism seemed to fit the drug release data 
equally well. All the matrices made from the three formulations (CE16/Bl/Prop- 
CE18/Bl/Prop) gradually disintegrated with time.
With CE18/B 1/Prop, which contained Junlon, propranolol hydrochloride release 
was complete within 3 hours (figure 4.1), indicating that these tablets had the 
minimum release-sustaining characteristics. The superior effect of Junlon in 
accelerating drug release was probably due to its marked contribution to create 
pores in the matrix. Junlon has a high affinity for water and is soluble in 
water. 129 It is a polymer of acrylic acid and therefore has got free carboxylic 
groups (-COOH) with the majority probably in the ionised state (-COO- + H*) 
in the de-aerated distilled water (pH =5.5 ±0.1) used in the dissolution tests.
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Table 4.1:- In Vitro Release Kinetics of Propranolol Hydrochloride from
CE16/B 1/Prop - CE18/B 1/Prop Tablets made at approximately 12 kN (n = 6)
CE18/Bl/Prop CE17/Bl/Prop CE16/Bl/Prop




First Order:- logm(100 %  - Q) = kt
-0.51959 ±0.12989 -0.18927 ± 0.02482 -0.15935 ± 0.02245
2.0834 ± 0.0576 1.9089 ± 0.0090 1.8992 ± 0.0087
0.99370 ± 0.00377 0.99968 ± 0.00026 0.99960 ± 0.00041
Higuchi Mechanism:- O = k t1/2 
84.52 ±9.30 44.45 ±3.22 39.79 ±3.13
-24.05 ±4.63 3.17 ±1.84 5.46 ± 1.70
0.99936 ± 0.00078 0.99975 ± 0.00015 0.99960 ± 0.00041
NB:- for details of CE16/Bl/Prop - CE18/Bl/Prop formulations, see tables
2.1 (c) and 2.2
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Figure 4.1:- The Effect o f the Type of Hydrophilic Material on 
Propranolol Hydrochloride Release from CE16/B 1 /Prop-CE 18/B1 /Prop 


















NB:- for details of CE5/Bl/Prop, CE16/Bl/Prop-CE18/Bl/Prop formulations, 
see tables 2.1(a), 2.1 (c) and 2.2
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These highly hydrophilic groups probably increased the wettability and rapid 
solvent penetration into the tablets, to dissolve the propranolol hydrochloride 
rapidly so that it would diffuse out. Therefore Junlon might have increased the 
porosity, e , of the tablets and reduced the diffixsional distance of the drug, 
propranolol hydrochloride, by rupturing the tablets.
Starch is a well known binder and disintegrant. Like Junlon, it is also 
hydrophilic and dissolves slowly in hot water. It can form a paste with cold 
water. It probably exerted its effect on the HVO matrix (CE17/B 1/Prop) 
by swelling and wicking. 15 Starch is a mixture of naturally occurring high 
molecular weight polysaccharides, amylose and amylopectin. Amylose (straight 
chains) make up 20-30 % of starch grains while amylopectin (branched chains) 
make up 70-80 % of the grains. The starch used in this study, Starch 1500, is 
partially hydrolysed and probably contains more amylose than natural starch 
does. It is only the amylose component, which although insoluble in cold 
water, absorbs a large amount of water and swells. It is therefore most likely 
responsible for the rupture of the HVO matrix. However, the extent of 
swelling in starch grains and the nature of the force created is not fully 
accepted and understood. 15 Starch is also known to increase porosity of tablets 
due to its non-compressibility and low cohesiveness. Therefore water can wick 
into the tablet as a result of pore capillarity or sorption and dissolve the drug 
before allowing it to elute out. Further, the general opinion is that at high 
compaction forces, starch grains deform plastically, although at low compaction 
forces, starch grains are generally thought to deform elastically. 15 These
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deformed starch grains are energy rich and swell rapidly in water, rupturing the 
matrix. In addition, these 3 factors (swelling, wicking, deformation) of starch 
grains, probably reduced tortuosity, t, increased porosity, e , of the matrices and 
reduced the diffusional distance for propranolol hydrochloride.
Although Avicel (MCC) is insoluble in water, it has hydroxyl groups (-OH) 
which render it hydrophilic. These groups probably help in wicking water into 
the CE16/B 1/Prop tablets which dissolves and elutes out the propranolol 
hydrochloride. The matrix gradually disintegrated with time due to the 
hydrophilicity of the Avicel. The Avicel probably enhanced matrix wettability 
and reduced the diffusional distance which improved propranolol hydrochloride 
release.
4.3 A l t e r a t io n  o f  M e c h a n ism  of  Dr u g  R e l e a se  f r o m  Pr o c e sse d  HVO
M a t r ic e s
As indicated in chapter 2, oral controlled release formulations targeted to the 
proximal colon, preferably, ought to have an increasing release rate with time 
so as to counteract the consolidation of faecal matter as the drug delivery 
system moves up the colon. 66 Therefore this section was aimed at altering the 
predominately Higuchi model release mechanism of processed HVO matrices to 
at least zero order or more preferably to an increasing release rate with time. 
Total drug release was targeted to be complete within 12 hours as this is 
approximately the total proximal colon transit time. 66
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4.3.1 Effect of Biological Enzymes on Propranolol Hydrochloride Release
from Processed HVO Matrices
Lipase and esterase were used at pH 7.00 to try and degrade the processed 
HVO within 12 hours. Tablets were made from CE5/B 1/Prop (tables 2.1 (a) 
and 2.2) at approximately 12 kN. CE5 was prepared as described in section 
2.3.1.1. An excess of enzyme was added to each dissolution vessel (lipase = 75 
units; esterase =171 units; per dissolution vessel). The results are shown in 
figure 4.2.
There was no significant difference between the release profile without enzyme 
and the ones with enzymes. Since the vegetable oil is hydrogenated it probably 
ceased to be a natural enzyme substrate. This, coupled with the fact that 
enzymatic activity is at molecular level with effects hardly recognisable after 12 
hours, is probably sufficient to account for the insignificant alteration in drug 
release. Most enzymatic activities on bioerodible polymers and materials become 
manifest after a couple of weeks or even months.42
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Figure 4.2;- The Effect o f Biological Enzymes on Propranolol 
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Key:- — ■—  No enzyme
— • —  Lipase
 ^   Esterase
NB:- for details of CE5/Bl/Prop formulation, see tables 2.1 (a) and 2.2
200
4.3.2 Propranolol Hydrochloride Release from Tablets made from Mwerol- 
Based Water-Free Composite Excipient Formulations
In order to assess alteration of propranolol hydrochloride release from 
processed HVO matrices containing Myverol, propranolol hydrochloride release 
from Myverol compacts without the HVO was investigated first. Since the 
Myverol was too soft to be processed into tablets on its own, it was adsorbed 
on carriers, silicas (Aerosil® 200, Sipemat® D17, Sipemat® 22 and Aerosil® 
R 974), as described in section 2.3.1.3, to form the following composite 
excipients:- CE19, CE20, CE21 and CE22 (table 2.1 (d)). Tablets were then 
made from the resulting formulations:- CE19/B3/Prop, CE20/B3/Prop 
CE21/B3/Prop and CE22/B3/Prop (see also table 2.2) at approximately 3 - 1 2  
kN. It was difficult to make tablets at compaction forces greater than 12 kN 
due to excess tablet tooling adhesion and compact lamination and picking.
The formulations had very high die fill volumes, especially CE19/B3/Prop and 
CE22/B3/Prop which contained Aerosil 200 and Aerosil R 974 respectively, as 
carriers. Therefore each sample had to be manually packed into the die using a 
long thin spatula. Besides this, due to the low melting point of the Myverol 
there was an excess of tablet tooling adhesion by the formulations. Hence 
before and after each tablet compaction, a mixture of MCC and magnesium 
stearate (1:1) was compressed in order to lubricate the die and punches so as 
to reduce adhesion. With all precautions taken, tablets made from 
CE19/B3/Prop - CE22/B3/Prop formulations still were somewhat flaky especially 
at high compaction forces and with Aerosil 200 and Aerosil R974 as carriers.
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When Aerosil 200, Sipemat D17 and Aerosil R 974 were used as carriers 
(CE19/B3/Prop, CE20/B3/Prop and CE22/B3/Prop respectively), drug release 
was faster at high compaction forces than at low ones. This was possibly 
due to minute tablet lamination and picking at these high forces. Aerosil R974 
and Sipemat D17 which have been termed “hydrophobic silicas” produced 
formulations (CE22/B3/Prop and CE20/B3/Prop respectively), with higher release 
rates than those of Aerosil 200 (CE19/B3/Prop) and Sipemat 22 
(CE21/B3/Prop), at all compaction forces. When Sipemat 22 was used as 
carrier, tablets produced were more compact and less flaky than those made 
from the other three carriers (Aerosil 200, Aerosil R 974 and Sipemat D17), 
with release from the former tablets gradually decreasing with increase in 
compaction force. From this study, the order of increasing hydrophilicity of the 
three carriers was as follows:-
Sipemat D17 < Aerosil R 974 < Sipemat 22 < Aerosil 200
Propranolol hydrochloride release rates from CE19/B3/Prop and CE21/B3/Prop 
tablets made at approximately 9 kN and calculated as illustrated below are
shown in figure 4.3. Propranolol hydrochloride release profile of CE22/B3/Prop
tablets made at approximately 9 kN is in figure 4.4, while the corresponding
release rates calculated in the same manner illustrated below are shown in
figure 4.5.
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Figure 4.3;- Propranolol Hydrochloride Release Rate from
CE19/B3/Prop and CE21/B3/Prop Tablets M ade at approximately 9 kN
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NB:- for details of CE19/B3/Prop and CE21/B3/Prop formulations, see 




























Figure 4.4:- Propranolol Hydrochloride Release from CE22/B3/Prop
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Figure 4.5;- Propranolol Hydrochloride Release Rate from
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NB:- for details of CE22/B3/Prop formulation, see tables 2.1 (d) and 2.2
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As an example, drug release rates from CE19/B3/Prop tablets were calculated 
as follows: -
Cumulative drug release (%) 0.00 25.83 34.90 41.68 48.20 54.12 ...........98.57
Time (hours) 0.00 0.50 1.00 1.50 2.00 2.50 .........  12.00
drug release rate at tn< = {r25.83-0.00Vr0.50-0.00l} %/hour = 51.66 %/hour
What is of important significance is that CE21/B3/Prop tablets were capable of 
releasing propranolol hydrochloride at a constant release rate from 2.0 to 3.5 
hours (1.5 hours) (Fcai = 0.2, Ftab = 3.10, p = 0.05). CE22/B3/Prop tablets’ release 
profile (figure 4.4) had two distinct regions (regions 1 & 2) with different 
release rates. Region 1 (0.3-1.6 hours) had a higher constant (Fcai = 0.30, F^b ~ 
1.98, p = 0.05), release rate than region 2 (1.7-4.0 hours) (Fcai = 1.58, Ftob « 1.63, 
p = 0.05), as shown in figure 4.5. The initial constant release rate was possibly 
due to drug release from the deaggregating tablets. The second constant release 
rate was attributed to drug release from the deaggregated tablet particles. In 
this stage the Myverol was probably in the cubic phase form, hence a lower 
sustained release fashion. 119
Therefore Myverol was incorporated into HVO composite excipients during 
processing in order to attempt to alter the drug release mechanism of 
processed HVO tablets (square root of time dependency) so as to achieve at 
least zero order drug release.
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4.3.3 Determination of Optimum Myverol Concentration
Various Myverol concentrations (10 - 40 % w/w) were incorporated into HVO 
formulations as described in section 2.3.1.2.2, to produce CE23 - CE26 (table
2.1 (e)). Tablets were then made at approximately 12 kN from the resulting 
formulations:- CE23/B 1/Prop, CE24/B 1/Prop, CE25/B 1/Prop and CE26/B 1/Prop 
(see also table 2.2). The resulting tablets were subjected to dissolution testing. 
Propranolol hydrochloride release rates from the tablets are summarised in 
figure 4.6. These release rates were calculated in the same manner as in 
section 4.3.2.
As Myverol concentration increased there was a corresponding increase in tablet 
tooling adhesion of the formulations, hence there was need to compress MCC 
and magnesium stearate mixture (1:1) before and after each tablet compaction. 
Concentrations of Myverol greater than 40 % w/w produced composite 
excipients impossible to process due to stickiness.
Tablets made from CE23/B 1/Prop - CE26/B 1/Prop formulations gradually 
disintegrated with time dining dissolution testing. This was probably due to the 
Myverol acting as a surfactant and plasticizer, weakening the matrix structure. 
This effectively decreased the drug diffiisional distance. Figure 4.6 shows 
Myverol formulations’ release rates relative to baseline (no Myverol) release 
rates. These values increased with Myverol concentration from 10-30 % 
(CE23/B 1/Prop - CE25/B 1/Prop tablets respectively). At 40 % Myverol 
concentration (CE26/B 1/Prop tablets), release rates were lower than those of
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Figure 4.6;- The Effect of Myverol Concentration on Propranolol
Hydrochloride Release Rate from CE23/Bl/Prop - CE26/Bl/Prop
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tablets made from CE25/B 1/Prop (30 % Myverol concentration). CE25/B 1/Prop 
tablets were found to have enhanced release rates that were constant for 1.5 
hour (1.0-2.5 hours) (Fcai = 0.33, Ftab = 3.10, p = 0.05). Therefore CE25/B 1/Prop 
was further investigated.
CE30/B 1/Prop (tables 2.1 (e) and 2.2) tablets which contained hydrogenated 
rapeseed oil at an equivalent Myverol concentration (i.e. 30 % w/w) in 
CE25/B 1/Prop, still released drug via the Higuchi mechanism, although the 
release rates were higher than those of CE5/B 1/Prop (tables 2.1 (a) and 2.2) 
matrices made at the same compaction force.
4.3.4 Drug Release Properties of Tablets made from Composite Excipient 25
Formulation (30 %  Myverol!
Propranolol hydrochloride release from CE25/B 1/Prop (tables 2.1 (e) and 2.2) 
tablets (up to approximately 90 % release) made at approximately 3, 6 and 15 
kN was analysed according to zero order, Higuchi mechanism and diffusion- 
relaxation models. Release greater than 60 % was selected because constant 
release rates were obtained after approximately 50-60 % release. For zero order 
and Higuchi plots for each individual tablet, linear regression analysis was 
applied. The linear regression analysis data for each tablet according to the 
above mechanisms is in appendix 1, tables A ll  and A10 respectively. For the 
diffusion - relaxation model, multiple regression analysis was done on the data, 
with amount of drug released, Q, as the dependent variable, and time, t046 and 
t,092 (see equation 1.37 in section 1.5.1.6.2), as the independent variables.
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Multiple regression analysis data on each individual tablet according to this 
model is in appendix 1, table A 12. All linear regression analysis and multiple 
regression analysis were carried out with the aid of a microcomputer software, 
Microcal Origin. The in vitro release kinetics of propranolol hydrochloride from 
CE25/B 1/Prop tablets made at approximately 3, 6 and 15 kN are shown in 
table 4.2.
Propranolol hydrochloride release from CE25/B 1/Prop tablets made at 
approximately 3, 6 and 15 kN was poorly explained by the zero order model 
(table 4.2). The diffusion - relaxation model was a superior fit to the Higuchi 
mechanism in explaining drug release from CE25/B 1/Prop tablets especially at 3 
and 6 kN (r = 0.99975 and 0.99977 respectively). However, the relaxation 
contribution (denoted by k2), at low compaction forces (« 3 kN) was 
significantly higher than that at high compaction forces (« 15 kN) (tcai = 3.01, 
ttab = 2.26, p = 0.05). Therefore low compaction forces were selected over 
high ones, since they enhanced the relaxation and ultimate erosion of the 
matrix.
Therefore, by incorporating Myverol at 30 % w/w into the HVO formulation, 
the predominantly diffusion controlled square root of time dependent release 
mechanism of the tablets was altered to a diffusion coupled with relaxation 
mechanism, especially at low compaction forces. All the tablets gradually 
disintegrated with time, possibly due to effects of Myverol. Even though 
Myverol is a non - dispersible non - ionic water insoluble material, it is still a
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Table 4.2:- In Vitro Release Kinetics of Propranolol Hydrochloride from 
CE25/B 1/Prop Matrices made at approximately 3. 6 and 15 kN (n = 6)
« 3 k N « 6 kN « 1 5  kN
Zero Order:- O = kt
Slope (% hr1) 23.30 ± 1.68 22.46 ± 1.26 22.09 ± 2.27
Intercept (%) 22.28 ± 1.73 21.59 ±0.95 22.98 ±2.01
r 0.99288 ±0.00323 0.99311 ±0.00237 0.98883 ± 0.00244
Higuchi model:- O = k t1/2
Slope (%hr'1/2) 54.09 ±3.73 53.34 ±5.42 54.19 ±2.94
Intercept (%) -5.77 ± 3.16 -5.77 ±3.64 -7.41 ± 1.71
r 0.99852 ±0.00088 0.99865 ±0.00117 0.99931 ±0.00084
Diffusion Relaxation Model:- O = kit046 + k,t®92
ki (%hr'0 46) *36.57 ±2.50 36.59 ±7.94 48.40 ±7.30
k2 (%hr 092) *10.42 ±2.90 9.91 ±4.11 4.40 ±3.65
Intercept (%) *0.15 ±0.12 -0.53 ±3.91 -5.42 ±2.75
r *0.99975 ± 0.00007 0.99977 ± 0.00026 0.99951 ±0.00063
NB:- for details of CE25/Bl/Prop formulation see tables 2.1 (e) and 2.2
* n = 5
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“surface active” substance. Its two free hydroxyl groups (-OH) on the glyceryl 
moiety are hydrophilic and probably helped in rapid tablet surface wetting 
followed by gradually relaxation and ultimate erosion of the matrix.
Release - sustaining characteristics of CE25/B 1/Prop tablets could be inferred 
from the Higuchi constant (even though drug release from CE25/B 1/Prop was 
best explained by the diflusion-relaxation model), or T50 (time for 50 % drug 
release). Release - sustaining characteristics were inversely related to the Higuchi 
constant and directly related to T50. T50 was the preferred method for 
evaluating the above properties for the same reasons mentioned in chapter 3, 
section 3.5.
The T50 values used in release - sustaining characteristics evaluation are shown 
in table 4.3. Release - sustaining characteristics of CE25/B 1/Prop tablets were 
constant over approximately 3 - 15 kN compaction force range (Fcai = 0.64, Ftab = 
2.76, p = 0.05). Compacts made at approximately 18 kN had significantly 
inferior release - sustaining characteristics in comparison to the rest of the 
compacts (tcai ^ 3.76, tub = 2.23, p = 0.05). This was possibly due to tablet 
lamination at these high compaction forces. Therefore, CE25/B 1/Prop tablets 
had compaction force independent release - sustaining characteristics from 
approximately 3 to 15 kN. In contrast, CE5/B 1/Prop matrices had compaction 
force independent release - sustaining characteristics from approximately 9 to 18 
kN (see section 3.5.4.2).
212
Table 4.3:- Release - Sustaining Characteristics of CE25/B 1/Prop Matrices made
at Different Compaction Forces
Tab. « 3 k N  » 6  kN «9 kN «12 kN « 1 5 k N  « 1 8 k N
T50 VALUES (Hours)
1 1.13 1.08 1.16 0.94 1.01 0.95
2 0.99 1.17 1.02 1.14 1.26 0.92
3 1.01 1.06 1.18 1.19 1.11 1.09
4 1.10 1.16 1.11 1.17 1.25 0.96
5 1.11 1.17 1.27 1.07 1.08 0.92
6 1.13 1.25 1.14 1.17 0.97 0.94
mean 1.08 1.15 1.15 1.11 1.11 0.96
sd 0.06 0.07 0.08 0.09 0.12 0.05
NB:- for details of CE25/Bl/Prop formulation see tables 2.1 (e) and 2.2
Tab. = Tablet
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Propranolol hydrochloride release rates from CE25/B 1/Prop and CE5/B 1/Prop
tablets made at approximately 3 kN, from 1.0 to 3.5 hours, are shown in 
figure 4.7. Release rates were calculated in the same manner as in section
4.3.2. Drug release rate from CE25/B 1/Prop tablets was constant from 1.50 -
3.25 hours (Fcai = 0.49, Ftab = 2.25, p = 0.05). These compacts released 
propranolol hydrochloride via zero order mechanism for 1.75 hours within the 
release profile (figure 4.7). In contrast, CE5/B 1/Prop tablets’ release rate 
decreased with time within the same time period (figure 4.7). CE25/B 1/Prop 
tablets made at approximately 6 and 9 kN had release rate profiles similar to 
those of tablets made at approximately 3 kN, although the actual release rates 
were lower and the duration for constant release rate were smaller as well 
Compacts made at compaction forces greater than 9 kN did not have constant 
release rates within their release profiles. Their release rates gradually decreased 
with time just as CE5/B 1/Prop tablets’ did. Therefore low compaction forces 
were selected since they enhanced constant release rates within the release
profiles.
The effect of particle size on release - sustaining characteristics of CE25/Prop 
compacts made at approximately 3 kN is summarised in figure 4.8. Maximum 
release - sustaining characteristics were achieved at approximately 428 jim (355- 
500 (im) particle diameter (tcai = 0.21). Probably at this particular particle 
diameter, CE25/Prop compacts achieved the minimum porosity. However, below 
355-500 pm particle diameter, release - sustaining characteristics steadily increased 
with increase in particle diameter.
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Figure 4.7:- Propranolol Hydrochloride Release Rate from






























1.0 1.5 2.0 2.5 3.0 3.5
T i m e  ( H o u r s )
Key:- — ■—  CE25/B 1/Prop tablets
— 9 —  CE5/B 1/Prop tablets
NB:- for details of CE5/B 1/Prop and CE25/Bl/Prop formulations, see tables








Figure 4.8:- The Effect of Particle Diameter on Release - Sustaining
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NB:- for details of CE25/Prop formulation, see table 2.1 (e)
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CE25 tablets made at approximately 3 kN from four particle size fractions
(500-710 pm, 355-500 pm, 250-355 pm, and 180-250 pm) plus propranolol
hydrochloride (ratio = 110 : 40 respectively) did not have constant release rate 
within their release profiles such as that observed with CE25/B 1/Prop tablets 
where a multi-blend particle size composite excipient was used. These tablets 
from size fractionated CE25 plus drug had release rates that mainly decreased 
with time. However, tablets made at approximately 3 kN from the smallest 
particles of CE25 (< 180 pm), plus propranolol hydrochloride (ratio = 110 : 40 
respectively), had a constant drug release rate within the release profile, but 
this was not as pronounced and prolonged as that obtained with CE25/B 1/Prop 
tablets made at the same compaction force. It seems as if a blend of the 
particle size fractions of CE25, such as B l, B2 or B3 (table 2.2), was 
necessary for the constant release rate within the release profile to be obtained.
To investigate whether the constant release rate within the release profile of
CE25/B 1/Prop compacts was either a matrix property or a drug property, an
alternative drug, theophylline was used in place of propranolol hydrochloride. 
Tablets made at approximately 3 kN from CE25/Bl/Theo (tables 2.1 (e) and
2.2) were subjected to dissolution testing. The results are summarised in figures 
4.9 and 4.10.
With theophylline, release rate became constant from approximately 7 hours but 
after approximately 13 hours, there was a “second burst” release followed by 






















Figure 4.9;-Theophylline Release from CE25/Bl/Theo Tablets made
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NB:- for details of CE25/Bl/Theo formulation see tables 2.1 (e) and 2.2
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Figure 4.10:- Theophylline Release Rate from CE25/Bl/Theo Tablets

















0 5 15 2510 20
Time (Hours)
NB:- for details of CE25/Bl/Theo formulation see tables 2.1 (e) and 2.2
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second burst release was a matrix property. Due to the fact that theophylline 
has a lower solubility than propranolol hydrochloride, the potential of the 
HVO/Myverol matrix was more apparent with the former than with the latter. 
These results also seem to suggest that the relaxation and erosion of the 
HVO/Myverol matrix is time dependent.
4.3.5 Optimisation of the Constant Release Rate or “Second Burst” Release
Even though a constant release rate and a second burst release was obtained 
by incorporating Myverol into HVO formulation and processing to produce a
composite excipient, CE25 (table 2.1 (e)), it was not as pronounced and 
prolonged as desired. Consequently, a fifth ingredient, Eudragit S100, at two 
different concentrations (20 % w/w and 30 % w/w) was incorporated into the 
HVO formulations and processed to respective composite excipients, CE27 and 
CE28 (see table 2.1 (e)), as described in section 2.3.1.2.2. Tablets were
prepared at 3 - 18 kN from CE27/B3/Prop and CE28/B3/Prop (see also table
2.2) and then subjected to dissolution testing. Drug release profiles from 
CE27/B3/Prop and CE28/B3/Prop tablets made at approximately 6 kN are 
shown in figure 4.11.
CE28/B3/Prop compacts were found to have a more enhanced second burst 
release than CE27/B3/Prop compacts (figure 4.11). All the six tablets of each 
formulation had this characteristic second burst release starting after
approximately 2 hours. This second burst release was found to be more 
pronounced at low compaction forces than at high ones. Since CE28/B3/Prop
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Figure 4.11:- Propranolol Hydrochloride Release from Tablets made 
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NB:- for details of CE27/B3/Prop and CE28/B3/Prop formulations, see 
tables 2.1 (e) and 2.2
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tablets had a more enhanced second burst release than CE27/B3/Prop tablets, 
CE28 was selected over CE27.
An optimum formulation, CE29/B2/Prop (tables 2.1 (e) and 2.2), based on the 
results obtained in the various sections of the study was prepared. CE29 was 
prepared as described in section 2.3.1.2.2. CE29/B2/Prop contained a high 
percentage of large particles as these enhanced release - sustaining characteristics 
and compact tensile strength (sections 3.5.4.1). Myverol and Eudragit S100 
were incorporated so as to alter and enhance the drug release mechanism 
respectively (sections 4.3.2 - 4.3.5). PVP K-90 was used as the binder (section
3.5.2), while leucine functioned as the anti-adherent (section 3.6). Tablets were 
made at relatively low compaction forces (approximately 6 kN) since these 
enhanced matrix relaxation and erosion (section 4.3.4). Dissolution was carried 
out in distilled water and in buffer solutions. The results are summarised in 
figures 4.12 - 4.15.
CE29/B2/Prop’s adherence to tablet tooling was much less than that of 
CE25/B 1/Prop. This was partly due to the effects of leucine, the anti-adherent, 
and Eudragit S100. However, CE29/B2/Prop adhered more to tablet tooling 
than CE5/B 1/Prop, with the former’s compact tensile strength (0.693 ± 0.052 
MN/m2) being approximately half that of the latter (1.253 ± 0.120 MN/m2), (n = 
15), (as measured by Schleuniger, type 2E, Germany).
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Figure 4.12:- Propranolol Hydrochloride Release from CE29/B2/Prop
Tablets made at approximately 6 kN, in Distilled W ater



























Figure 4.13:- Propranolol Hydrochloride Release Rate from
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NB:- for details of CE29/B2/Prop formulation, see tables 2.1 (e) and 2.2
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Figure 4.14:- Propranolol Hydrochloride Release from CE29/B2/Prop
Tablets made at approximately 6 kN. in Buffer Solutions
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F igure 4 .15:- Propranolol Hydrochloride Release Rate from







NB:- for details of CE29/B2/Prop formulation, see tables 2.1 (e) and 2.2
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CE29/B2/Prop tablets gradually eroded with time, both in distilled water and in 
the buffer solutions. Propranolol hydrochloride release from these tablets in 
distilled water appeared to follow zero order release mechanism as shown in 
figure 4.12. However, on consideration of figure 4.13, which is the summary of 
the corresponding drug release rate from 0.7 - 2.5 hours, after approximately 
1.5 hours there was a gradual increase in release rate with time for 
approximately half an hour.
Propranolol hydrochloride was initially released into pH 1.4 (simulated gastric 
pH) buffer solution for 2 hours which approximates the mean gastric residence 
time. The tablets were then transferred into pH 6.8 (simulated small intestine 
pH) buffer solution (figure 4.14). There was a significant increase in drug 
release and drug release rate in pH 6.8 (tcai = 3.22).
According to the Henderson-Hasselbalch equation:- 
pH = pKa + logio {[base]/[salt]}, 
the percent fraction of the salt form of the drug (propranolol hydrochloride), 
which is soluble in water, at pH 1.4 is 99.99 % while at pH 6.8 this is 99.8 
% (pKa « 9.5). 114 Since there were no propranolol hydrochloride solubility 
problems with the buffer solutions used, the increase in release rate with time 
in the buffer solutions was solely a time factor rather than a pH factor.
Approximately 70 % of the propranolol hydrochloride was released in the 
gastric simulated pH while the remainder was released in the small intestine
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simulated pH. For a per-oral controlled release system intended for the 
proximal colon, it is preferable that no drug is released in the stomach, 
followed by minimal release along the small intestine and maximum release as 
the system enters the proximal colon.
Therefore drug release from processed HVO tablets can be altered from the 
predominantly Higuchi mechanism of release to a constant release rate and/or 
increase in release rate with time, within the release profile, by the 
incorporation of a non - dispersible non - ionic surfactant, Myverol, into the 
formulation and controlling the particle size distribution and the compaction 
force.
4.3.6 Analysis of Mechanism of Propranolol Hydrochloride Release from 
Tablets Made from Composite Excipient 29 Formulation, in Distilled Water
As previously stated in section 4.3.5, tablets made from CE29/B2/Prop (tables 
2.1(e) and 2.2) gradually eroded with time in the dissolution medium and this 
effectively reduced the drug diffusional distance, altering the predominately 
square root of time dependent release kinetics. The release data up to 
approximately 90 % (so as to include analysis of the second burst release 
which started after approximately 60 % release), from CE29/B2/Prop tablets 
made at approximately 6 kN, was analysed according to zero order, Higuchi 
mechanism, first order and diffusion - relaxation models. The regression analysis 
data on each individual tablet according to the above mechanisms is shown in 
appendix 1, tables A ll ,  A10, A9 and A12 respectively. The in vitro release
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kinetics of propranolol hydrochloride from CE29/B2/Prop matrices according to 
the above mechanisms is shown in table 4.4. The Fickian diffusion and case II 
relaxation fractions at each time, t, are shown in figure 4.16.
Clearly, propranolol hydrochloride release from CE29/B2/Prop tablets did not 
follow first order release kinetics (table 4.4). Although zero order and Higuchi 
mechanisms had approximately the same fit (r = 0.99503 and 0.99450 
respectively), the Higuchi mechanism suggested a relatively long lag time before 
drug release (intercept = -12.48 ± 1.84). Since the Myverol, a surfactant, is 
supposed to enhance tablet wetting, the Higuchi intercept was expected to be 
zero or at least close to zero. Zero order mechanism gave a relatively high 
intercept (intercept = 15.23 ± 1.19). Drug release from CE29/B2/Prop matrices 
was best described by the diffusion - relaxation model (r = 0.99960). The Fickian 
release constant (ki = 28.38 ± 3.03) was significantly higher than the relaxation 
constant (k2 = 21.06 ± 2.52) (tcai = 4.54, tub = 2.23, p = 0.05).
Figure 4.16 shows that the Fickian diffusion contribution was initially 
predominant over the relaxation contribution. The relaxation contribution became 
predominant after approximately 1.9 hours. The Fickian diffusion fraction, F, 
was calculated according to equation 1.39 in section 1.5.1.6.2:-
F = 1/{1 + (kj/kijt046}
The relaxation (Case II) fraction, Fr, was calculated according to the following 
equation:-
Fr= 1 - F
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Table 4.4:- In Vitro Release Kinetics of Propranolol Hydrochloride from 
CE29/B2/Prop Tablets made at approximately 6 kN. in Distilled Water (n = 6)
First Order:- logmdOO %  - O) = kt 
Slope (h r1) -0.3780310.06098
Intercept 2.0482 ± 0.0327
r 0.96792 ±0.01990
Zero Order:- O = kt
Slope (% hr1) 32.17 ±1.80
Intercept (%) 15.23 ±1.19
r 0.99503 ±0.00215
Higuchi Mechanism:- Q = kt1/2
Slope (%hr'1/2) 63.93 ±3.61
Intercept (%) -12.48 ±1.84
r 0.99450 ±0.00354
Diffusion - Relaxation Mechanism:- O -  kit0,46 + k?t092
ki (%hr'046) 28.38 ±3.03
k2 (%hr'092) 21.06 ±2.52
Intercept (%) 0.03 ± 0.09
r 0.99960 ±0.00034
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Figure 4.16:- Fickian Diffusion Release Fractions and Case-II 
Relaxation Release Fractions from CE29/B2/Prop Tablets made at 
approximately 6 kN, in Distilled W ater
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NB:- for details of CE29/B2/Prop formulation, see tables 2.1 (e) and 2.2
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Therefore drug release from CE29/B2/Prop tablets probably involved rapid 
wetting due to Myverol, followed by a predominantly Fickian diffusion coupled 
with gradual relaxation and ultimate erosion of the matrix. The gradual 
relaxation and erosion of the matrix were primarily due to Myverol and 




The physico-mechanical properties of hydrogenated vegetable oil (HVO), 
Sterotex K, tablets were significantly improved by processing the HVO with 
binders. Incorporation of an additional meltable binder such as stearic acid 
during processing, reinforced compact strength. Tablet tensile strength was 
found to be dependent on type and concentration of binder. Highly hydrophilic 
binders such as Polyplasdone reduced release-sustaining characteristics of the 
matrix.
Large particles of processed HVO composite excipient (500-710 pm exclusively), 
were found to produce compacts of significantly superior tensile strength to the 
remainder of the particle sizes (355-500 pm, 250-355 pm, 180-250 pm, < 180 
pm exclusively). This was attributed to the greater extent in partial melt-fusion 
in the former than the latter due to:- (a) increased pressure per unit surface 
area, (b) increased fragmentation potential and (c) reduced inter-particle and die- 
tablet wall contact. The medium particle sizes (355-500 pm, 250-355 pm, 180- 
250 pm exclusively), produced tablets with the same tensile strength. It was 
hypothesised that there was compensation between partial melt-fusion effects and 
ductile effects in these particles. The smallest particles (< 180 pm) produced 
tablets with significantly inferior tensile strengths in comparison to the rest of 
the particle sizes. The above trend almost mirrored the effect of particle size 
on release - sustaining characteristics of processed HVO tablets. The only
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difference was that 355-500 pm, 250-355 pm, 180-250 (am and < 180 jam 
particles produced compacts with the same release sustaining characteristics.
Compact strength and release-sustaining characteristics of processed HVO 
formulations were found to be dependent on compaction force up to 
approximately 9 kN. Thereafter compact strength and release-sustaining 
characteristics were independent of compaction force. However, processed HVO 
formulation containing 30 % Myverol had compaction force independent release- 
sustaining characteristics from 3 to 15 kN.
Addition of lubricants to processed HVO formulations significantly, reduced 
tablet tooling adhesion. Anti-adherent activity was dependent on the type and 
concentration of lubricant. However, lubricants significantly reduced the tensile 
strength of the matrix by effectively reducing the total area of clean surfaces 
capable of forming bonds. Due to the fact that tensile strength of processed 
HVO tablets was dependent on particle size and tablet lubricants concentration, 
it was concluded that the main mechanism of consolidation in this material is 
plastic deformation.
The beneficial effects of processing a HVO include:-
• significantly improved tablet strength,
• significantly improved anti-adhesion properties,
• improved release-controlling efficiency and
• compaction force independent drug release and tablet strength.
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However, incorporation of a hydrophobic binder with strength imparting 
properties of Polyplasdone would be desirable. A HVO with a higher melting 
point than Sterotex K/soybean oil would help in reducing tablet tooling 
adhesion.
Drug release from processed HVO matrices was explained by a 
diffusion/dissolution model corresponding to the Higuchi mechanism Addition of 
hydrophilic materials such as Avicel, Starch 1500 and Junlon improved drug 
release without altering the release mechanism Enzymes such as lipase and 
esterase failed to degrade the ester-linkages of the HVO within 12 hours. This 
was attributed to the relatively short time period and the fact that Sterotex K
probably ceases to be a natural enzymatic substrate due to hydrogenation.
Incorporation of a mainly monoglyceride material, Myverol, (30 %), into HVO 
formulations and processing to composite excipients altered the drug release 
mechanism of the resulting tablets. This form of processed HVO released drug 
via a diffusion - relaxation model. Tablets altered from a monolithic formulation 
to disintegrating tablets. An increase in release rate with time was obtained for 
at least half an hour within the dissolution profile. Such a release profile would
be desirable in drug targeting to the proximal colon. However, in order to
target such a system to the proximal colon, there ought to be a lag time 
corresponding to gastric residence time plus small intestine transit time. Delay 
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CE5/Bl/Prop Tablets: Effect of Compaction Force on Tensile Strength
UP force R - value Tot. Time Tab. Weight Tab. Thick. Tens. Str. 
(kN) (s) (mg) (mm) (MN/m2)
3.4 0.622 0.35 152.5 2.970 0.994
3.3 0.581 0.35 152.3 2.965 1.112
3.2 0.558 0.35 151.8 2.958 1.168
3.2 0.575 0.37 151.7 2.949 1.134
3.3 0.574 0.37 152.0 2.963 1.099
3.4 0.610 0.39 152.2 2.968 1.034
3.4 0.617 0.35 152.2 2.963 0.998
3.3 0.597 0.41 151.7 2.962 1.064
3.3 0.587 0.38 151.8 2.957 1.160
3.3 0.592 0.41 151.8 2.957 1.134
3.4 0.604 0.35 151.8 2.968 1.119
3.3 0.622 0.36 151.8 2.963 1.141
3.4 0.607 0.35 151.7 2.959 1.100
3.3 0.591 0.36 151.6 2.970 1.172
3.4 0.612 0.38 152.0 2.963 1.180
I
Table A1 continued
UP Force R - value Tot. Time Tab. Weight Tab. Thick. Tens. Str. 
(kN) (s) (mg) (mm) (MN/m2)
6.0 0.725 0.43 151.1 2.905 1.248
6.2 0.731 0.41 152.1 2.920 1.154
6.2 0.716 0.43 152.0 2.919 1.233
6.0 0.720 0.44 151.1 2.918 1.128
6.1 0.726 0.42 151.3 2.919 1.235
6.0 0.725 0.42 151.6 2.915 0.925
6.3 0.722 0.44 152.3 2.932 1.211
6.2 0.717 0.40 152.1 2.925 1.129
6.2 0.727 0.41 152.1 2.934 1.187
6.0 0.718 0.40 151.9 2.927 1.079
5.9 0.716 0.41 152.2 2.927 1.185
5.8 0.718 0.40 152.0 2.923 0.965
9.1 0.802 0.42 151.8 2.902 1.234
9.1 0.795 0.39 151.3 2.906 1.198
9.0 0.790 0.44 151.3 2.902 1.232
9.1 0.805 0.41 151.6 2.903 1.237
9.2 0.803 0.44 152.5 2.912 1.142
9.3 0.791 0.44 151.6 2.906 1.254
n
Table A1 continued
UP Force R - value Tot. Time Tab. Weight Tab. Thick. Tens. Str. 
(kN) (s) (mg) (mm) (MN/m2)
9.1 0.808 0.44 151.5 2.908 1.280
9.3 0.793 0.43 151.4 2.904 1.303
9.2 0.810 0.39 151.7 2.907 1.359
9.1 0.810 0.42 151.8 2.906 1.285
9.0 0.809 0.42 151.2 2.901 1.231
9.2 0.809 0.42 151.6 2.909 1.137
9.1 0.801 0.45 151.4 2.900 1.262
9.0 0.802 0.46 151.5 2.900 1.213
9.3 0.802 0.45 152.1 2.917 1.038
11.9 0.869 0.54 151.3 2.904 1.248
11.9 0.860 0.44 151.5 2.905 1.093
11.7 0.865 0.42 151.5 2.905 1.241
12.0 0.866 0.48 152.2 2.908 1.343
11.6 0.863 0.44 151.3 2.904 1.330
11.9 0.862 0.46 151.8 2.906 1.205
11.6 0.868 0.45 151.4 2.904 1.188
11.6 0.860 0.50 151.4 2.904 1.263
11.8 0.872 0.48 151.3 2.903 1.290
m
Table A1 continued
UP Force R -value Tot Time Tab. Weight Tab. Thick. Tens. Str. 
(kN) (s) (mg) (mm) (MN/m2)
11.7 0.857 0.47 151.5 2.905 1.257
11.7 0.858 0.52 151.8 2.906 1.258
11.7 0.859 0.50 151.7 2.905 1.235
11.6 0.851 0.46 151.2 2.900 1.201
11.5 0.859 0.44 151.0 2.896 1.256
11.8 0.851 0.51 151.3 2.903 1.255
15.1 0.855 0.48 151.1 2.897 1.388
15.1 0.855 0.52 151.4 2.897 1.239
15.0 0.852 0.49 151.0 2.898 1.256
15.3 0.853 0.51 151.7 2.906 1.270
15.1 0.852 0.50 151.5 2.903 1.351
15.2 0.848 0.52 151.3 2.898 1.264
15.2 0.852 0.51 151.7 2.904 1.263
15.0 0.855 0.50 151.2 2.889 1.112
15.1 0.848 0.52 151.6 2.908 1.272
15.4 0.847 0.52 151.8 2.903 1.174
15.1 0.848 0.52 151.5 2.907 1.208













15.1 0.845 0.53 151.3 2.893 1.336
15.3 0.843 0.55 151.8 2.904 1.107
15.0 0.844 0.54 150.8 2.889 1.112
18.4 0.864 0.57 151.3 2.898 1.228
18.2 0.866 0.57 151.3 2.886 1.256
18.2 0.866 0.67 151.0 2.891 1.062
18.2 0.866 0.57 150.9 2.891 1.047
18.2 0.868 0.62 151.0 2.886 1.231
18.4 0.862 0.60 151.6 2.896 1.251
18.4 0.863 0.57 151.3 2.891 1.251
18.4 0.863 0.52 151.4 2.897 1.199
18.2 0.862 0.58 150.9 2.888 1.301
18.2 0.870 0.59 151.3 2.891 1.154
18.2 0.868 0.59 151.4 2.891 1.199
18.4 0.872 0.61 151.4 2.899 1.209
18.3 0.870 0.59 151.0 2.883 1.278
18.3 0.870 0.59 150.9 2.886 1.171
18.1 0.868 0.60 150.5 2.880 1.171
V
Table A2
CE5/Prop Tablets: Effect of Particle Size on Tensile Strength
UP Force 
(kN)








500 - 710 jim
12.2 0.897 0.56 151.3 2.896 1.332
12.1 0.894 0.50 151.5 2.909 1.294
11.9 0.898 0.49 151.0 2.893 1.360
12.0 0.897 0.52 151.7 2.903 1.396
11.9 0.894 0.51 151.1 2.885 1.473
11.9 0.896 0.51 150.9 2.890 1.436
11.9 0.885 0.53 151.4 2.902 1.205
11.8 0.890 0.52 150.7 2.886 1.278
11.8 0.884 0.48 151.4 2.901 1.276
12.0 0.898 0.54 151.4 2.895 1.173
11.9 0.892 0.51 151.2 2.902 1.242
12.1 0.893 0.54 151.4 2.900 1.263
12.1 0.889 0.49 151.6 2.908 1.427
11.8 0.894 0.51 151.3 2.891 1.283














12.4 0.890 0.49 151.1 2.906 1.211
12.0 0.881 0.47 150.4 2.886 1.196
11.9 0.892 0.46 150.6 2.892 1.235
12.2 0.898 0.47 151.0 2.901 1.054
11.9 0.890 0.45 150.6 2.896 1.140
12.0 0.887 0.47 150.7 2.889 1.094
12.2 0.891 0.47 151.0 2.899 1.197
12.1 0.899 0.46 151.2 2.894 1.340
11.9 0.892 0.47 151.1 2.897 1.270
11.9 0.892 0.49 150.4 2.888 1.263
12.3 0.899 0.48 151.2 2.909 1.173
12.2 0.887 0.45 151.3 2.908 1.211
12.3 0.895 0.46 151.1 2.909 1.234
12.2 0.888 0.48 151.0 2.896 1.232














11.9 0.893 0.50 150.4 2.892 1.284
11.8 0.890 0.53 150.7 2.900 1.257
11.8 0.886 0.52 150.9 2.906 1.189
11.6 0.877 0.54 149.7 2.880 1.189
12.7 0.903 0.54 150.4 2.895 1.303
12.6 0.896 0.50 150.2 2.895 1.158
12.8 0.903 0.55 150.9 2.904 1.223
12.9 0.891 0.53 151.0 2.906 1.317
11.6 0.883 0.48 150.7 2.897 1.202
11.6 0.885 0.47 151.0 2.904 1.238
11.5 0.881 0.46 150.3 2.901 1.263
11.6 0.879 0.47 150.8 2.900 1.199
12.0 0.881 0.45 151.9 2.914 1.195
11.8 0.880 0.49 151.3 2.916 1.287













180 - 250 |im
12.4 0.887 0.45 150.3 2.902 1.080
11.8 0.893 0.45 149.0 2.879 1.196
12.5 0.897 0.47 150.7 2.902 1.184
12.3 0.895 0.47 150.1 2.898 1.082
12.0 0.895 0.47 149.7 2.891 1.278
12.2 0.890 0.45 150.0 2.897 1.219
11.7 0.890 0.45 149.2 2.879 1.166
11.9 0.882 0.45 149.7 2.887 1.221
11.7 0.887 0.47 149.0 2.878 1.214
12.3 0.894 0.47 150.2 2.907 1.369
11.8 0.884 0.49 149.6 2.880 1.257
11.9 0.890 0.50 149.8 2.898 1.133
12.2 0.892 0.52 150.5 2.909 1.346
12.5 0.889 0.47 151.3 2.920 1.156














12.1 0.889 0.46 149.4 2.885 1.178
12.1 0.891 0.45 149.0 2.886 1.151
12.4 0.892 0.47 149.9 2.904 1.147
12.4 0.887 0.44 150.0 2.903 1.024
12.0 0.890 0.46 149.2 2.896 1.131
12.0 0.882 0.46 149.2 2.896 1.069
11.7 0.884 0.44 149.0 2.890 1.108
12.4 0.893 0.44 149.7 2.911 1.140
12.0 0.888 0.46 149.7 2.901 1.173
11.9 0.886 0.44 149.4 2.890 1.123
11.8 0.882 0.47 149.7 2.903 1.044
11.8 0.894 0.47 149.5 2.898 1.159
12.0 0.885 0.44 150.5 2.902 1.006
11.7 0.890 0.44 149.0 2.895 1.060
12.4 0.893 0.44 150.3 2.919 1.223
X
Table A3
Effect of Binder Concentration on TensPe Strength
UP Force 
(kN)






0% w /w  (CEl/Bl/Prop)
12.0 0.823 0.46 152.1 2.910 1.242
12.1 0.822 0.52 151.8 2.925 1.116
12.3 0.825 0.47 152.6 2.920 1.139
11.9 0.825 0.47 152.0 2.914 1.145
12.1 0.825 0.48 151.5 2.915 1.017
12.3 0.825 0.50 151.9 2.913 1.254
12.2 0.823 0.49 151.5 2.910 1.210
12.4 0.832 0.49 152.2 2.919 1.177
12.1 0.822 0.47 152.0 2.918 1.151
12.4 0.830 0.54 151.7 2.912 1.174
12.3 0.826 0.48 152.2 2.930 0.935
12.6 0.823 0.48 152.5 2.931 1.230
12.4 0.824 0.46 152.6 2.934 1.074
12.4 0.830 0.46 152.5 2.922 1.138











3% w /w  (CE2/Bl/Prop)
12.0 0.844 0.49 151.8 2.939 1.220
11.8 0.847 0.48 151.6 2.925 1.165
11.8 0.844 0.47 151.6 2.934 1.054
11.8 0.842 0.46 151.5 2.931 1.099
11.7 0.841 0.45 151.4 2.917 1.120
11.7 0.842 0.46 151.2 2.919 1.262
11.9 0.846 0.47 151.7 2.937 1.217
11.7 0.852 0.46 151.7 2.930 1.155
11.9 0.846 0.49 151.7 2.927 1.159
11.9 0.850 0.47 151.4 2.922 1.249
11.9 0.885 0.46 151.6 2.939 1.048
11.9 0.847 0.44 152.3 2.938 1.144
11.8 0.844 0.47 152.4 2.937 1.327
11.9 0.847 0.51 152.3 2.940 1.090











5 %  w/w (CE3/Bl/Prop)
12.1 0.841 0.48 151.4 2.915 1.232
12.3 0.839 0.45 151.5 2.918 1.306
12.1 0.855 0.47 151.4 2.910 1.269
12.3 0.853 0.52 152.0 2.918 1.188
12.4 0.849 0.46 151.7 2.918 1.056
12.2 0.856 0.51 151.4 2.912 1.064
12.5 0.852 0.50 152.0 2.923 1.085
12.3 0.847 0.46 151.5 2.914 1.044
12.3 0.845 0.47 151.5 2.908 1.319
12.2 0.844 0.47 151.2 2.905 1.201
12.5 0.840 0.49 151.5 2.908 1.211
12.5 0.842 0.47 151.5 2.912 1.297
12.5 0.845 0.47 151.6 2.911 1.282
12.5 0.849 0.47 151.1 2.915 1.056











6 %  w/w (CE4/Bl/Prop)
12.0 0.857 0.46 151.8 2.915 1.284
12.4 0.856 0.44 152.5 2.929 1.113
11.8 0.850 0.45 151.8 2.912 1.273
11.8 0.847 0.49 151.9 2.908 1.233
11.9 0.853 0.46 151.8 2.916 1.339
12.0 0.847 0.47 152.2 2.919 1.191
11.9 0.851 0.46 151.9 2.920 0.909
11.9 0.856 0.48 152.2 2.914 1.328
11.9 0.841 0.48 152.1 2.910 1.170
11.9 0.848 0.45 151.7 2.916 1.214
11.8 0.842 0.48 151.3 2.906 1.027
12.1 0.851 0.44 152.0 2.914 1.076
11.9 0.849 0.44 151.7 2.910 1.222
12.0 0.850 0.44 152.0 2.916 1.191













7.5 %  w/w (CE5/Bl/Prop)
11.9 0.869 0.54 151.3 2.904 1.248
11.9 0.860 0.44 151.5 2.905 1.093
11.7 0.865 0.42 151.5 2.905 1.241
12.0 0.866 0.48 152.2 2.908 1.343
11.6 0.863 0.44 151.3 2.904 1.330
11.9 0.862 0.46 151.8 2.906 1.205
11.6 0.868 0.45 151.4 2.904 1.188
11.6 0.860 0.50 151.4 2.904 1.263
11.8 0.872 0.48 151.3 2.903 1.290
11.7 0.857 0.47 151.5 2.905 1.257
11.7 0.858 0.52 151.8 2.906 1.258
11.7 0.859 0.50 151.7 2.905 1.235
11.6 0.851 0.46 151.2 2.900 1.201
11.5 0.859 0.44 151.0 2.896 1.256













10 %  w/w (CE6/Bl/Prop)
12.0 0.826 0.47 151.6 2.906 1.455
12.1 0.825 0.45 151.6 2.912 1.216
12.3 0.828 0.48 151.8 2.919 1.290
12.1 0.824 0.47 151.2 2.902 1.414
12.1 0.823 0.48 151.6 2.907 1.370
12.1 0.823 0.48 151.9 2.919 1.336
11.9 0.819 0.45 151.7 2.908 1.388
12.3 0.820 0.51 152.0 2.917 1.299
12.1 0.824 0.48 151.5 2.904 1.061
12.0 0.822 0.48 151.9 2.916 1.214
12.4 0.831 0.47 151.5 2.914 1.314
12.4 0.826 0.50 152.2 2.925 1.158
12.3 0.823 0.53 151.7 2.914 1.329
12.4 0.826 0.53 151.8 2.919 1.238
12.0 0.818 0.50 151.6 2.912 1.203
XVI
Table A3 continued
UP Force R -value Tot. Time Tab. Weight Tab. Thick. Tens. Str. 
(kN) (s) (mg) (mm) (MN/m2)
11.8 0.844












































20 %  w/w (CE8/Bl/Prop)
11.9 0.836 0.48 152.3 2.889 1.297
11.9 0.833 0.46 152.4 2.884 1.340
11.8 0.836 0.47 152.0 2.880 1.467
11.7 0.839 0.43 152.3 2.879 1.463
11.7 0.839 0.47 152.0 2.885 1.401
11.6 0.843 0.48 152.1 2.887 1.529
11.8 0.842 0.48 152.1 2.886 1.406
11.7 0.843 0.48 152.4 2.892 1.270
11.6 0.840 0.46 151.8 2.883 1.403
11.9 0.844 0.50 152.2 2.889 1.443
12.2 0.845 0.50 152.8 2.900 1.214
11.7 0.839 0.46 152.0 2.881 1.376
11.9 0.849 0.52 152.0 2.886 1.389
12.1 0.844 0.48 152.5 2.894 1.454













25 %  w/w (CE9/Bl/Prop)
12.1 0.840 0.53 152.2 2.876 1.506
12.0 0.837 0.49 152.0 2.876 1.502
12.4 0.837 0.55 152.6 2.884 1.412
12.1 0.834 0.47 151.8 2.875 1.307
12.2 0.838 0.48 152.2 2.879 1.560
12.3 0.829 0.51 152.0 2.879 1.594
12.1 0.833 0.49 152.0 2.874 1.597
12.1 0.839 0.50 151.8 2.866 1.598
12.3 0.841 0.46 152.1 2.878 1.595
12.2 0.831 0.52 151.8 2.874 1.444
11.9 0.836 0.45 151.1 2.867 1.475
12.4 0.848 0.49 152.1 2.873 1.482
12.0 0.847 0.48 151.6 2.861 1.468
12.3 0.841 0.48 152.2 2.877 1.464











30 %  w/w (CEIO/Bl/Prop)
12.0 0.826 0.51 152.4 2.866 1.548
11.8 0.825 0.46 152.2 2.861 1.605
11.8 0.820 0.44 151.9 2.860 1.443
12.0 0.832 0.46 152.3 2.880 1.426
12.1 0.828 0.47 152.4 2.867 1.567
12.2 0.821 0.50 152.2 2.870 1.550
12.2 0.826 0.50 152.6 2.869 1.600
12.1 0.831 0.48 152.3 2.870 1.600
12.3 0.839 0.50 152.7 2.877 1.595
12.0 0.834 0.46 152.5 2.888 1.559
12.2 0.835 0.50 152.7 2.866 1.601
12.2 0.830 0.47 152.3 2.880 1.591
12.1 0.835 0.51 152.5 2.863 1.581
11.9 0.832 0.46 152.3 2.868 1.551
12.3 0.835 0.47 152.9 2.880 1.592
XX
Table A4
Effect of Binder (PVP K-30) concentration on Release Sustaining
Characteristics 
T50 (Hours)
0% 2.01 1.63 1.82 1.99 1.81 1.85
3% 2.03 1.95 1.90 1.64 2.38 1.70
5 % 2.03 1.82 1.81 1.71 1.92 1.61
7.5 % 1.86 1.73 1.89 1.84 1.70 1.73
9% 1.65 1.76 1.34 1.76 1.38 1.90
10% 1.58 1.31 1.50 1.57 1.58 1.28
15 % 1.25 1.01 1.52 1.37 0.93 1.06
25 % 1.38 1.00 0.90 1.14 1.30 1.13
30% 0.84 1.03 1.09 1.34 0.92 0.79
XXI
Table A5
CE5/Prop Tablets : Effect of Particle Size on Release Sustaining Characteristics
fim T50 (Hours)
500-710 1.39 2.15 2.35 3.18 2.45 2.39
355-500 1.86 1.57 1.44 1.46 1.56 1.90
250-355 1.54 1.62 1.55 1.44 1.22 1.57
180-250 1.31 1.12 1.41 1.58 1.55 1.68
< 180 1.37 1.49 1.39 1.65 1.45 1.46
Table A6
CE5/Bl/Prop Tablets : Effect of Compaction Force on Release Sustaining
Characteristics
kN T50 (Hours)
3.3 1.17 0.93 1.36 1.23 1.17 1.00
6.1 1.21 1.43 1.55 1.47 1.66 1.33
8.9 1.78 1.68 1.34 2.01 1.63 1.84
12.2 1.86 1.73 1.89 1.84 1.70 1.73
18.2 1.68 1.97 1.85 1.82 1.71 1.78
x x n
Table A7
CE25/Prop Tablets : Effect of Particle Size on Release Sustaining Characteristics
(im T50 (Hours)
500-710 1.42 1.33 1.42 1.49 1.44 1.41
355-500 1.27 1.48 1.37 1.41 1.55 1.51
250-355 1.13 1.08 1.11 1.10 1.05 1.14
180-250 1.01 1.08 1.06 1.07 1.11 1.08
< 180 0.98 1.01 1.06 1.02 0.98 0.82
Table A8
CE25/Bl/Prop Tablets : Compaction Force Effect on Release Sustaining
Characteristics
kN T50 (Hours)
2.5 1.13 0.99 1.01 1.10 1.11 1.13
5.7 1.08 1.17 1.06 1.16 1.17 1.25
9.3 1.16 1.02 1.18 1.11 1.27 1.14
11.9 0.94 1.14 1.19 1.17 1.07 1.17
15.2 1.01 1.26 1.11 1.25 1.08 0.97


















First Order Kinetics:- logi«(100 % - O) = kt




































First Order Kinetics:- lo2in(100 % - Q) = kt





































First Order Kinetics:- logm(100 % - CM = kt






















First Order Kinetics:- logmdOO % - Q) = kt
Tablet No. Slope (h r1) Intercept r
CE29/B2/Ptod
1 -0.43306 2.0777 0.94298
2 -0.44289 2.0757 0.95590
3 -0.30497 2.0182 0.96622
4 -0.40035 2.0712 0.95956
5 -0.38299 2.0461 0.98716
6 -0.30389 2.0003 0.99568
Mean -0.37803 2.0482 0.96792


















Higuchi Mechanism Kinetics:- O = kt1/2




































Higuchi Mechanism Kinetics:- O -  kt1/2


































Higuchi Mechanism Kinetics:- O = kt1/2






















Higuchi Mechanism Kinetics:- O = kt1/2
Tablet No. Slope (%hr'1/2) Intercept (%) r
CE17/Bl/Prop
1 42.37 5.63 0.99950
2 48.95 1.85 0.99970
3 39.80 2.42 0.99995
4 46.60 0.69 0.99974
5 45.22 3.87 0.99973
6 43.75 4.55 0.99987
Mean 44.45 3.17 0.99975
sd 3.22 1.84 0.00015
CE18/Bl/Prop
1 78.22 -21.01 0.99995
2 93.46 -27.98 0.99988
3 94.22 -29.42 0.99997
4 89.12 -27.16 0.99960
5 81.26 -19.25 0.99840
6 70.84 -19.49 0.99834
Mean 84.52 -24.05 0.99936
sd 9.30 4.63 0.00078
XXXI
Table A10 Continued
Higuchi Mechanism Kinetics:- O = kt1/2
Tablet No. Slope (%hr'1/2) Intercept (%) r
CE25/B1/Ptod a t» i 3 kN
1 50.79 -3.96 0.99884
2 51.59 -1.75 0.99965
3 58.97 -8.54 0.99815
4 57.42 -9.42 0.99753
5 55.88 -7.63 0.99765
6 50.19 -3.32 0.99931
Mean 54.09 -5.77 0.99852
sd 3.73 3.16 0.00088
CE25/Bl/Proo at « 6 kN
1 55.03 -7.10 0.99933
2 53.06 -6.69 0.99687
3 57.80 -8.25 0.99853
4 56.59 -10.19 0.99770
5 53.04 -7.19 0.99973
6 49.60 -5.05 0.99974
Mean 54.19 -7.41 0.99865
















Higuchi Mechanism Kinetics:- O = kt1/2
Slope (%hr'1/2) Intercept (%) r



















Table A l l
Zero Order Kinetics:- O = kt
Tablet No. Slope (% hr1) Intercept (%) r
CE25/Bl/Prop a t « 3 k N
1 21.87 22.41 0.99274
2 22.07 25.26 0.98709
3 25.46 21.95 0.99492
4 24.82 20.22 0.99536
5 24.03 21.07 0.99551
6 21.57 22.79 0.99167
Mean 23.30 22.28 0.99288
sd 1.68 1.73 0.00323
CE25/Bl/Prop at ~ 6 kN
1 22.28 22.45 0.99146
2 22.17 21.55 0.99554
3 24.09 22.63 0.99449
4 23.63 19.96 0.99563
5 22.00 21.34 0.99082
6 20.57 21.63 0.99069
Mean 22.46 21.59 0.99311















Table A l l  Continued
Zero Order Kinetics:- O = kt



































Diffusion - Relaxation Kinetics;- O = kit0-46 + k?t° 92
ki (%hr046) k2 (%hr'092) Intercept (%) r
CE25/Bl/Prop at ^  3 kN
38.40 7.73 0.11 0.99972
36.69 12.51 0.15 0.99981
33.40 13.23 0.19 0.99967
34.83 11.74 0.33 0.99971
39.51 6.89 -0.01 0.99982
36.57 10.42 0.15 0.99975
2.50 2.90 0.12 0.00007
CE25/B1/Ptod at -*6kN
43.38 7.37 -3.34 0.99972
25.63 14.12 5.35 0.99928
35.06 12.28 1.15 0.99991
29.12 14.27 1.72 0.99981
44.52 5.94 -4.97 0.99996
41.85 5.45 -3.09 0.99994
36.59 9.91 -0.53 0.99977


















Diffusion - Relaxation Kinetics:- O = kit0,46 + k?t°'92
ki (% hr046) k2 (%hr092) Intercept (%) r
CE25/Bl/Pron a t « 1 5 k N
58.23 1.64 -9.42 0.99901
47.73 1.85 -5.87 0.99989
45.72 3.73 -2.40 0.99984
39.20 6.92 -2.26 0.99992
43.66 10.58 -5.61 0.99846
55.83 1.67 -6.96 0.99994
48.40 4.40 -5.42 0.99951




31.73 20.82 -0.01 0.99993
26.25 19.54 0.14 0.99898
23.98 24.71 0.09 0.99962
27.24 22.81 -0.06 0.99972
30.73 17.45 -0.08 0.99982
28.38 21.06 0.03 0.99960
3.03 2.52 0.09 0.00034
xxxvn
Table A13
Linear Regression Calibration Data
Vessel No. Slope Intercept r
Propranolol Hydrochloride in Distilled W ater
1 0.01884 0.00300 0.99989
2 0.01902 0.00260 0.99990
3 0.01898 -0.00440 0.99972
4 0.01887 0.00010 0.99987
5 0.01912 -0.00060 0.99995
6 0.01878 0.01140 0.99988
Mean 0.01894 0.00202 0.99987
sd 0.00013 0.00531 0.00008
Theophylline in Distilled W ater
1 0.01737 0.00015 0.99997
2 0.01737 0.00196 0.99994
3 0.01736 0.00104 0.99997
4 0.01737 0.00032 0.99996
5 0.01733 0.00118 0.99990
6 0.01737 0.00078 0.99995
Mean 0.01736 0.00091 0.99995
sd 0.00002 0.00065 0.00003
xxxvm
Table A13 Continued
Linear Regression Calibration Data
Repeat No. Slope Intercept r
Propranolol Hydrochloride in Buffer Solution:- pH ~ 6.8
1 0.01881 -0.00034 0.99996
2 0.01862 0.00031 0.99993
Mean 0.01872 -0.00002 0.99995
sd 0.00013 0.00044 0.00002
Propranolol Hydrochloride in Buffer Solution:- p H »1 .4
1 0.01928 0.00260 0.99988
2 0.01908 0.00096 0.99984
Mean 0.01918 0.00178 0.99986
sd 0.00014 0.00116 0.00003
XXXIX
APPENDIX 2
B a s ic  P r o g r a m m e  f o r  T a b l e t in g
10 REM **HAND TABLETING 
20 MODE 128
30 DIM U% (500), D% (500), L% (500), T% (500) 
40 PRINT “CALIB ?Y/N”
50 PRINT ‘X  TO EXIT CALIB ROUTINE”
60 Z%=GET
70 IF Z%< >78 AND Z%< > 89 THEN 60 
80 IF Z%=89 THEN PROCCAL 
90 PRINT ‘MONITOR FORCE ? Y/N”
100 PRINT ‘X  TO EXIT MONITOR ROUTINE”
110 Z%=GET
120 IF Z%< >78 AND Z%< > 89 THEN 110 
130 IF Z%=89 THEN PROCMONIT 
140 PRINT‘TABLET MAKING”
150 PRINT “PRESS SPACE WHEN READY”
160 PRINT‘X  TO EXIT ROUTINE”
170 IF INKEY (-67) = -1 GOTO 40





230 DEF PROCCOLL 
240 ?&FC02=2 
250 ?&FC00=0
260 IF (?&FC00*256+?&FC01) <300 THEN 250 
270 ?&FC00=0
280 IF (?&FC00*256+?&FC01) >300 THEN 250 
290 PRINT “COLLECTING”
300 TIME=0 
310 FORN%=l TO 500 
320 ?&FC02=1 
330 ?&FC00=0
340 U%(N%) = ?&FC00*256+?&FC01 
350 ?&FC02=2 
360 ?&FC00=0




410 D%(N%) = ?&FC00*256+?&FC01 
420 NEXT N%
430 ET%=TIME
440 PRINT‘TIME = “ET%
XL
450 UMX%=U%(1) : STI=ET%/500 
460 F0RN% =1 TO 500 
470 IF U%(N%) < UMX% GOTO 490 
480 UMX%=U%(N%): PK%=N%
490 NEXT
500 UMN%=UMX% : MN%=PK%
510 FOR N%=PK% TO 500




560 FORN%=l TO 500
570 IF L%(N%) < LMX% GOTO 590
580 LMX%=L%(N%) : PL%=N%
590 NEXT 
600 FL%=0
610 FOR I%=PK% TO 500 
620 IF U%(I%) < 1000 FL%=1 




680 FORN%=l TO 500
690 IF D%(N%) < DMX% GOTO 710
700 DMX%=D%(N%)
710 NEXT
730 PRINT ‘DIGITAL VALUE, TOP PUNCH = “UMX%
740 PRINT ‘DIGITAL VALUE, LOWER PUNCH = “LMX%
750 REM PRINT‘DIGITAL VALUE, DISP = ‘DMX%
760 PRINT “N TOP PUNCH = “UMX%/2.34 
770 PRINT “N LOWER PUNCH = “(LMX% - 3375)/1.292 
780 PRINT “PUNCH RATIO UP/LP 
790 PRINT “PUNCH RATIO
800 PRINT “UPPER PF - LOWER PF = “(UMX%/2.34)-((LMX%-3375)/1.292) 
810 PRINT RESID F LOWER PUNCH = “(L%(MN%+10)-3375/1.292)
820 @%=10
830 PRINT ‘TIME TO PF = “STI*PK%/100 
840 PRINT ‘TOT. COMP. TIME = “STI*FI%/100 
850 IF GET <>32 THEN 850 
860 CLS
870 FORN% =l TO 500
880 PLOT69, N%*2, U%(N%)/2.34/20
890 NEXT
900 FORN% =l TO 500







970 FORN%=J% TO J%+19 
980 PRINT U%(N%), L%(N%)
990 NEXT
1000 PRINT “NEXT 20” “N%=“ N%
1010 J%=J%+20
1020 REPEAT : UNTIL GET$<>“”
1030 UNTIL J%=500 
1040 ENDPROC 
1050 DEF PROCSTAT 
1060 PRINT “STATUS = “~S%
1070 PRINT “IF STATUS IS F8 ERROR IN SWITCH SETTING ELSE CONV. 
INCOMPLETE”
1080 ENDPROC 
1090 DEF PROCCAL 
1100 ?&FC02=1 
1110 ?&FC00=0 
1120 FOR I%=1 TO 5 
1130 NEXT 1%
1140 S%=?&FC03




1190 FORI% =l TO 5 
1200 NEXT 1%
1210 S%=?&FC03




1260 FORI% =l TO 5 
1270 NEXT 1%
1280 S%=?&FC03
1290 IF S% < > &F9 AND S% < > &FA AND S% < > &FC THEN PROCSTAT 
1300 PRINT CH” “CH2” “(?&FC00*256+?&FC01)
1310 IF INKEY (-67) = -1 GOTO 1320 ELSE 1100
1320 ENDPROC
1330 DEF PROCMONIT
1340 PRINT ‘TRESS SPACE BAR WHEN READY”








1420 IF INKEY (-67) = -1 GOTO 1430 ELSE 1360 
1430 ENDPROC
B a s ic  P r o g r a m m e  f o r  D isso l u t io n
10 FACTOR 1
20 ON ERROR GOTO 130
30 REM AUTO DISSOL
40 REM SAB(0,X)=TIME, SAB(1-6,X)=REPS 1-6, SAB(7,X)=MEAN, 
SAB(8,X)=STD DEV, SAB(9,X)=SE, SAB(10,X)=TEMPSTORE FOR REP, X, 
SAB( 1-6,0)=TAMTAB 







120 ONFL5 GOTO 110, 90, 60, 150
130 PROCEND
140 PRINT ERR, ERL
150 PROCEND
160 STOP
170 DEF PROCMENU 
180 CLS
190 PRINT “F0 - CALIBRATE/ZERO” 4 
200 PRINT “FI - CONTINUE WITH RUN” ‘
210 PRINT ‘T2 - PRINTOUT RESULTS” ‘
220 PRINT “F3 - SAVE DATA ON DISC” 4 
230 PRINT “F4 - START ANOTHER RUN” ‘
240 PRINT ‘F5 - FINISHED” 4
250 ENDPROC
260 DEF PROCKEY
270 IF INKEY (-33) = -1 PROCCALIB
280 IF INKEY (-114) = -1 PROCRUN
290 IF INKEY (-115) = -1 PROCPRINT
300 IF INKEY (-116) = -1 PROCSAVE
310 IF INKEY (-21) = -1 FL%=3





370 INPUT “ENTER NUMBER OF REPS ‘K%
380 INPUT “ENTER RUN TIME h “TM
390 INPUT ‘"ENTER SAMPLE FREQUENCY (NO. OF SAMPLES PER HOUR 
“JJ%
XLm
400 PRINT “ENTER TOTAL AMOUNT IN TABLET 
410 FOR I%=1 TO K%
420 PRINT 1%
430 INPUT SAB (1%, 0)
440 NEXT
450 J%=(JJ%*TM) + 1
460 PRINT ‘TO  START DATA COLLECTION RUN PRESS”
470 @%=&20306
480 IF GET <>  32 THEN 480
490 FORN% =l TO J%
500 SAB (0, N%) = (TM/(J%-1)*(N%-1))
510 I%=0
520 PROCWAIT
530 FOR I%=1 TO K%
540 IF I%=1 THEN 560
550 PROCWAIT
560 PRINT “SAMPLE “N%
570 PRINT “REP. T%
580 PROCAV
590 SAB (1%, N%) = ((AV%*2.82E-5) + 0.019) *A1 
600 IF N%=1 THEN Z(I%) = SAB (1%, N%)
610 SAB (1%, N%) = SAB (1%, N%) - Z(I%)
620 IF SAB (1%, N%) < 0.0189 THEN SAB (1%, N%) = 0.0001 
630 IF PR1%=1 THEN 650 
640 VDU2





700 IF PR1%=1 THEN 720 
710 VDU2
720 FORN%=l TO J%
730 FOR I%=1 TO K%





790 FOR I%=1 TO K%
800 FORN%=l TO J%
810 SAB (1%, N%) = SAB (1%, N%) - 0.0001
820 SAB (1%, N%) = SAB (1%, N%) / 0.01893













950 IF SAB (0, J%) > 12 THEN TI%=1 
960 PRINT “SAMPLE “SC$
970 PRINT DESC$ 4 4 
980 PRINT 44TIME”;
990 F0RI% =1 TO 6 
1000 PRINT 44REP”; 1%;
1010 NEXT
1020 PRINT 44MEAN SD SE”
1030 PRINT t4AM. TAB”;
1040 @%=&20206 
1050 F0RI% =1 TO 9 
1060 PRINT SAB (1%, 0) 44 
1070 NEXT 
1080 PRINT 
1090 F0RN% =1 TO J%
1100 PRINT44
1110 FOR I%=0 TO 9





1170 IF SK%=1 THEN 1200 
1180 PRINT “T50 = “T50 




1230 DEF PROCCLEAR 
1240 FOR I%=0 TO 10 
1250 FOR N%=0 TO 25 








1340 PRINT 4 WILL YOU HAVE A PRINTER AT THE END ? Y/N” 
1350 Z%=GET
1360 IF Z% > 90 THEN Z%=Z%-32
XLV
1370 IF Z% < >78 AND Z% < > 89 THEN 1350 
1380 IF Z%=78 PR%=1 
1390 IF Z%=89 PR%=0
1400 PRINT ‘DO  YOU HAVE A PRINTER DURING THE RUN ? Y/N” 
1410 Z%=GET
1420 IF Z% > 90 THEN Z%=Z%-32
1430 IF Z% < >78 AND Z% < > 89 THEN 1410
1440 IF Z%=78 PR1%=1
1450 IF Z%=89 PR1%=0
1460 *FX15, 1






1530 FOR N%=0 TO J%
1540 FORI% =l TO K%
1550 SAB (7, N%) = SAB (7, N%) = SAB (1%, N%)
1560 NEXT
1570 SAB (7, N%) = SAB (7, N%)/K%
1580 NEXT
1590 FORN%=l TO J%
1600 FOR 1% TO K%
1610 SAB (8, N%) = SAB (8, N%) + ((SAB (1%, N%) - SAB (7, N%)) A2) 
1620 NEXT
1630 SAB (8, N%) = SQR (SAB (8, N%)/(K%-1))




1680 INPUT “ENTER SAMPLE CODE “SC$




1730 T50 = -1 : T90 = -l
1740 FORN%=l TO J% -1
1750 IF SAB (7, N%)>=50 THEN 1780
1760 C50%=N%+1
1770 GOTO 1800
1780 IF SAB (7, N%)>=90 THEN 1800 
1790 C90%=N%+1 
1800 NEXT
1810 IF C50%=0 THEN T50=0
1820 IF T50=0 THEN 1870
1830 P50D=SAB (7, C50%) - SAB (7, (C50%-1))
1840 P50=(SAB (7, C50%) -50)/P50D
XLVI
1850 TI50=SAB (0, C50%) -SAB (0, (C50%-1))
1860 T50=SAB (0, C50%) - (P50*TI50)
1870 IF C90=0 THEN T90=0
1880 IF T90=0 THEN 1930
1890 P90D=SAB (7, C90%) - SAB (7, (C90%-1))
1900 P90=(SAB (7, C90%) -90) /P90D 
1910 TI90=SAB (0, C90%) -SAB (0, (C90%-1))
1920 T90=SAB (0, C90%) - (P90*TI90)
1930 ENDPROC 
1940 DEF PROCSAVE 
1950 FL%=2
1960 INPUT ‘ENTER FILENAME “FLNM$
1970 FLNM$=LEFT$ (FLNM$, 7)
1980 X%=OPENIN (FLNM$)
1990 IF X%=0 THEN 2120 
2000 CLOSE# X%
2010 PRINT ‘TILENAME ALREADY IN USE”
2020 PRINT ‘RENAME FILE ? Y/N”
2030 Z%=GET
2040 IF Z%>90 THEN Z%=Z%-32 
2050 IF Z%=89 THEN 1960 
2060 IF Z%< >78 THEN 2030
2070 PRINT “THIS OPTION OVERWRITES THE FILE OK ? Y/N” 
2080 Z%=GET
2090 IF Z%>90 THEN Z%=Z%-32 
2100 IF Z%=78 THEN 1960 
2110 IF Z%< >89 THEN 2080 
2120 X%=OPENOUT (FLNML$)
2130 PRINT “CODE “SC$
2140 PRINT ‘DESCRIPTION ‘DESC$
2150 PRINT# X%, SC$, DESCS, K%, J%, T50, T90 
2160 FOR I%=0 TO 10 
2170 FOR N%=0 TO J%






2240 IF I%=0 AND N%=1 THEN 2260
2250 IF ?&FC00=254 THEN 2250
2260 IF INKEY (-113) = -1 THEN FG%=1
2270 IF FG%=1 THEN 2290





x l v d
2330 TT%=TIME
2340 F0RM %=1 TO 100
2350 AV%=AV%+ADVAL (2)







2430 PRINT “ABSORBANCE ON SPEC SHOULD BE “A1 
2440 PRINT ‘DWELL TIME MUST BE AT LEAST 10 SECONDS” 
2450 PRINT “PRESS SPACE TO CONTINUE”
2460 IF GET< >32 THEN 2460
2470 FORL% =l TO 6
2480 PROCWAIT
2490 IF FG%=1 THEN 2550
2500 PROCAV
2510 IF FG%=1 THEN 2550
2520 @%=&20306




2570 IF FG%=1 THEN 2590 





2630 DEF PROCEND 
2640 CLOSE #X%
2650 *FX229, 0 
2660 FL%=4 
2670 ENDPROC
XLVm
XLIX
